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Abstract
Low concentrations of adiponectin, the protein product of the adiponectin 
gene (ADIPOQ), and high concentrations of resistin have been reported 
to be associated with obesity and insulin resistance. Several adiponectin 
gene polymorphisms have been described, and their association with 
obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome, in 
different populations and sample types, is controversial. The purpose of 
the present study was to investigate the association of the two most well- 
known single nucleotide polymorphisms (SNPs) of ADIPOQ (+45T>G 
and +276G>T) with serum adiponectin concentrations, metabolic 
parameters associated with diabetes, and risk of T2DM in the Bahraini 
population. We also aimed to investigate the associations between 
serum adiponectin and resistin levels with the metabolic parameters and 
the prevalence of T2DM in Bahraini population.
We performed a cross-sectional study using a representative sample of 
140 unrelated Bahraini patients with T2DM and 66 non-diabetic healthy 
subjects. The polymerase chain reaction-restriction fragment length 
polymorphism (PCR-RFLP) method was used to determine the 
distribution of allele and genotype frequency of the SNP +45T>G 
polymorphism (exon2) and SNP +276G>T polymorphism (intron 2) in 
ADIPOQ. Lipid profile was measured by enzymatic methods. An ELISA 
was used to determine serum adiponectin and resistin levels.
It was observed that obesity, insulin resistance and T2DM are associated 
with low serum adiponectin levels. Compared with the control group, the 
T2DM group exhibited lower adiponectin levels and higher resistin levels. 
The G allele and TG/GG genotype of SNP +45T>G occurred more 
frequently than the common T allele and TT genotype in T2DM patients 
compared to the controls (P<0.05). Subjects with the GG/TG genotype of 
SNP +45T>G were associated with lower serum adiponectin levels. 
There was no statistically significant difference in allele and genotype 
frequencies of SNP +276G>T comparing control group with T2DM group.
No association with metabolic parameters was detected with either of the 
SNPs. In summary, our results demonstrated that, adiponectin SNP 
+45T>G, rather than SNP +276G>T is more associated with adiponectin 
levels. However, we could not confirm an association of these two SNPs 
with metabolic parameters of the metabolic syndrome.
Keywords: adiponectin; resistin; ADIPOQ; single nucleotide
polymorphisms; SNP +45T>G; SNP +276G>T; metabolic parameters; 
insulin resistance; T2DM; metabolic syndrome
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1.1 Type 2 Diabetes Mellitus
Type 2 Diabetes mellitus (T2DM) is a major public health problem 
worldwide. It is particularly prevalent among Gulf states countries 
(Haslam and James, 2005). Five Arabian Gulf countries are among the 
world’s ten highest for diabetes prevalence. These countries are Kuwait, 
Oman, Saudi Arabia, United Arab Emirates and Bahrain which is ranked 
the third (International Diabetes Federation, 2009). Al-Mahroos and 
McKeigue performed the first cross sectional survey in Bahrain to detect 
the prevalence of diabetes mellitus among Bahraini natives. A total of 
2128 Bahrainis, aged between 40 and 69-years participated in the study. 
Based on the study, the total rate of diabetes among the Bahraini 
population was 30%. The highest numbers of diabetics were seen in the 
50-59 years age group in which the total prevalence of diabetes was 29% 
in men and 35% in women. The results showed that about 35% of 
Bahraini diabetics between the ages of 40 and 69 years were 
undiagnosed previously (Al-Mahroos and McKeigue, 1998). In 2002, it 
was estimated that 9% of total deaths in Bahrain were due to diabetes 
(WHO, 2002).
Figure 1.1 shows the pathogenesis of type 2 diabetes mellitus. T2DM is 
characterized by peripheral insulin resistance coupled with a failure of 
pancreatic p-cells to produce compensatory levels of insulin and typically 
accompanies advancing age, inactivity, and weight gain (Stumvoll et al., 
2005). Low levels of circulating insulin results in decreased glucose 
absorption into the cells leading to hyperglycemia and eventually to 
T2DM. In addition to the metabolic and environmental causes, T2DM 
has a strong genetic component. Kaprio et al. studied the cumulative 
incidence, concordance rate and heritability for diabetes mellitus in a 
nationwide cohort of 505 type 2 (non-insulin-dependent) diabetes twins. 
The concordance rate in monozygotic twins was 34% whereas in 
dizygotic twins it was 16% (Kaprio et al., 1992). In another Japanese 
study which included 87 pairs of twins, these figures were 83% for 
monozygotic twins and 40% for dizygotic twins (Committee on Diabetic
Twins, 1988). The authors concluded that these figures imply a high 
degree of heritability for T2DM as well as the involvement of 
environmental factors. Further evidence for a genetic role is suggested 
by the high prevalence of the disease in particular ethnic groups and its 
modification by genetic admixture (Stern and O’Connell, 1999). The 
extent to which multiple genes and the environment impact on disease 
predisposition and progression has been studied widely through 
association studies, either of individual genes (candidate gene approach) 
or using high-density single nucleotide polymorphisms (SNPs) randomly 
spaced across the entire genome (genome-wide association study). 
Recently, a number of genes and polymorphisms have been extensively 
studied and reproducibly associated with T2DM in a variety of studies, 
reviewed in (McCarthy, 2010).
Type 2 Diabetes Proposed Pathogenesis
G e n e t i c  P r e d i s p o s i t i o n  E n v i r o n m e n t
Multiple genetic defects Obesity
I  I
Primary p-cell defects <------► Peripheral tissue insulin
resistance
Deranged insulin
secretion ------------* lnadecluate glucose utilization
»
H Y P E R G L Y C E M I A
I
p-cell exhaustion
Type 2 Diabetes
Figure 1.1 Pathogeneis of type 2 diabetes mellitus. Digram adapted 
from: http://ocw.tufts.edu/Content/51/lecturenotes/673764/674515
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1.2 Insulin Resistance
insulin resistance is considered the core factor in the pathogenesis of 
T2DM. It is often associated with a wide array of other pathophysiologic 
disorders including, obesity, dyslipidemia, hypertension and 
atherosclerosis. The coexistence of these diseases, termed the 
metabolic syndrome or syndrome X, was first described in 1988 (Reaven, 
1988). Insulin resistance is characterized by the inability of insulin to 
produce its numerous actions in maintaining a normal blood glucose 
level, independent of the impaired secretion from the pancreatic p-cells 
(Flakoll et al., 2004, Reaven, 2004).
Insulin resistance occurs by various genetic and acquired conditions 
such as a high fat diet, reduced physical activity, and “glucose toxicity” 
due to hyperglycemia (Hirose et al., 2010). Impairments in cellular 
events, distal to the interaction between insulin and its surface receptor, 
through alterations in the activities of signaling molecules, enzymes, and 
transcription factors are known to be the major cause (Reaven, 1988, 
Reaven, 1995, Saltiel and Kahn, 2001). Antibodies against the insulin 
receptor (Kawanishi, 1977, Kobayashi, 1992) or mutations in the insulin 
receptor gene (Taylor et al., 1990, Taylor et al., 1991, Kadowaki and 
Kasuga, 1991) have also been reported as possible causes.
Several studies emphasize the importance of insulin resistance in the 
pathogenesis of T2DM. In a recent prospective study of 6538 British civil 
servants without diabetes at baseline, 505 subjects were diagnosed with 
diabetes during a median follow-up period of 10 years (Tabak et al.,
2009). Those who developed diabetes showed a marked decrease in 
insulin sensitivity during the five years prior to diagnosis compared with 
those who did not develop the disease. Insulin secretion from (3- cells 
increased three to four years prior to diagnosis and then decreased until 
diagnosis. This highlights the importance of the quantification of insulin 
resistance in clinical practice since this metabolic state is a treatable 
precursor of T2DM (Weyer et al., 1999). Established direct methods to
quantify insulin sensitivity, such as the hyperinsulinemic euglycemic 
clamp have been described. In this procedure, insulin is administered at 
a constant rate to raise the insulin concentration while glucose is infused 
to maintain euglycemia. The glucose infusion rate needed to maintain 
euglycemia is a reflection of insulin action. Insulin sensitivity could be 
estimated using other methods, such as the minimal model which 
consists in a mathematical analysis of frequently sampled labeled 
glucose, given as part of an intravenous glucose tolerance test (IVGTT) 
(Robert, 1995). The homeostatic model assessment-insulin resistance 
(HOMA- IR) was also developed as a surrogate measurement of in vivo 
insulin sensitivity by Matthews et al. in 1985 (Matthews et al., 1985). 
HOMA- IR is an empirical mathematical formula based on measuring 
fasting plasma glucose levels and fasting plasma insulin levels:
HOMA-IR = fasting plasma insulin (uiu/mh x fasting plasma glucose (mmol/i)
22.5
HOMA-IR value of 3 or lower is considered normal. Any values above 7 
to 10 is considered insulin resistance (Lavin, 2009).
1.3 Obesity
Obesity poses an emerging global health care problem and is considered 
a major risk factor in the development of diabetes and cardiovascular 
disease. Al-Mahroos and Al-Roomi (2001) conducted a cross-sectional 
national epidemiological community survey involving 2013 Bahraini 
subjects aged 40-69. The age-standardized prevalence rate among 
native Bahraini men and women was high. Approximately 32% of women 
and 25% of men were obese (Body mass index (BMI) > 30.0 kg/m2) (Al- 
Mahroos and Al-Roomi, 2001) . Obesity has been defined as increased 
adipose tissue mass due to chronic imbalances between energy intake 
and expenditure (Tataranni and Ravussin, 2002). There are two types of 
adipose tissue: white adipose tissue (WAT) which takes up the vast 
majority of energy and is thought to be the site of energy storage, and
5
brown adipose tissue (BAT), which is mainly found in human neonates 
and is important for the regulation of body temperature. White adipose 
tissue contains adipocytes, which are the most abundant cell type, 
endothelial cells, fibroblasts, leukocytes and most importantly
\
macrophages whose number directly correlates with obesity (Weisberg et 
al., 2003). WAT can be further divided, according to its body distribution, 
into visceral and subcutaneous adipose tissue (Avram et al., 2005). The 
relative importance of each sub-type of WAT in producing insulin 
resistance is under debate in current literature (Dolinkova et al., 2008, 
Gomez-Ambrosi et al., 2004, Murdolo et al., 2008). However, strong 
clinical evidence indicates that visceral (android) obesity, a condition 
where adipose tissue preferentially accumulates in the mesenteric 
region, is more related to insulin resistance and the progression to T2DM 
than the peripheral (gynecoid) type (Wajchenberg, 2000).
The degree of obesity is usually estimated by the use of simple 
anthropometric parameters (body mass index (BMI) which is calculated 
as weight (Kg) divided by height squared (m2), waist circumference (WC), 
waist-to-hip ratio (WHR), and waist-to-height ratio (WHTR) or/and the use 
of percentage of body fat (%BF) mass. WC and WHR have been used to 
estimate abdominal fat accumulation as components of the metabolic 
syndrome (Grundy et al., 2005), and WHTR has also been reported as a 
measurement strongly associated with cardiovascular risk factors 
(Schneider et al., 2007). However, no consensus exists for specific 
obesity indicator associated with diabetes and metabolic risk factors. 
Some studies reported that simple anthropometric parameters were more 
strongly related to those risks compared to the measurement of body fat 
composition for example (Bosy-Westphal et al., 2006), while others 
showed that %BF was a better predictor of risks compared to 
anthropometry (Kobayashi et al., 2006).
To find the best obesity indicator for obesity-related metabolic risk 
factors, Lee et al. studied a total of 995 healthy Korean women and 577 
healthy Korean men. Anthropometric measurements including BMI, WC,
WHR, and WHTR were estimated. Direct body composition measures 
including the percentage of body fat (%BF) measured by dual-energy X- 
ray absorptiometry scanners and bioelectrical impedance analyzer (BIA) 
were also used. They found that WC, WHTR, and BMI were consistently 
associated with all metabolic risk factors regardless of the subject’s 
gender. Abnormal metabolic risk factors were significantly higher for 
these three indicators of obesity than for %BF. Their study validates the 
usefulness of anthropometry over direct body fat measures to predict 
metabolic risks (Lee et al., 2008). The same results were confirmed in a 
recent study which included 1,518 Peruvian adults. Knowles et al. 
examined the extent to which measures of adiposity can be used to 
predict selected components of metabolic syndrome (MetS), WC, BMI, 
WHR, and WHTR, were examined. They found that for both genders, as 
adiposity increased, the prevalence of MetS components increased. The 
authors showed that men and women with high-BMI and high- WC had 
elevated levels of fasting glucose and triglyceride (TG), high blood 
pressure, and reduced high density lipoprotein (HDL) compared to 
individuals with low-BMI and low-WC (Knowles et al., 2011).
Circumstantial and experimental evidence indicate that obesity causes 
hyperinsulinemia and insulin resistance in different proposed ways. 
Initially, important observations demonstrated that fat metabolism is 
extensively impaired with excess weight. Non-esterified fatty acids 
(NEFA) delivered from adipose tissue by enzymatic cleavage of 
triglycerides are found at increased concentrations in blood of obese 
individuals and are associated with a higher risk of developing T2DM 
(Charles et al., 1997). Experimental elevations of NEFA have been 
shown to induce insulin resistance in animal models and humans (Roden 
et al., 1996). In addition, Piro et al. have shown that chronic exposure to 
elevated free fatty acid increases apoptosis in rat pancreatic islets and 
these cytotoxic effects could be mediated by oxidative stress (Piro et al.,
2002). However, the most commonly accepted theory is that obesity is 
associated with a state of chronic, low grade inflammation, suggesting 
that inflammation may be a potential mechanism whereby obesity leads
to insulin resistance (Schenk et al., 2008, Hotamisligil, 2006, Rocha and 
Libby, 2009). Trayhum and Wood have revealed that the initiation of 
hypoxia, which develops as fat mass within the adipose tissue outgrows 
its vascular supply, leads to the stimulation of the release of inflammatory 
cytokines, chemokines and angiogenic factors, the function of which is to 
increase blood flow and stimulate vascularization (Trayhum and Wood,
2004). Increased levels of markers and mediators of inflammation, acute- 
phase reactants and white cell count have been seen to correlate with 
incident T2DM (Tataranni and Ortega, 2005, Spranger et al., 2003) and 
cause insulin resistance in experimental models (Shoelson et al., 2006).
1.4 Adipokines
The biologic role of the adipose tissue has dramatically changed over 
the last decade. Once considered an inert energy depot, adipose tissue is 
now known to serve as an active endocrine and paracrine organ, 
secreting an ever increasing number of mediators known as adipokines 
(Trayhurn et al., 2006). These secreted proteins, which now amount to 
more than 50 different molecular entities, influence body weight 
homeostasis and participate in diverse metabolic processes including 
glucose and lipid metabolism (Antuna-Puente et al., 2008). Table 1.1 
summarizes some of the adipokines secreted by adipose tissue and their 
metabolic functions.
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Table 1.1 Adipokines function and their role in metabolism
(Ikeoka et al., 2010, Rabe et al., 2008, Ronti et al., 2006)
Adipokines Function, characteristics, target tissues, effects on 
metabolism
Tumor Mainly produced by inflammatory cells and lymphocytes,
Necrosis but also by adipocytes and stromal cells. Stimulates
Factor-alpha release of free fatty acids by lipolysis, reduces adiponectin
(TNF-a) synthesis and impairs insulin signaling.
lnterleukin-6 Produced by inflammatory cells, lymphocytes and
(IL-6) adipocytes. Reduces sensitivity to insulin by inhibiting 
gene transcription. Blood levels correlate with body 
weight.
Adiponectin Secreted mainly by adipocytes. Circulating levels are 
reduced in obesity and positively correlate with insulin 
sensitivity. Suppressed by TNF-a, IL-6. Induces tyrosine 
phosphorylation of the insulin receptor and reduces 
gluconeogenesis in the liver. Increases fatty acid oxidation 
in the liver.
Leptin Stimulated by insulin and TNF-a. Exclusively synthesized 
and secreted by adipocytes. Inhibits appetite and reduces 
food consumption. Is found at elevated levels in obese 
subjects. Influences the reproductive functions. Reduces 
insulin- mediated glucose uptake.
Resistin Induction of insulin resistance in mice. Lack of clear 
function in glucose metabolism in humans. Elevated in 
plasma of obese individuals. Induces endothelial 
dysfunction and can be involved in the genesis of 
atherosclerosis.
Adipsin Enhances triglyceride storage in adipose cells through 
stimulation of glucose transport, enhances fatty-acid re- 
esterification and inhibits lipolysis.
Visfatin Expressed and secreted in adipose tissue. Reduces blood 
glucose levels, acting as an insulin-like hormone.
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Adipokines have physiological effects on a multitude of metabolic 
pathways and their dysregulation caused by hypertrophic adipocytes is 
known as a potential contributor to insulin resistance in humans 
(Kershaw and Flier, 2004). Lee et al. investigated the effect of adipocyte 
size on adipokine production and secretion in cultured adipocytes, 
separated according to cell size, from 30 individuals undergoing elective 
plastic surgery. The results clearly suggested that adipocyte size is an 
important determinant of adipokine secretion. There seems to be a 
differential expression of pro- and anti-inflammatory factors, with 
increasing adipocyte size. Dysregulation of hypertrophic, very large cells 
results in a shift toward dominance of pro-inflammatory adipokines (Lee 
et al., 2009). The discovery of such endocrine function of the adipose 
tissue has prompted the hypothesis that some adipose tissue-derived 
hormones, such as adiponectin and resistin, represent a possible 
connection between obesity, insulin resistance and other components of 
the metabolic syndrome, such as glucose intolerance, dyslipidemia, 
and high blood pressure (Steppan et al., 2001, McTernan et al., 2006, 
Krizova et al., 2008). Serum levels of resistin and adiponectin hormones 
as well as common variants of the adiponectin gene will be investigated 
within the framework of this thesis.
1.5 Resistin
Human resistin, also known as Found In Inflammatory Zone 3 (FIZZ3) or 
Adipocyte Secreted Factor (ADSF), is a cysteine-rich 12.5-kDa protein. It 
contains 108 amino acids as a prepeptide, and it's hydrophobic signal 
peptide is cleaved before it's secretion. Resistin circulates in human 
blood as a dimeric protein consisting of two 92-amino acid polypeptides 
that are linked by a disulfide bridge at cysteine residues-26 (Aruna et al.,
2003). The resistin gene family and it's tissue-specific distribution were 
first described by Holcomb et al. (Holcomb et al., 2000). In later studies, 
Curat et al. have seen that in human adipose tissue, resistin seems to be
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produced mainly by infiltrating macrophages (Curat et al., 2006), which 
could indicate a potential role in inflammation.
Resistin acquired initial attention as a potential link between obesity and 
glucose regulation. Initial experimental studies in rodents pointed to an 
important role of resistin as a mediator of obesity-associated insulin 
resistance. Steppan et al. showed that resistin expression was increased 
in obese animals, and decreased in the presence of thiazolidinediones 
(TZDs). In particular, administration of recombinant resistin to normal 
animals produced insulin resistance, whereas resistin immune 
neutralization by antibody improved insulin sensitivity in obese animals 
with insulin resistance. In adipocyte cultures, resistin decreased glucose 
transport in response to insulin, while an anti-resistin antibody produced 
the opposite effect (Steppan et al., 2001). In a further recent study, 
Banerjee et al. observed a decrease in fasting glucose, improved glucose 
tolerance and enhanced insulin sensitivity in resistin-gene knockout mice 
supporting the findings of Steppan et al. (Banerjee et al., 2004). The work 
conducted by Steppan et al. was the first to illustrate resistin as a link 
between obesity and insulin resistance, and quickly led to contradictory 
publications. In contrast to the Steppan et al. findings, various groups 
have observed a fall in resistin gene expression in obese and insulin 
resistance animal models. Way et al., Moore et al. and Le Lay et al. 
observed lower resistin mRNA in adipose tissue in different models of 
mouse obesity, such as diet-induced obesity, and in rat models 
characterized by hyperinsulinemia, hyperglycemia, hypertriglyceridemia, 
and hypertension (Way et al., 2001, Moore et al., 2001, Le Lay et al., 
2001).
The physiologic relevance of resistin for obesity related conditions in 
humans remains controversial; several studies have examined whether 
altered circulating resistin levels are associated with T2DM, insulin 
resistance, and/or obesity. Some of these studies found increased 
circulating resistin levels and Its mRNA expression in adipose tissue in 
patients with obesity and T2DM, (Degawa-Yamauchi et al., 2003) while
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other studies failed to confirm this finding (Lee et al., 2003, Anderlova et 
al., 2006) and did not show a significant correlation between resistin 
circulating levels and body mass index or insulin resistance. Regardless 
of the amount of data presented in previous studies, the true and 
complete role of resistin in either rodents or humans is still not fully 
elucidated until the resistin receptor is identified.
1.6 Adiponectin
Adiponectin is a protein of 244-amino acids (30-kDa), secreted mainly . 
from adipocytes and plays an important role in the regulation of lipid and 
glucose metabolism (Karbowska and Kochan, 2006). Adiponectin was 
originally identified by four groups in the mid 1990s using different 
experimental approaches, in both mice and humans. Scherer et al. 
referred to it as adipocyte complement-related protein of 30 kDa (ACRP 
30) (Scherer et al., 1995). Hu et al. called it ADIPOQ (Hu et al., 1996), 
Maeda et al. used the term adipose most abundant gene transcript 
(APM1) (Maeda et al., 1996) and Nakano et al. named their discovery 
gelatin binding protein of 28 KDa (GBP28) (Nakano et al., 1996). The 
circulating plasma range of adiponectin in human is 3-30 pg/ml, 
accounting for 0.01% of total plasma protein (Scherer et al., 1995, Maeda 
et al., 1996, Nakano et al., 1996, Hu et al., 1996) thus making it 
considerably the most abundant adipokine compared to other adipokines 
such as leptin (2-8 pg/L) or tumor necrosis factor (TNF)-a (<8 ng/L) (Arita 
et al., 1999). To quantitate the plasma adiponectin concentration, Arita et 
al. have produced monoclonal and polyclonal antibodies for human 
adiponectin and developed an enzyme-linked immunosorbent assay 
(ELISA) system (Arita et al., 1999).
Initially, adiponectin was thought to be exclusively synthesized by 
adipocytes; however, a recent study suggests that adiponectin is also 
synthesized and secreted by human cardiomyocytes (Pineiro et al.,
2005). Despite being produced mainly by adipose tissue, adiponectin
secretion is paradoxically decreased in obesity (Arita et al., 1999, Hajer 
et al., 2008). This may be attributable to inhibition of adiponectin gene 
transcription by inflammatory and angiogenic factors secreted by 
hypertrophic adipocytes as suggested by several in vivo studies (Hajer et 
al., 2008, Bruun et al., 2003) . Maeda et al. and Ahn et al. showed that 
the elevated level of TNF-a, which is secreted in states of increased 
adiposity, inhibits adiponectin secretion leading to reduced plasma levels 
(Maeda et al., 2001, Ahn et al., 2007).
Currently, adiponectin is among the strongest and most consistent 
biochemical predictors of T2DM (Sattar et al., 2008). It exerts profound 
antidiabetic, anti-atherogenic and anti-inflamatory effects (Bik and 
Baranowska, 2009, Matsuzawa, 2008, Funahashi and Matsuzawa, 2006, 
Swarbrick and Havel, 2008, Meier and Gressner, 2004, Gannage-Yared 
et al., 2006, Kadowaki et al., 2006). Using cell ELISA analysis, Ouchi et 
al. determined that adiponectin suppressed TNF-cnnduced monocyte 
adhesion to aortic endothelial cells and suppressed endothelial adhesion 
molecule expression which interferes with monocyte adhesion/ migration 
and transition to foam cells. These results indicate that adiponectin may 
attenuate the inflammatory response (Ouchi et al., 1999). Findings from 
animal studies and metabolic studies in humans suggest several 
mechanisms through which adiponectin may decrease the risk of T2DM, 
including suppression of hepatic gluconeogenesis, stimulation of fatty 
acid oxidation in the liver, stimulation of fatty acid oxidation and glucose 
uptake in skeletal muscle, and stimulation of insulin secretion as 
demonstrated in Figure 1.2.
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Figure 1.2 Proposed metabolic functions of adiponectin (Menzaghi 
et al., 2007).
1.6.1 Genomic DNA Structure, mRNA and Protein of Adiponectin
By genomic sequence analysis, Saito et al. determined that the ADIPOQ 
gene spans 16 kb, contains 3 exons and 2 introns and that the promoter 
lacks a TATA box (a sequence involved in the process of transcription). 
The exon-intron organization of this gene was very similar to that of 
obese gene, encoding leptin. Saito et al. reported the chromosome 
mapping of this gene by fluorescence in situ hybridization (FISH) using a 
genomic DNA fragment as a probe. The ADIPOQ gene was located on 
human chromosome band 3q27 (Saito et al., 1999). Takahashi et al. 
confirmed that the ADIPOQ gene maps to 3q27 using radiation hybrid 
analysis (Takahashi et al., 2000). A genome wide scan in later studies
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indicated that a susceptibility locus linked to T2DM (Kondo et al., 2002), 
insulin resistance and the metabolic syndrome (Kissebah et al., 2000) 
may reside in this chromosomal region. Heid et al. have combined 
genome-wide association scans of three population-based studies 
including 4659 people and found that the ADIPOQ gene is the only major 
gene responsible for plasma adiponectin (Heid et al., 2010). Northern 
blot analysis detected a 4.5-kb adiponectin transcript in adipose tissue 
but not in muscle, intestine, placenta, uterus, ovary, kidney, liver, lung, 
brain or heart (Ouchi et al., 1999, Das et al., 2001) (Figure 1.3 a). The 
molecule encoded by ADIPOQ gene has an N-terminal collagen-like 
motif and C-terminal globular domain and is present in a multimeric form 
in the plasma (Figure 1.3 b, c). The adiponectin gene has notable 
homology with collagen X, VIII and complement factor C1q as shown in 
Figure 1.4.
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Figure 1.3 Adipose-specific collagen-like protein, adiponectin. A.
Northern blot analysis detected a 4.5-kb adiponectin transcript in adipose 
tissue but not in muscle, intestine, placenta, uterus, ovary, kidney, liver, 
lung, brain or heart. B. The molecule encoded by ADIPOQ gene has an 
N-terminal collagen-like motif and C-terminal globular domain, and has 
notable homology with collagen X, VIII and complement factor C1q. C. 
Adiponectin is present in plasma in a unique multimeric form 
(Matsuzawa, 2010).
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Figure 1.4 Genomic structure of the human adiponectin gene and 
comparison with homologous genes. Three exons are represented by 
solid boxes and numbered. The presumed translation initiation sites in 
exon 2 and the translation stop site in exon 3 are indicated by an arrow. 
The structures of collagen VIII, X and C1q genes were also shown 
(Takahashi et al., 2000).
In human plasma, adiponectin exists in a wide range of multimeric 
complexes and combines via its globular or collagen domains to create 
various oligomeric complexes. Using SDS-PAGE to analyze human and 
mouse adiponectin isolated from serum or adipocytes and recombinant 
adiponectin expressed in mammalian cells, Waki et al. detected three 
different molecular mass species and characterized them as low- 
molecular weight (LMW) trimer (via globular domain interactions (67 kD), 
a middle-molecular weight (MMW) hexamer (136 kD), and high-molecular 
weight (HMW) 12- to 18-multimer adiponectin (via collagenous domain 
interactions) (greater than 300 kD) as shown in Figure 1.5. A disulfide 
bond through an N-terminal cysteine was required for the formation of 
multimers larger than a trimer. The authors demonstrated that simple 
SDS-PAGE, under non-reducing and non-heat-denaturing conditions, 
clearly separates multimer species of adiponectin (Waki et al., 2003).
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Also, existing in lower quantities is a smaller form of adiponectin that 
consists of globular C-terminal domain fragments cleaved from full-length 
adiponectin (Pajvani et al., 2003). Recently, a novel sandwich enzyme- 
linked immunosorbent assay (ELIZA) kit has been developed that 
accurately determines the serum levels of various types of adiponectin 
without requiring any sample pretreatment (Nakano et al., 2006).
as full-length molecules or smaller globular C-terminal domain fragments. 
The full-length adiponectin in plasma exists as a trimer (low molecular 
weight, LMW), hexamer (medium molecular weight, MMW), and 12- 18- 
multimer (high molecular weight, HMW) whereas extremely low amount 
of the Globular C-terminal domain fragments cleaved from full-length 
adiponectin is present (Wi§cek et al., 2007).
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The different multimeric forms of adiponectin may potentially have 
different physiological properties. To investigate this, Waki et al. have 
found that human adiponectin with rare missense mutations (G84R and 
G90S) didn’t form HMW multimers. These mutations were associated 
with T2DM, hypoadiponectinemia and insulin resistance. The authors 
have also shown that an amino-terminal (Cys-Ser) mutation, which could 
not form multimers larger than a trimer, abrogated the effect of 
adiponectin on the adenosine monophosphate-activated protein (AMP) 
kinase pathway in hepatocytes. Moreover, R112C and I164T mutants, 
which are shown to be associated with hypoadiponectinemia, did not 
assemble into trimers, resulting in impaired secretion from the cell. These 
data suggested impaired multimerization and/or the consequent impaired 
secretion to be among the causes of a diabetic phenotype or 
hypoadiponectinemia in subjects having these mutations (Waki et al.,
2003).
HMW adiponectin has been purified and suggested to have more 
biological activity than either LMW or MMW adiponectin (Pajvani et al.,
2004). A very recent study showed that measurements of total and 
HMW adiponectin have similar utility for the identification of insulin 
resistance (Almeda-Valdes et al., 2010, Heidemann et al., 2008). To 
compare the utility of total adiponectin, HMW adiponectin and the HMW 
adiponectin/total adiponectin index (SA index) for the identification of 
insulin resistance (IR) and related metabolic conditions, Almeda-Valdes 
et al. performed a cross-sectional analysis in a group of 101 men and 
168 women, aged 20 to 70 years, in Mexico City. Total, HMW 
adiponectin and the SA index were characterized and plotted for the 
identification of metabolic disturbances. Sensitivity and specificity for the 
identification of IR were calculated. The data showed that total 
adiponectin, HMW adiponectin and the SA index all had similar utility for 
the identification of IR and metabolic disturbances (Almeda-Valdes et al.,
2010).
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1.6 .2  A d lp o n e c tin  R e cep to rs
The molecules mediating the biological functions of adiponectin were not 
known until 2003, when adiponectin receptors 1 and 2 (AdipoRI and 
AdipoR2) were cloned by Yamauchi et al. using expression cloning 
methods. AdipoRI is abundantly expressed in skeletal muscle, whereas 
AdipoR2 is predominantly expressed in the liver. These two adiponectin 
receptors are predicted to contain seven transmembrane domains, but to 
be structurally and functionally distinct from G-protein-coupled receptors. 
Yamauchi et al. have seen that expression of AdipoRI/R2 or suppression 
of AdipoRI/R2 expression by small-interfering RNA supports their 
conclusion that they serve as receptors for globular and full-length 
adiponectin, and that they mediate increased adenosine 
monophosphate-activated protein (AMP) kinase and peroxisome 
proliferator-activated receptor- gamma (PPAR- y) ligand activities, as well 
as fatty-acid oxidation and glucose uptake (Yamauchi et al., 2003).
Studies aimed at both receptors mRNA and protein expression levels in 
various diabetic insulin resistant states have produced contradictory 
results. Civitarese et al. have reported that the expression of these 
receptors is reduced in people with a family history of T2DM, whereas 
Tan et al. have reported that their levels are induced in adipose and 
muscle tissues from obese and insulin resistant women with polycystic 
ovary syndrome, (Tan et al., 2006, Civitarese et al., 2004). Nevertheless, 
the majority of studies support the hypothesis that the expression of 
these receptors is significantly decreased in muscle and adipose tissue in 
hyperinsulinemic and hyperglycemic states associated with T2DM, 
obesity and insulin resistance (Civitarese et al., 2004, Bluher et al., 2007, 
Nannipieri et al., 2007). Moreover, Weigert et al. have shown in a recent 
study that monocytes from overweight and obese individuals with T2DM 
have an impaired expression and lower levels of adiponectin receptors 
(AdipoRI and AdipoR2) compared to normal-weight controls (Weigert et 
al., 2008).
20
Recently, a third adiponectin receptor, T-cadherin has been isolated and 
found to be capable of binding to the adiponectin molecule. Hug et a/, 
performed a series of expression cloning studies using a magnetic bead- 
based panning method. They identified T-cadherin as a receptor for the 
hexameric and high molecular weight species of adiponectin but not for 
the trimeric or globular species. T-cadherin represents extracellular 
protein and lacks known cellular functions. However, it is expressed in 
vascular cells, where it is positioned to interact with adiponectin (Hug et 
al., 2004). These data implicate T-cadherin to be involved in regulation of 
vascular functioning and remodeling.
1.6.3 Plasma Adiponectin Levels and Disease Associations
Adiponectin levels vary according to sex, body fat distribution, genetic 
background, dietary factors and metabolic status (Arita et al., 1999, 
Nishizawa et al., 2002, Salmenniemi et al., 2005, Kadowaki et al., 2006). 
Arita et al. have found total adiponectin concentrations to be higher in 
females than in males (Arita et al., 1999), Nishizawa et al. have 
estimated that men have approximately 15% lower levels compared with 
women (Nishizawa et al., 2002). To determine the association of 
adiponectin level with clinical phenotypes of metabolic syndrome, 
including glucose and lipid oxidation, energy expenditure, insulin 
sensitivity, and visceral obesity, Salmenniemi et al. performed detailed 
metabolic studies in a cohort (n = 158) of offspring of patients with T2DM 
by applying the euglycemic clamp technique and indirect calorimetry. 
They found that adiponectin levels were lower in offspring of T2DM 
patients than in control subjects. When the data were analyzed, an 
elevated adiponectin level was associated with high glucose disposal and 
high energy expenditure; low levels of free fatty acids and low rates of 
lipid oxidation; low levels of inflammatory cytokines; and a low amount of 
intraabdominal fat evaluated by computed tomography. They concluded 
that adiponectin has multiple effects on glucose, lipid and free fatty acid
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metabolism and inflammatory markers in offspring of T2DM subjects 
(Salmenniemi et al., 2005).
Adiponectin gene expression and circulating adiponectin levels were 
seen to be lower in patients with T2DM than in nondiabetic individuals. In 
a prospective study of 3,599 nondiabetic men followed up for 5 years, 
low adiponectin levels were associated with increased risk of T2DM, 
even after adjustment for traditional risk factors including BMI, lifestyle 
factors, preexisting cardiovascular disease, and systolic blood pressure. 
The inverse relation between low adiponectin and diabetes was 
significantly stronger in men who were obese (waist circumference >102 
cm or BMI > 30 kg/m2) relative to leaner men (Wannamethee et al., 
2007). Similar results have been found in a cohort study representing 
the ~9-year experience of the 10,275 middle-aged U.S. African American 
and Caucasian participants where higher adiponectin levels were found 
to be associated with a lower incidence of diabetes (Duncan et al., 2004). 
Adiponectin is decreased in obesity and seems to be involved in insulin 
resistance. Arita et al. found a negative correlation between body mass 
index and plasma adiponectin levels in Japanese men and women. 
Interestingly, there were marked variations in adiponectin levels even 
among obese subjects (Arita et al., 1999). Negative correlation between 
plasma adiponectin levels and body mass index or body fat was further 
supported by studies of Weyer et al. performed on Caucasian and Pima 
Indian populations (Weyer et al., 2001).
In contrast to decreased adiponectin levels in obese individuals, weight 
loss was found to enhance adiponectin concentrations by 40-60% (Hotta 
et al., 2000). Simonyte et al. studied the changes in plasma adiponectin 
levels with body weight reduction among twenty-seven obese women 
who underwent gastric bypass surgery. Two years after gastric bypass 
surgery, significant reductions were observed in the mean BMI (from 44.4 
to 30.8 kg/m2) and mean waist circumference (from 121.9 to 90.6 cm) 
with concomitantly increased circulating adiponectin levels. The authors
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concluded that body weight reduction increased the plasma levels of 
adiponectin (Simonyte et al., 2010).
Recent studies have shown that adiponectin levels can be changed 
through lifestyle and pharmaceutical interventions. Kim et al. evaluated 
the effects of a 10-month lifestyle intervention on blood concentrations of 
adiponectin and the components of the metabolic syndrome in 130 
Koreans with metabolic syndrome. All participants followed a 10-month 
lifestyle modification interventional program, including dietary counseling, 
advice on increasing physical activity, and recommendations to stop or 
limit smoking and alcohol drinking. Blood concentrations of adiponectin 
and anthropometric and biochemical parameters related to the 
components of the metabolic syndrome were measured. They found that 
at baseline, adiponectin concentrations were moderately negatively 
correlated to insulin concentrations and insulin resistance evaluated by 
the homeostasis model assessment. In response to lifestyle modification, 
statistically significant changes were found in adiponectin concentration, 
postintervention levels were higher compared with the preintervention 
levels. The authors concluded that lifestyle modification program in 
Korean patients with metabolic syndrome led to favorable changes in 
metabolic parameters and adiponectin levels (Kim et al., 2011). Dietary 
factors may also potentially influence adipokine levels and insulin 
sensitivity. Several studies showed that higher consumption of foods with 
high glycemic index/glycemic load values is associated with lower 
adiponectin levels in both healthy and diabetic individuals (Qi et al., 2005, 
Pischon et al., 2005).
One obvious pharmaceutical intervention would be the administration of 
peroxisome proliferator-activated receptor-gamma (PPAR-y) agonists 
(Olefsky, 2000). PPAR-y is the master regulator of adipocyte 
differentiation and controls many adipocyte genes. Maeda et al. have 
shown that the administration of thiazolidinedione (TZDs) which are 
synthetic PPARy ligands significantly increased the plasma adiponectin 
concentrations in insulin resistant humans and rodents without affecting
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their body weight (Maeda et al., 2001). Yamauchi et al. and Berg et al. 
also found separately in studies using various types of obese mice and 
diabetic mice, that the administration of adiponectin improves both insulin 
resistance and blood glucose levels (Yamauchi et al., 2001, Berg et al., 
2001).
1.6.4 Genetic Polymorphisms of the Adiponectin Gene and Disease 
Association
The first genetic analysis of adiponectin levels was conducted by 
Comuzzie et al. who assayed serum levels of adiponectin in 1100 adults 
of predominantly northern European ancestry distributed across 170 
families. Quantitative genetic analysis of adiponectin levels detected an 
additive genetic heritability of 46% (Comuzzie et al., 2001). Mutation 
screening for the ADIPOQ gene in T2DM established a total of 42 single 
nucleotide polymorphisms (SNPs) with minor allele frequency (MAF) > 
1.5% (Gu, 2009). Genetic association of SNPs in the ADIPOQ gene with 
T2DM and other metabolic disorders in different ethnic populations that 
showed significant associations is summarized in Table 1.2.
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Table 1.2 Associations between adiponectin genetic polymorphisms 
and metabolic disorders in different ethnic populations with
significant associations (Gu, 2009).
SNP Clinically associated conditions Ethnic group
rs16861194 
-11426 A>G
Adiponectin levels 
T2DM
French Caucasians, 
Swedish, European 
Caucasians
rs 17300539 
-11391 A>G
Adiponectin levels 
T2DM 
Obesity
Insulin resistance 
Insulin sensitivity 
Diabetic nephropathy
French Caucasians 
UK Caucasian women 
German, Italian 
Black South Africans 
Spanish, Polish
rs266729 
-11377 O G
Adiponectin levels 
T2DM 
Obesity
Insulin resistance 
Insulin sensitivity 
Diabetic nephropathy
French Caucasians 
Swedish, Danish 
German, Italian 
Chinese, Spanish 
Polish
rs2241766
+45T>G
Adiponectin levels 
Fasting glucose levels 
T2DM 
Obesity
Insulin resistance 
Insulin sensitivity 
Diabetic retinopathy 
Diabetic nephropathy 
Atherosclerosis 
Cardiovascular diseases
Japanese, Chinese 
Korean, Italian 
Uygurs, Swedish, 
Finnish
African Americans 
Spanish, German 
European Caucasians 
Polish
rs 1501299 
+276G>T
Adiponectin levels 
T2DM 
Obesity
Insulin resistance 
Insulin sensitivity 
Diabetic nephropathy 
Polycystic ovary syndrome 
Cardiovascular diseases
European Caucasians 
Japanese, Italian, 
German
Chinese, Korean 
Swedish, Finnish 
African Americans 
Uygurs, Chinese, 
Spanish 
Polish
rs17366743 
+331T>C
Adiponectin levels 
Body mass index 
T2DM
German, Polish 
Finnish 
Framingham 
Americans
Positive and negative numbers refer to residue position from the transcription start site
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The linkage disequilibrium (LD) of the ADIPOQ gene is moderate, but 
there are two small LD blocks, one including SNPs in the promoter region 
and another one spanning the boundary of exon 2-intron 2 (Gu, 2009). 
Figure 1.6 shows ADIPOQ gene, locations of the genotyped variants and 
their pairwise linkage disequilibrium (LD) patterns. Two SNPs at the 
ADIPOQ locus are a silent T to G substitution in exon 2 (+45T>G, 
rs2241766) and a G to T substitution in intron 2 (+276G>T, rs1501299) 
have been extensively studied. However, the association studies of these 
two SNPs, either independently or as a haplotype, have resulted in 
conflicting evidences in different populations and sample types. Stumvoll 
et al. reported a positive association between the G allele of the +45T>G 
polymorphism and obesity traits in a 371 nondiabetic German individuals 
(P=0.02) (Stumvoll et al., 2002), whereas in Taiwanese nondiabetic 
subjects (n= 245), the same allele was related to a lower risk of obesity 
(Yang et al., 2003). Recently, the G allele at the +45T>G polymorphism 
has been associated with higher serum adiponectin concentrations 
(Mackevics et al., 2006, Berthier et al., 2005), higher adiponectin mRNA 
expression in adipose tissue (Yang et al., 2003), and improved insulin 
sensitivity in Caucasian and Quebec populations (Menzaghi et al., 2002, 
Ruchat et al., 2008). On the other hand, Xita et al. found that the G 
allele of the SNP +45T>G was associated with increased risk of IR in a 
sample of Greek women with polycystic ovary syndrome (n= 100 women 
with polycystic ovary syndrome and 140 healthy controls, (P <0.05)) (Xita 
et al., 2005). Similar findings were observed in a group of 747 unrelated 
Spanish subjects where the G allele of SNP +45T>G was associated with 
impaired glucose tolerance (P=0.020) (Gonzalez-Sanchez et al., 2005).
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Figure 1.6 ADIPOQ gene, locations of the genotyped variants and 
their pairwise linkage disequilibrium (LD) patterns. Schematic 
presentation of the ADIPOQ, indicating the locations of the analysed 
variants, the two observed haploblocks and the pairwise LD measures D’ 
(above) and r2 (below). Grey boxes, untranslated region; black boxes, 
coding region; MAF, minor allele frequency (Siitonen et al., 2011).
The T allele of the SNP +276G>T has been associated either with 
increased or decreased levels of plasma total adiponectin in different 
Caucasian populations. Filippi et al. have studied the association 
between SNP +276G>T of the adiponectin gene and adiponectin plasma 
levels. The SNP was analyzed in a cohort of 595 subjects. They 
observed a significant association between the SNP +276G>T in the 
adiponectin gene and adiponectin serum level. The presence of T allele 
of the SNP +276G>T was a significant determinant of lower levels of 
serum adiponectin levels (Filippi et al., 2005). Despite that, Hara et al.
have observed that the T allele at position +276 was linearly associated 
with higher plasma adiponectin levels in the Japanese population (n= 480 
nondiabetic and 384 diabetic subjects, P=0.01). They also showed that 
subjects with the G/G genotype at position +276 had a significantly 
increased risk of type 2 diabetes and a higher insulin resistance index 
compared with those having the TfT genotype (P =0.002, OR 2.16, 95% 
Cl 1.22-3.95) (Hara et al., 2002). Kyriakou et al. and Gonzalez-Sanchez 
et al. found separately that the T allele of the SNP +276G>T was 
significantly associated with elevated adiponectin in samples of 
Caucasian women ( the Chingford Study; n = 808, mean age 62.8 ± 5.9 
years and Twins UK; n = 2,718, mean age 47.4 ±12.6 years, P< 0.05) 
and in 747 unrelated Spanish subjects with metabolic syndrome, 
P=0.015) respectively confirming Hara et al. findings (Kyriakou et al., 
2008, Gonzalez-Sanchez et al., 2005).
However, other studies have not found any effect of either SNPs +45T>G 
and SNP +276G>T on adiponectin level and risk for type 2 diabetes. For 
example Vozarova de Courten et al. found no association between SNP 
+45T>G and serum adiponectin or diabetes in Pima Indians (n= 790 
nondiabetic and 548 diabetic subjects) (Vozarova de Courten et al.,
2005). Similarly, recent studies in French (n= 1373 diabetic and obese 
subjects) (Vasseur et al., 2002), American (n= 642 incident cases of type 
2 diabetes and 995 matching control) (Hu et al., 2004), and Swedish (n= 
166 patients with type 2 diabetes) (Kang et al., 2005) subjects have not 
detected any association of SNP +276G>T with risk of type 2 diabetes.
Haplotypes comprised of the two SNPs have also provided evidence of 
association with plasma total adiponectin levels, obesity, lipid profile and 
insulin resistance. Menzaghi et al. genotyped 413 nondiabetic 
individual's phenotypes to assess whether the haplotypes of these two 
variants contribute to the prevalence of insulin resistance in Caucasians. 
They detected that the haplotype defined by the two together was 
strongly associated with many components of the insulin resistance 
syndrome compared with each polymorphism alone. Homozygotes for
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the risk haplotype had higher body weight (P=0.03), waist circumference 
(P=0.004), systolic (P=0.01) and diastolic (P=0.003) blood pressure, 
fasting glucose (P=0.02) and insulin (P=0.005) levels, homeostasis 
model assessment (HOMA) for insulin resistance (P=0.003), and total to 
HDL cholesterol ratio (P=0.01). Homozygotes also had significantly lower 
plasma levels of adiponectin (P=0.03), independent of sex, age, and 
body weight. Menzaghi et a/, concluded that SNPs +45T>G and 
+276G>T haplotype at the adiponectin locus is strongly associated with 
obesity and other features of the insulin resistance syndrome (Menzaghi 
et al., 2002). Mackevics et al. replicated a strong association of ADIPOQ 
SNPs +45T>G/ +276G>T genotypes and haplotypes with adiponectin 
levels in 1745 well-phenotyped asymptomatic unrelated Caucasian 
subjects that was previously reported by Menzaghi et a/., however, they 
did not find significant associations between the metabolic parameters of 
the insulin resistance syndrome and the SNPs +45T>G /+276G>T 
haplotype (Mackevics et al., 2006). With all these findings, it is still hard 
to evaluate the data on these studies. The biggest problem with this field 
and particularly older studies is lack of power associated with small 
numbers of subjects studied.
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1.7 H y p o th es is
Low concentrations of adiponectin have been reported to be associated 
with obesity, insulin resistance and type 2 diabetes mellitus. However, 
contrasting reports have been published regarding the effect of genetic 
variability in ADIPOQ on adiponectin serum concentrations as well as 
characteristics of the metabolic syndrome among different populations. In 
Bahrain, the association between adiponectin gene polymorphisms and 
obesity-related clinical markers is not well researched. Therefore, the 
purpose of this study was to investigate the association of the two most 
well-known SNPs of ADIPOQ gene (+45T>G and +276G>T) with serum 
adiponectin concentrations and metabolic syndrome parameters in a 
cross-sectional survey in a representative sample of 140 incident cases 
of type 2 diabetes and 66 control subjects. We also evaluated another 
adipokine resistin, and assessed its relation with the anthropometric 
parameters and lipid profile in the study subjects. As far as we are aware, 
this study is the first to investigate the association of adiponectin, resistin 
and metabolic parameters in a Bahraini population with diabetes mellitus. 
This study highlights a potential role for the use of adipokines particularly 
adiponectin and resistin as a biomarker for the early diagnosis of insulin 
resistance and type 2 diabetes mellitus.
30
rThe research presented in this thesis investigates the association of the 
two most well-known SNPs of adiponectin gene (+45T>G and +276G>T) 
with serum adiponectin concentrations and metabolic parameters in a 
case control study. The overall aims of this thesis are outlined below.
• To investigate the relationship between serum adiponectin levels,
type 2 diabetes mellitus and metabolic parameters including lipid 
profile, glycated hemoglobin (Hb A1c), fasting blood glucose
(FBG), body mass index (BMI) and systolic and diastolic blood 
pressure among Bahraini type 2 diabetic patients and healthy 
control subjects. To compare gender differences on these
associations in both type 2 diabetic patients and control subjects. 
To identify which among the metabolic syndrome parameters are 
closely associated with pathological levels of adiponectin. To 
assess the impact of BMI on adiponectin.
• To investigate the associations between serum resistin levels,
type 2 diabetes mellitus and metabolic parameters including lipid 
profile, Hb A1c, FBG, BMI and systolic and diastolic blood
pressure among Bahraini type 2 diabetic patients and healthy 
control subjects. To compare gender differences on these
associations in both type 2 diabetic patients and control subjects. 
To identify which among the metabolic syndrome parameters are 
closely associated with pathological levels of resistin. Compare 
between adiponectin and resistin levels in relation to the metabolic 
and clinical parameters in the whole study population.
• To examine the genetic variability in the adiponectin gene, 
characteristics of the metabolic syndrome and adiponectin serum 
concentrations. To investigate the association of the two most 
well-known single nucleotide polymorphisms (SNPs) of 
adiponectin gene (+45T>G and +276G>T), with serum adiponectin
1.8 T h e s is  O v e rv ie w
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concentrations, metabolic parameters and type 2 diabetes. The 
SNPs were characterized by detecting restriction fragment length 
polymorphisms post amplification by polymerase chain reaction 
(RFLP-PCR).
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Chapter 2- Materials and Methods
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2.1 S tu d y  S u b je c ts
A cross-sectional study was conducted from October 2009 until October 
2011 among 140 native Bahraini patients suffering from T2DM (mean 
age 58.4 ±11.4 years; 74 women and 66 men; mean BMI 34 ± 7; mean 
HbA1c 8.1 ± 1.7%) and 66 non diabetes control subjects (mean age
41.2 ± 6.3 years; 6 women and 60 men; mean BMI 29 ± 4.5). All subjects 
were Bahraini unrelated individuals and were randomly recruited from 
Bahrain Defense Force (BDF) hospital from August 2009 to April 2010.
The inclusion criteria for the diabetic subjects involved patients referred 
to the Diabetic Clinic in the BDF hospital; with the presumptive diagnosis 
of type 2 diabetes mellitus. The presence of type 2 diabetes was 
established according to the American Diabetes Association criteria 
(American Diabetes Association, 2009). A subject was considered 
diabetic if he/she exhibited a fasting blood glucose (FBG) value of 7 
mmol/l (126 mg/dl) or greater, if his/her 2-hr glucose value during a 75-g 
oral glucose tolerance test (OGTT) was 11.1 mmol/l (200 mg/dl) or 
greater, or if antidiabetic therapy (oral hypoglycemic agent such as 
sulphonylureas or metformin, or insulin) was required. Impaired fasting 
glucose (IFG) was defined as fasting glucose between 5.6 and 6.9 
mmol/l (100 to 125 mg/dl inclusively). Patients with type 1 diabetes 
mellitus and women with gestational diabetes were excluded.
For the comparison, a total of 66 controls without a personal history of 
any metabolic abnormalities were recruited to the study. The controls 
were taken from the same geographic areas as the patients. The 
following exclusion criteria were applied: fever (temperature > 38°C), 
hospitalization in the previous two weeks, known diabetes (FBG ^ 7 
mmol/l), arterial hypertension (systolic blood pressure (SBP) >130 mm 
Hg or diastolic blood pressure (DBP) > 85 mm Hg), dyslipidemia [total 
cholesterol (TC) ^ 6.21 mmol/l (240mg/dl), triglyceride (TG) >1.7 mmol/l 
(150 mg/dl), high density lipoprotein cholesterol (HDL-C) < 1.03 mmol/l 
(40 mg /dl)], coronary heart disease, congestive heart failure, stroke,
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chronic renal disease, active hepatic disease, chronic diseases or any 
other acute or chronic inflammatory illness. Subjects were also excluded 
if they were on any medication known to affect the metabolic profile (anti­
hypertensives, statins, fibrates, metformin, thiazolidinediones, and 
salicylic acid). At the time of blood sampling, all controls were free of any 
pharmacological treatments. These criteria were evaluated through 
personal interview structured by a questionnaire (Appendix 1) and/or by 
direct measurements to assess the participants’ condition. The 
questionnaire included questions about date of birth, gender, nationality, 
smoking habits, history of any diseases particularly metabolic diseases 
and type 2 diabetes mellitus and characterized if any current medications 
are being used. In addition, each individual’s systolic and diastolic blood 
pressure, height and weight was measured and recorded.
Samples were collected and analyzed over a two-year period. The 
experimental design of this study was approved by the ethics committee 
of the Royal College of Surgeons in Ireland (RCSI Bahrain and RCSI 
Dublin). This study was also approved by the research and ethics 
committee of the local hospitals (BDF Hospital and Salmanyia Medical 
Complex) and informed consent was obtained.
2.2 Patients Medical History
Type 2 diabetic patients were characterized using a patient clinical data 
sheet (Appendix 2), which included the following four main sections:
• General information section: to characterize patient's gender, date 
of birth, nationality, smoking state and family history of type 2 
diabetes mellitus.
• Clinical parameters section: which measures height, weight, 
fasting blood glucose, systolic and diastolic blood pressure, 
glycated haemoglobin (HbA1c) and lipid profiles (triglycerides,
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total cholesterol, high density lipoprotein cholesterol and low 
density lipoprotein cholesterol) for each diabetic case.
• Management section: to assess the current medications used and 
their doses.
• Complications section: This characterizes any sort of
complications associated with the disease.
The clinical data were retrospectively collected from patient's medical 
records and/or through personal interview. The patients were subjected 
to direct anthropometric and laboratory measurements to assess the 
clinical parameters. The data highlighted the clinical manifestations 
associated with the disease and were essentially used to establish any 
possible phenotypic-genotypic correlation in type 2 diabetic cases.
2.3 Anthropometric Measurements
Height, weight, random blood sugar (RBS), pulse rate and systolic and 
diastolic blood pressures were measured for participants by trained 
nurses. Weight and height were measured in kilogram (Kg) and 
centimeter (cm) respectively. Body weight was measured by a balance 
scale to the nearest half-kilogram with the individuals in light clothing and 
without shoes. Height was measured by a stadiometer to the nearest half 
centimeter. Body mass index (BMI) or Quetelet index was calculated as 
weight (Kg) divided by squared height (m2). Subjects were classified as 
being obese, overweight or normal on the basis of BMI. BMI cut points 
chosen to make this distinction were according to WHO standards 
(WHO, 2004). Obesity was defined as having a BMI of >30 Kg/m2, while 
overweight was defined as a BMI of 25 to 29.9. Subjects with BMI of 
18.5-24.9 were considered as being normal.
RBS was measured by blood glucose level testing kit. The measurement 
was done by first pricking patient’s finger with a sharp lancet designed to
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penetrate the skin only as far as needed to draw a drop of blood. A small 
amount of blood was put on the correspondent strip and placed into the 
glucose measuring device (Accu-Chek Active Blood Glucose Meter, 
Roche). The blood glucose level was displayed after about 30 seconds.
Systolic and diastolic blood pressures were measured using standard 
digital sphygmomanometer with the cuff on the right arm and the subjects 
in a sitting position. The measurements were taken after resting for at 
least three minutes. Systolic and diastolic blood pressures were 
measured in duplicate, the results were averaged, and the average value 
was used for data analysis. Pulse rate was also recorded. Diagnosis of 
hypertension was based on the presence of elevated systolic 
(>130mmHg) and/or diastolic (> 85mmHg) blood pressure, and/or the 
current use of antihypertensive medications (Alberti et al., 2006).
2.4 Blood Collection
After obtaining an informed consent, study participants were referred to 
the phlebotomy unit in the BDF hospital. Whole blood collection was 
conducted by vein puncture in three different blood tubes: EDTA-coated 
tubes for HbA1c determination and genetic studies, sodium fluoride tubes 
for glucose estimation, and serum separator tubes without anticoagulant 
for studying the lipid and hormones profiles. Venous blood was drawn 
from all subjects after an overnight fast for at least 12 hours. The serum 
and red blood cells were separated by centrifugation at 3,000 x g for 10 
minutes at room temperature and were directly subjected to the 
laboratory measurements at the biochemistry laboratory of the BDF 
hospital. After obtaining the biochemical results, the blood and serum 
samples were then transported to the research laboratory of the RCSI 
Bahrain for subsequent assays. The samples were received, checked, 
and the patient's information was confirmed. An internal numbering 
system corresponding to each patient was allocated to guarantee 
patient's confidentiality. Samples inadequately labeled, or inappropriately
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obtained, handled, preserved, processed, transported or stored were 
rejected. Accepted blood samples were stored non-frozen at +4°C for 
DNA extraction and serum samples were stored frozen at -20°C for 
subsequent hormonal assays. The analysis was performed within three 
days from receiving the samples.
2.5 Laboratory Measurements
Blood samples were analyzed for biochemical variables at the 
biochemistry laboratory of the BDF hospital. Serum glycated hemoglobin 
(HbA1c), fasting blood glucose (FBG), total cholesterol (TC), triglyceride 
(TG), high density lipoprotein cholesterol (HDL-C), and low density 
lipoprotein cholesterol (LDL-C) were measured. HbA1c was assayed 
using the latex agglutination reaction on Roche cobas c 111 automatic 
biochemistry analysis system (Roche Diagnostics, Indianapolis, IN). 
FBG, TC, TG, HDL-C and LDL-C were assayed using the Roche cobas® 
6000 automatic biochemistry analysis system (Roche Diagnostics, 
Indianapolis, IN). FBG was measured using the hexokinase/glucose-6- 
phosphate dehydrogenase method (Neeley, 1972), the serum levels of 
TG, TC and HDL-C were measured by enzymatic colorimetric test, and 
LDL-C concentration was calculated by the Friedewald formula: LDL= 
Total cholesterol level - HDL - [Triglyceride level / 5] (Warnick et al., 
1990).
2.6 Metabolic Syndrome and Its Components
The presence of metabolic syndrome was established using the US 
National Cholesterol Education Program Adult Treatment Panel III (ATP 
III) (NCEP, 2001). The five metabolic syndrome criteria were waist 
circumference (WC), FBG, TG, HDL-cholesterol, and blood pressure. 
Patients were concluded to have metabolic syndrome if they exhibited at 
least three of the following criteria: (a) central (abdominal) obesity with a
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waist circumference >120 cm (males) or > 88 cm (females), (b) fasting 
plasma glucose values of> 6.1 mmol/L (110 mg/dL); (c) TG values of>
1.7 mmol/l (150 mg/dl); (d) HDL cholesterol concentrations below 1.03 
mmol/l (40 mg/dl) for males or below 1.29 mmol/l (50 mg/dl) for females; 
or (d) blood pressure measurements of 130/85 mmHg or higher or use of 
antihypertensive agents. Since the WC measurements were not 
available, the criteria used for defining the patient as having the 
metabolic syndrome were only the values of FBG, TG, HDL-cholesterol, 
and blood pressure.
Since insulin serum level was not measured either, insulin resistance 
was evaluated and considered present when the triglyceride/HDL- 
cholesterol index was > 3 (Almeda-Valdes et al., 2010, Gonzalez-Chavez 
et al., 2011).
2.7 Hormone Assay
Adiponectin and resistin levels were detected by immunoassay analysis 
with a sandwich enzyme-linked immunosorbent assay (ELISA) system 
from R&D Systems (Abingdon, Oxon, UK).
2.7.1 Adiponectin
Serum levels of adiponectin were measured using a Quantikine Human 
Adiponectin Immunoassays kit from R&D Systems (Abingdon, Oxon, UK) 
(Catalogue No. SRP300). The assay was conducted according to the 
manufacturer’s instructions.
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2 .7 .1 .1  S a m p le s  D ilu tio n
Serum samples were diluted to 100-fold dilution. 2 pi of sample was 
added to 198 pi of Calibrator Diluent RD6-39.
2.7.1. 2 Adiponectin Standards Preparation
The adiponectin standard was reconstituted with 2.0 ml of Calibrator 
Diluent RD6-39 to produce a stock solution of 250 ng/ml. The standard 
was mixed to ensure complete reconstitution and allowed to sit for a 
minimum of 15 minutes with gentle agitation prior to making dilutions. 
The stock solution was used to produce a dilution series of 125, 62.5,
31.2, 15.6, 7.8 and 3.9 ng/ml (Figure 2.1). Each tube was mixed 
thoroughly before the next transfer. The 250 ng/ml standard served as 
the high standard. Calibrator Diluent RD6-39 served as the zero standard 
(0 ng/ml).
250 125 62.5 31.2 15.6 7.8 3.9
ng/mL_____ ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL
Figure 2.1 Adiponectin standard preparations. Six series of dilution 
was conducted in 200 pi Calibrator Diluent RD6-39. In the first dilution, 
200 pi of the stock solution (250 ng/ml) was pipetted into the 200 pi 
Calibrator Diluent RD6-39. In subsequent dilution steps, 200 pi of the 
previous dilution was added to prepare the next dilution. The dilution 
series produced were 125, 62.5, 31.2, 15.6, 7.8 and 3.9 ng/ml.
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2 .7 .1 .3  A s s a y  P ro c e d u re
First, 50 pi of diluted serum sample and standards and 100 pi of Assay 
Diluent RD1W were pipetted into each of 96 wells of a microplate coated 
with monoclonal anti-adiponectin antibody. The content of the wells was 
incubated for 2 hours at room temperature. Following the incubation, the 
wells were aspirated and washed with 400 pi of diluted wash buffer 
repeating the process three times for a total of four washes. After the last 
wash, the plate was inverted and blotted against clean paper towels for 
complete removal of liquid and un-captured molecules. 200 pi of 
polyclonal conjugate antibody was added to each well and incubated for 
2 hours to allow binding to the captured molecule. A second washing 
step (like previous) was done following the incubation. 200 pi of substrate 
solution (equal volumes of Colour Reagents A and B mixed together) 
was added and incubated for 30 minutes. The reaction was stopped by 
adding 50 pi of stop solution which bound to the complex and changed 
the colour in the wells from blue to yellow. The optical density of each 
well was measured within 30 minutes, using a 680 microplate reader 
from Bio-Rad Laboratories set to 450 nm with wavelength correction set 
at 540 nm.
2.7.1.4 Calculation of the Results
Samples were run in duplicate, averaged and the average value was 
corrected by subtracting the average zero standard optical density. The 
optical density for the standards was plotted versus the concentration of 
the standards and the best curve was drawn. The data was linearized 
and analyzed using the log transformation and regression analysis. The 
Adiponectin concentration (x) of each sample was determined by using 
the equation Y= b+ (m * x), where y= optical density (OD) of sample, m= 
slope of the plotted standard curve and b= standard curve intercept. The 
concentration read from the standard curve was multiplied by the dilution 
factor of the samples.
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2 .7 .1 .5  P rec is io n
The minimum detectable dose (MDD) of the assay ranged from 0.079 - 
0.891 ng/ml with a mean value of 0.246 ng/ml. The intra- and inter-assay 
variations were evaluated by measuring three samples of known 
concentration twenty times on one plate and in forty separate assays 
respectively. The intra-assay coefficient of variation (CV) was between 
2.5% and 4.7%, and the inter-assay CV of 5.8- 6.9%.
2.7.2 Resistin
Serum levels of resistin were measured using a Quantikine Human 
Resistin Immunoassays (R&D Systems, Abingdon, Oxon, UK) (catalogue 
number SRSN00). The assay was conducted according to the 
manufacturer’s instructions.
2.7.2.1 Samples Dilution
Serum samples were diluted to 5- fold dilution. 60 pi of sample was 
added to 240 pi of Calibrator Diluent RD5K.
2.7.2.2 Resistin Standard Preparation
The resistin standard was reconstituted with 1.0 ml of deionized water to 
produce a stock solution of 100 ng/ml. The standard was mixed to ensure 
complete reconstitution and allowed to sit for a minimum of 15 minutes 
with gentle agitation prior to making dilutions. The stock solution was 
used to produce a dilution series of 10, 5, 2.5, 1.25, 0.62, 0.31, 0.16 
ng/ml (Figure 2.2). Each tube was mixed thoroughly before the next 
transfer. The 10 ng/ml standard served as the high standard. Calibrator 
Diluent RD5K served as the zero standard (0 ng/ml).
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100 10 5 2.5 1.25 0.62 0.31 0.16
ng/mt ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL ng/mL
Figure 2.2 Resistin standard preparations. Seven series of dilution 
was performed in Calibrator Diluent RD5K. 900 |jl of the Calibrator 
Diluent RD5K was pipetted into the 10 ng/ml tube and 500 pi was 
pipetted into the remaining tubes. The first dilution step was conducted 
by adding 100 pi of the stock solution (100 ng/ml) to the 900 pi of 
Calibrator Diluent RD5K. In the subsequent dilution steps, 500 pi of the 
previous dilution was added to prepare the next dilution. The dilution 
series produced were 10, 5, 2.5, 1.25, 0.62, 0.31 and 0.16 ng/ml.
2.7.2.3 Assay Procedure
First, 100 pi of diluted serum sample, standards, and Assay Diluent RD1- 
19 were pipetted into each of 96 wells of a microplate coated with 
monoclonal anti-resistin antibody. The content of the wells was incubated 
for 2 hours at room temperature. Following the incubation, the wells were 
aspirated and washed with 400 pi of diluted wash buffer, repeating the 
process three times for a total of four washes. After the last wash, the 
plate was inverted and blotted against clean paper towels for complete 
removal of liquid and un-captured molecules. 200 pi of polyclonal 
conjugate antibody was added to each well and incubated for 2 hours to 
allow binding to the captured molecule. A second washing step (like 
previous) was done following the incubation. 200 pi of substrate solution 
(equal volumes of Colour Reagents A and B mixed together) was added 
and incubated for 30 minutes. The reaction was stopped by adding 50 pi
4 3
of stop solution which bound to the complex and changed the colour in 
the wells from blue to yellow. The optical density of each well was 
measured within 30 minutes using a 680 microplate reader from Bio-Rad 
Laboratories set to 450 nm with wavelength correction set at 540 nm.
2.7.2.4 Calculation of the Results
Calculation of adiponectin serum concentrations were performed as 
previously described in section 2.8.1.4.
2.7.2.5 Precision
The minimum detectable dose (MDD) of the assay ranged from 0.010 - 
0.055 ng/ml with a mean value of 0.026 ng/ml. The intra- and inter-assay 
variations were evaluated by measuring three samples of known 
concentration twenty times on one plate and in forty separate assays 
respectively. The intra-assay coefficient of variation (CV) was between 
3.8% to 5.3% and the inter-assay CV of 7.8% to 9.2%.
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2 .8  G e n e tic  S tu d ie s
2.8.1 DNA Extraction
Genomic DNA was isolated from whole blood sample of each subject 
using phenol- chloroform DNA extraction method. 1 ml of red blood cells 
(RBC) lysis solution was added to 1 ml of whole blood in a sterile tube. 
The tube was mixed gently by inversion and kept on crushed ice for 10 
minutes. The sample was then centrifuged at 1,132 x g (3,500 rpm) for 
10 minutes and the supernatant was discarded. This step was repeated 
2- 3 times until a clean white blood cells (WBC) pellet was obtained. The 
WBC pellet was suspended in 1 ml of resuspension buffer by gentle 
inversion. The tube was then vortexed for 30 seconds, centrifuged at 
2,310 x g (5,000 rpm) for 5 minutes and the supernatant was gently 
poured off. 500 pi of resuspension buffer, 75 pi TEN (Tris/EDTA/ NaCI) 
solution 10X, 75 pi 10% sodium dodycyl sulphate (SDS) and 5 pi 
proteinase K (10 mg/ml) were added, mixed well and incubated at 57°C 
for at least 1 hour to ensure efficient lysis. 500 pi of phenol was added to 
the lysed cells and vortexed until the sample became uniformly viscous 
and rendered milky. The tube was then centrifuged at 2,310 x g (5,000 
rpm) for 5 minutes and the aqueous upper layer was transferred to a new 
sterile eppendorf tube. 500 pi of chloroform- Isoamyl alcohol 24: 1 was 
added to the tube and mixed until the sample became homogenous and 
milky. The tube was re-centrifuged at 2,310 x g (5,000 rpm) for 5 minutes 
and the aqueous upper layer was transferred to a new sterile eppendorf 
tube. Following that, 1 ml of cold absolute ethanol was added to the 
sample and mixed by inversion until a precipitation of DNA forms. The 
tube was centrifuged at full speed (18,000 x g) for 20 minutes. Ethanol 
supernatant was completely discarded and the tube was left upside-down 
for 20 minutes. Finally, 75 pi of distilled water was added to the tube and 
kept for 30 minutes at room temperature. The tube was then vortexed, 
pulse centrifuged and incubated at 65°C for 5 minutes. The tube was re- 
vortexed, re-centrifuged and kept in rotating position overnight at room
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temperature. The quality and the integrity of the extracted total DNA was 
checked by standard ethidium-bromide 1% agarose gel electrophoresis 
and quantification was performed spectrophotometrically at 260 nm 
(Pharmacia Biotech, Ultrospec 3000 UVA/IS Spectrometer, Freiburg, 
Germany). All samples had a 260/280 nm absorbance ratio between 1.6 
and 1.79. The tube containing the DNA was labelled appropriately and 
stored at -20°C for subsequent characterization of the adiponectin gene 
SNPs +45T>G and +276G>T.
2.8.2 Assessment of the SNP +45T>G Restriction Fragment 
Polymorphism
Isolated DNA was used for determination of the single nucleotide 
polymorphism (SNP) in the adiponectin gene (+45T>G, rs2241766) in 
exon 2 (Figure. 2.3). The SNP +45T>G polymorphism of ADIPOQ was 
genotyped using the polymerase chain reaction (PCR) with subsequent 
restriction analysis of PCR products (RFLP). The method of the 
polymerase chain reaction-restriction fragmented length polymorphism 
(PCR-RFLP) was used as described previously by Mackevlcs ef a/. 
(Mackevics et al., 2006).
ATG +45T>G
— I —
— ■ — H —16 kb Promoter ■
Exonl Exon 2 Exon 3
Intron 1 Intron 2
Figure 2.3 Schematic representation of the adiponectin gene SNP 
+45T>G. Black boxes denote exons and introns are found between the 
exons. ATG represents translation start site. The polymorphism +45T>G 
is represented by blue vertical line in exon 2. Adapted from (Heid et al., 
2006).
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2.8 .2 .1  P rim ers
The DNA was amplified by PCR using specific primers for human 
adiponectin DNA, previously reported by Mackevics et al. (Mackevics et 
al., 2006). A 305-bp DNA fragment containing the polymorphic site was 
amplified by polymerase chain reaction (PCR) using forward primer 5’- 
TGT GTG TGT GGG GTC TGT CT-3’ and reverse primer 5’-TGT GAT 
GAA AGA GGC CAG AA-3\ The primers were ordered online from the 
MWG website. The primer sequences and their details are shown below 
in Table 2.1.
Table 2.1 The primer sequences used for SNP +45T>G PCR and 
their details
P
rim
er
N
am
e Primer sequence
G
C
content
H
3
o
O
M
W
(g/m
ol)
P
rim
er 
size 
(bp)
PC
R
 
P
roduct 
size 
(bp)
FWD
5’-
T GT GT GTGTGGGGT CT GT C 
T-3'
55% 59.4 6217 20
REV
5’-
T GT GAT GAAAGAGGCCAGA 
A-3’
45% 55.3 6239 20
305
FWD represents forward primer and REV represents reverse primer
2.8.2.1.1 Primers Reconstitution and Dilution
Each primer was reconstituted in sterile nuclease-free ultra-pure water 
from Epicentre (cat no. W7350ML). A stock solution was made of each 
primer at a concentration of 100 pM (Table 2.2). The primer mixture was 
vortexed to ensure complete homogenized solution. 10 pi of stock primer 
solution was diluted into 90 pi of sterile nuclease-free ultra-pure water 
(final conc. 10 pM) and stored in aliquots at -20°C (repeated freezing and 
thawing were avoided).
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T a b le  2 .2  R e c o n s titu tio n  c o n d itio n s  o f th e  p rim e rs  o f S N P  + 45T > G
Primer Description and reconstitution conditions
No. of moles Contained 12.3 nmoles lyophilized primer
FWD Reconstitution 123 pi of sterile nuclease-free ultra-pure water 
was added to give a stock solution of 100 pM
No. of moles Contained 8.1 nmoles lyophilized primer
REV Reconstitution 81 pi of sterile nuclease-free ultra-pure water 
was added to give a stock solution of 100 pM
FWD represents forward primer and REV represents reverse primer
2.8.2.2 PCR Mastermix
Trials to optimize the PCR reaction were conducted, including 
troubleshooting with annealing temperature and primer concentrations. 
PCR-mediated in vitro amplification of genomic DNA was carried out with 
BioTherm™ Taq DNA Polymerase (Catalogue No. GC-002-0500) using a 
DNA Engine® Peltier Thermal Cycler (PTC-0200 DNA Engine) from Bio- 
Rad Laboratories. Table 2.3 illustrates the PCR mastermix preparations 
for the SNP +45T>G. The PCR reaction was carried using 5 pi of DNA in 
a volume of 50 pi containing 5 pi of 10XPCR BioTherm buffer with a final 
concentration of 1.5 mM magnesium chloride, 0.2 pM of each primer, 200 
pM deoxyribonucleotide triphosphate (dNTPs), and 2.5 U of Biotherm®- 
Taq-Polymerase.
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T a b le  2 .3  P C R  m a s te rm ix  p re p a ra tio n s  fo r  th e  S N P  + 4 5 T > G
Stock
Cone.
Reagents Volume
Final
conc.
-
Sterile nuclease-free ultra-pure 
water
36.5 pi -
15mM 10x PCR buffer + MgC^ (15mM) 5.0 pi 1.5 mM
10 mM dNTPs 1.0 pi 200 pM
10 pM SNP +45T>G FWD Primer 1.0 pi 0.2 pM
10 pM SNP +45T>G REV Primer 1.0 pi 0.2 pM
5U/pl Biotherm®-Taq-Polymerase 0.5 pi 2.5 U
20ng/ pi DNA 5.0 pi 100 ng 
(1 ng-1 M9)
Total Volume 50 pi
2.8.2.3 PCR Thermal Cycler Program
The PCR thermal cycler program is illustrated in Table 2.4. Thirty five 
cycles of amplification were performed and each cycle consisted of 
denaturation at 95°C for 30 seconds, annealing at 55°C for 30 seconds, 
and extension at 72°C for 30 seconds, with additional steps of initial 
denaturation at 95°C for 5 minutes and final extension at 72°C for 7 
minutes.
Table 2.4 The thermocycler program of the SNP +45T>G
PCR step Temperature Time No. of cycles
Initial denaturation 95°C 5 minutes 1 x cycle
Denaturation 95°C 30 seconds
Annealing 55°C 30 seconds 35x cycles
Elongation 72°C 30 seconds
Extension 72°C 7 minutes 1x cycle
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2 .8 .2 .4  E s tim a tio n  o f P C R  P ro d u c ts
5 pi of PCR amplified product was mixed with 1 pi of 6x loading dye and 
loaded into 2% low electroendosmosis (LE) agarose gel mixed with 
ethidium bromide (0.5 pg/ml ethtidium bromide was added to the molten 
Agarose). The loaded gel was electrophorised under 50 V for 90 minutes 
using 1x Tris/Acetate/EDTA buffer (TAE) buffer along with a standard 
DNA Molecular Weight Marker (fermentas, DNA marker pBR322/Alu I 
(Marker 20), Catalogue no. SM0121) until the purple/blue dye markers 
reached the end of the gel. The stained gel was subsequently visualized 
under ultraviolet light using Cole-Parmer High Performance UV 
Transilluminator and the molecular weight of PCR products was 
estimated. If the gel showed the desired fragment, the remaining 45 pi of 
PCR products was either subjected to digestion reaction or stored frozen 
at -20°C for later analysis.
2.8.2.5 Digestion with the Restriction Enzyme Eco88l (Aval) for the 
SNP +45T>G
10 pi of the PCR product was digested with 10U of Eco88l (Aval) in the 
recommended 10X Tango™ Buffer (MBI fermentas, ER 0381) for 
overnight at 37°C. Table 2.5 shows the digestion reaction protocol.
To validate enzyme activity, 1 pg of Lambda DNA as well as 5 pi of PCR 
product mixed with 1 pg of Lambda DNA were digested using the same 
protocol shown in Table 2.5. In both cases, the digestion pattern of 
Lambda DNA was obtained indicating that the enzyme is active and PCR 
reagents did not inhibit enzyme activity.
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Table 2.5 The digestion reaction protocol used to assess the SNP 
+45T>G
Reagents Volume
Restriction enzyme Aval (10U) 1 |XI
10 X Buffer Tango™ 2|il
Nuclease-free ultra-pure water 17 |il
PCR product (0.1-0.5 fig of DNA) 10 |il
Total 30 nl
Incubate for overnight at 37 °C
2.8.2.6. Estimation of the Digested Products
After digestion with the restriction enzyme Aval, fragments were loaded 
onto a 12% native polyacrylamide gel (Table 2.6). Polymerization was 
initiated by the addition of 10 jul N, N, N', N'- Tetramethylethylenediamine 
(TEMED), the gel cast and the lane combs were immediately placed onto 
the gels. After polymerization, the lane combs were removed, and excess 
acrylamide removed from the lanes by rinsing with distilled water (dH20). 
For the preparation of DNA fragments for electrophoresis separation, 18 
}J of each sample mixed with 3 [i\ of 6x loading dye was loaded in each 
well. 1x Tris/Borate/EDTA (TBE) was used as electrophoresis buffer. To 
eliminate false positive results, i.e. eventual contamination, a negative 
control was included (5 ^l of sterile nuclease-free ultra-pure water instead 
of the DNA was added to 45 |il of the master mix). For each sample, the 
undigested and digested PCR products were loaded in wells beside each 
other on the gel to further rule out any false positive results and confirm 
whether the digestion had occurred or not. A known positive control was 
always included on each gel run to validate the processing. 
Electrophoresis was performed under 50 mA for 60 minutes. Finally gels 
were incubated in 1xTBE buffer containing 15-20 jil of ethidium bromide 
(12.5 jLig/jLLl) with shaking for 10 minutes. The DNA fragments were
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visualized by UV illumination and the sizes were estimated by 
comparison with known size markers (fermentas, DNA marker pBR322 / 
BsuRI (Marker 5), Catalog. No. SM0271).
Table 2.6 12% native polyacrylamide gel reagent recipe. Mini- 
PROTEAN® 3 from Bio-Rad Laboratories was used to produce 
polyacrylamide gels.
Reagents Volume
Acrylamide: Bis solution 1:29 4.8 ml
Deionised water 4.8 ml
5xTBE buffer 2.4 ml
10 % APS 100 nl
TEMED 10 ¿1
Total Approx. 12.5 ml
TBE buffer: Tris/Borate/EDTA buffer, TEMED: N, N, N', N'- 
Tetramethylethylenediamine, APS: Ammonium persulfate
Sequence from human adiponectin gene, base pairs spanning 93065918 
to 93066252 according to location on NCBI is indicated below. Primers 
are underlined; restriction site is indicated in bold and highlighted in 
green.
T AGGT CCCAACT GG GTGTGTGTGTGGGGTCTGT CT CT CCAT GGCT G 
ACAGTGCACAT GT GGATT CCAGGGCT CAGGAT GCTGTT GCT GGGAG 
CT GTT CTACT GCTATTAGCTCT GCCCGG0CAT G ACCAGG AAACCAC 
GACTCAAGGGCCCGG AGT CCT GCTT CCCCT GCCCAAGGGGGCCT G 
CACAGGTTGGATGGCGGGCATCCCAGGGCATCCGGGCCATAATGG 
GGCCCCAGGCCGTGATGGCAGAGATGGCACCCCTGGTGAGAAGGG 
T G AG AAAGG AG ATCC AG GTAAGAAT GTTT CTG GCCT CTTT CAT CAC A 
GACCTCCTACACTGA
K= the IUPAC ambiguity code for the T/G alternative bases.
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Primers (forward primer: TGTGTGTGTGGGGTCTGTCT, reverse 
primer: TTCTGGCCTCTTTCATC ACA) were designed to span the 
region producing a 305 bp product. Aval cuts the 305 bp PCR product 
at position 105. If the restriction cutting site is present in both alleles 
(G/G), the PCR product produces fragments of 105 and 200 bp length; if 
the restriction cutting site is present in only one allele (T/G), the size of 
the fragments are 305, 200, and 105 bp; if restriction cutting site is 
absent in both alleles (T/ T), only an undigested 305 bp fragment is 
visible on the gel. The gel patterns obtained for the (T/ T), (T/G), and 
(G/G) genotypes are shown in Table 2.7 and Figure 2.4 below.
Table 2.7 The sizes of the fragments obtained after the digestion 
reactions of SNP +45T>G for the (TI T), (T/G), and (G/G) genotypes
TIT T/G G/G
(homozygote wild type) (heterozygote) (homozygote mutant)
305 bp 305 bp
200 bp 200 bp
105 bp 105 bp
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Figure 2.4 The gel patterns obtained after loading the digested 
fragments fpr the (T/ T), (T/G), and (G/G) genotypes. M5 represents 
marker 5, (-ve) represents negative control, (sample 1) represents 
undigested sample, (sample 2) represents wildtype genotype, (sample 3) 
represents heterozygous genotype and (sample 4) represents 
homozygous genotype.
The detection details of the adiponectin SNP +45T>G is summarized in 
Table 2.8.
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Table 2.8 Summary of the detection details of adiponectin SNP 
+45T>G
Forward (sense) primer* 5’- TGTGTGTGTGGGGTCTGTCT-3’
Reverse (antisense) primer* 5’-T GT GAT GAAAGAGGCCAGAA-3’
Temperature Time No. of cycles
95°C 5 min 1 x cycle
95°C 30 s
55°C 30 s 35x cycles
72°C 30 s
72°C 7 min 1x cycle
PCR product length= 305bp
Restriction enzyme Eco88l (Avalf
RFLP conditions 37 °C/ overnight
RFLP product length
T/T T/G G/G
(homozygote wild type) (heterozygote) (homozygote mutant)
305 bp 305 bp
200 bp 200 bp
105 bp 105 bp
*Primer sequences from Mackevics etal. (Mackevics et al., 2006) 
* Fermentas life science
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2.8.3 Assessment of the SNP +276G>T Restriction Fragment 
Polymorphism
Isolated DNA was used for determination of the SNP in the adiponectin 
gene (+276G>T, rs1501299) in intron 2 (Figure. 2.5). The +276G>T 
polymorphism of ADIPOQ was genotyped using the polymerase chain 
reaction (PCR) with subsequent restriction analysis of PCR products 
(RFLP). The method of the polymerase chain reaction -restriction 
fragmented length polymorphism (PCR -RFLP) was used as described 
previously by Mackevics etal. (Mackevics et al., 2006).
AHipnnPrtm m .
ATG
Ü
+276G>T 
_  ___
16 kb Promoter ■
Exonl
Introni
Exon 2 Exon 3 
Intron 2
Figure 2.5 Schematic representation of the adiponectin gene SNP 
+276G>T. Black boxes denote exons and introns are found between the 
exons. ATG represent translation start site. The polymorphism +276G>T 
is represented by blue vertical line in intron 2. Adapted from (Heid et al.,
2006).
2.8.3.1 Primers
The DNA was amplified by PCR using specific primers for human 
adiponectin DNA, previously reported by Mackevics et al. (Mackevics et 
al., 2006). Because there was no restriction site in the polymorphic 
region, one base in the forward primer was exchanged thus artificially 
creating the restriction cut in the region of the polymorphic site of the 
PCR product. The primer in which one base is modified is described as a 
mismatch-primer.
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The natural sequence of the wild type allele is AAGGC. In the mutated 
allele it is AAGTC. By means of the mismatch primer the sequence was 
modified so that in the wild type allele it was GAGGC, in the mutated 
allele however it changed to GAGTC. Upon applying the restriction 
enzyme Hinfl, which recognizes the GAGTC sequence, both alleles could 
be distinguished, whereby only the mutated allele of the PCR fragment 
was recognized and cut by the HinfL
A 110-bp DNA fragment was amplified by PCR using forward primer 5’- 
CTA CAC TGA TAT AAA CTA TAT GGA G-3’ and reverse primer 5’-CCC 
CAA ATC ACT TCA GGT TG-3’.The primers were ordered online from 
the MWG website. The primer sequences and their details are shown 
below in Table 2.9.
Table 2.9 The primers sequence used for SNP +276G>T PCR and 
their details
z  5
q 3' Primer Sequence
FWD CT AC ACT GAT AT AAACT AT AT 32% 56.4 25
GGAG-3’_______________________________ 6
5’_
REV CCCC AAAT C ACTT C AG GTTG 50% 57.3 ®03 20
-3' 6
FWD represents forward primer and REV represents reverse primer
2.8.3.1.1 Primers Reconstitution and Dilution
Each primer was reconstituted in sterile nuclease-free ultra-pure water. A 
stock solution was made of each primer at a concentration of 100 pM 
(Table 2.10). The primer mixture was vortexed to ensure complete 
homogenized solution. 10 pi of stock primer solution was diluted into 90
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Ij| of sterile nuclease-free ultra-pure water (final conc. 10 |jM) and stored 
in aliquots at -20°C (repeated freezing and thawing were avoided).
Table 2.10 Reconstitution conditions of the primers of the SNP 
+276G>T
Primer Description and Reconstitution Conditions
No of moles Contained 11.2 nmoles lyophilized primer
FWD Reconstitution 112 pi of sterile nuclease-free ultra-pure 
water was added to give a stock solution of 
100 pM
No of moles Contained 16.1 nmoles lyophilized primer
REV Reconstitution 161 pi of sterile nuclease-free ultra-pure 
water was added to give a stock solution of 
100 pM
FWD represents forward primer and REV represents reverse primer
2.8.3.2 PCR Mastermix
Trials to optimize the PCR reaction were conducted, including 
troubleshooting with annealing temperature and primer concentrations. 
PCR-mediated in vitro amplification of genomic DNA was carried out with 
BioTherm™ Taq DNA Polymerase (Catalogue No. GC-002-0500) using a 
DNA Engine® Peltier Thermal Cycler (PTC-0200 DNA Engine) from Bio- 
Rad Laboratories. Table 2.11 illustrates the PCR mastermix preparations 
for the SNP +276G>T. The PCR reaction was carried using 5 pi of DNA 
in a volume of 50 pi containing 5 pi 10X Biotherm PCR buffer with a final 
concentration of 1.5 mM magnesium chloride, 0.2 pM of each primer, 200 
pM deoxyribonucleotide triphosphate (dNTPs), and 2.5 U of Biotherm®- 
Taq-Polymerase.
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T ab le  2.11 P C R  M a s te rm ix  P re p a ra tio n s  fo r th e  S N P  + 2 7 6 G > T
Stock
Cone.
Reagents Volume
Final
conc.
- Sterile nuclease-free ultra-pure 
water
36.5 Ml
■
15mM 10x PCR buffer + MgCI2 (15 mM) 5.0 Ml 1.5 mM
10 mM dNTPs 1.0 Ml 200 |jM
10 mM SNP +276G>T FWD 1.0 Ml 0.2 |jM
10 mM SNP +276G>T REV 1.0 Ml 0.2 |jM
5 U/ |jl Biotherm®-Taq-Polymerase 0.5 Ml 2.5 U
20ng/ pi DNA
5.0 Ml
100 ng 
(1 ng-1 Mg)
Total Volume 50 Ml
2.8.3.3 PCR Thermal Cycler Program
The PCR thermal cycler program is illustrated in Table 2.12. Thirty five 
cycles of amplification were performed and each cycle consisted of 
denaturation at 95°C for 30 seconds, annealing at 55°C for 30 seconds, 
and extension at 72°C for 30 seconds, with additional steps of initial 
denaturation at 95°C for 5 minutes and final extension at 72°C for 7 
minutes.
Table 2.12 The Therm ocycler Program o f the SNP +276G>T
PCR Step Temperature Time No. o f cycles
Initial denaturation 95°C 5 minutes 1x cycle
Denaturation 95°C 30 seconds
Annealing 55°C 30 seconds 35x cycles
Elongation 72°C 30 seconds
Extension 72°C 7 minutes 1x cycle
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2 .8 .3 .4  E s tim a tio n  o f P C R  P ro d u c ts
5 pi of PCR amplified product was mixed with 1 pi of the loading dye and 
loaded into 2.5% LE agarose gel mixed with ethidium bromide (0.5 Mg/ml 
ethtidium bromide was added to the molten Agarose). The loaded gel 
was electrophorised under 50 V for 90 minutes using 1x TAE buffer along 
with a standard DNA Molecular Weight Marker (fermentas, DNA marker 
pBR322 / BsuRI (Marker 5), Catalogue. No. SM0271) until the purple 
/blue dye markers reached the end of the gel. The stained gel was 
subsequently visualized under ultraviolet light using Cole-Parmer High 
Performance UV Transilluminator and the molecular weight of PCR 
products was estimated. If the gel showed the desired fragment, the 
remaining 45 Ml of PCR products was either digested or stored frozen at - 
20°C for later digestion reaction.
2.8.3.5 Digestion with the Restriction Enzyme Hinfl for the the SNP 
+276G>T
10 |jl of the PCR product was digested with 10 U of Hinfl in the 
recommended 10X Buffer R (MBI fermentas, ER 0801) for overnight at 
37°C. Table 2.13 shows the digestion reaction protocol.
To validate enzyme activity, 1 M9 of Lambda DNA as well as 5 m> of PCR 
product mixed with 1 m9 of Lambda DNA were digested using the same 
protocol shown in Table 2.5. In both cases, the digestion pattern of 
Lambda DNA was obtained indicating that the enzyme is active and PCR 
reagents did not inhibit enzyme activity.
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Table 2.13 The digestion reaction protocol used to assess the SNP 
+276G>T
Reagents Volume
Restriction enzyme Hinfl (10U) 1 Hi
10 X Buffer Tango™ 2 vi
Nuclease-free ultra-pure water 17 |il
PCR product (0.1-0.5 ¡ig of DNA) 10 |il
Total 30 til
Incubate for overnight at 37 °C
2.8.3.6 Estimation of Digested Products
After digestion with the restriction enzyme Hinfl, fragments were loaded 
onto a 12% native polyacrylamide gel (Table 2.6). Polymerization was 
initiated by the addition of 10 |il N, N, N\ N'- Tetramethylethylenediamine 
(TEMED), the gel cast and the lane combs were immediately placed onto 
the gels. After polymerization, the lane combs were removed, and excess 
acrylamide removed from the lanes by rinsing with dH20. For the 
preparation of DNA fragments for electrophoresis separation, 18 |il of 
each sample mixed with 3 |il of 6x loading dye was loaded in each well. 
1x TBE was used as electrophoresis buffer. To eliminate false positive 
results, i.e. eventual contamination, a negative control was included (5 jil 
of sterile nuclease-free ultra-pure water instead of the DNA was added to 
45 |J of the master mix). For each sample, the undigested and digested 
PCR products were loaded in wells beside each other on the gel to 
further rule out any false positive results and confirm whether the 
digestion has occurred or not. A known positive control was always 
included on each gel run to validate the processing. Electrophoresis was 
performed under 50 mA for 60 minutes. Finally, gels were incubated in 
1xTBE buffer containing 15-20 |il of ethidium bromide (12.5 jig/jil) with 
shaking for 10 minutes. The DNA fragments were visualized by UV
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illumination and the sizes were estimated by comparison with known size 
markers (fermentas, DNA marker pBR322 / BsuRI (Marker 5), Catalogue. 
No. SM0271).
Sequence from human adiponectin gene, base pairs spanning 1501259 
to 1501399 according to location on NCBI is indicated below. Primers are 
underlined; restriction site is indicated in bold and highlighted in green.
TT CAT CACAG ACCT CCT AC ACT GATATAAACTAT AT G AAGBC ATT CAT 
TATTAACTAAGGCCTAGACACAGGGAGAAAGCAAAGCTTTTTTATGT 
TAACCATAAGCAACCTGAAGTGATTTGGGGTTGGTCTTCCAAGGAT 
K= the IUPAC ambiguity code for the T/G alternative bases
Primers (Froward Primer: CTAC ACT GATATAAACTATAT G AAG. reverse 
Primer: CAACCTGAAGTGA TTTGGGG) were designed to span the 
region producing a 110 bp product. Hinfl cuts the 110 bp PCR at position 
27. If the restriction cutting site is present in both alleles (T/T), the PCR 
product produces fragments of 27 and 84 bp length; if the restriction 
cutting site is present in only one allele (T/G), the size of the fragments 
are 110, 84, and 27 bp; if restriction cutting site is absent in both alleles 
(G/ G), only undigested 110 bp fragment is visible on the gel. The gel 
patterns obtained for the (GIG), (T/G), and (TI T) genotypes are shown in 
the Table 2.15 and Figure 2.6 below.
Table 2.14 The sizes of the fragments obtained after the digestion 
reactions of the SNP +276G>T for the (G/ G), (T/G), and (T/T) 
genotypes
GIG T/G T/T
(homozygote wild type) (heterozygote) (homozygote mutant)
110 bp 110 bp
84 bp 84 bp
27 bp 27 bp
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Figure 2.6 The gel patterns obtained after loading the digested 
fragments of SNP +276G>T for the (T/ T), (T/G), and (GIG) 
genotypes. M5 represents marker 5, (-ve) represents negative control, 
(sample 1) represents undigested sample, (sample 2) represents 
wildtype genotype, (sample 3) represents heterozygous genotype and 
(sample 4) represents homozygous genotype. To get clear definition 
between the bigger bands of the marker 5 and the digested samples, the 
27bp runs off the gel.
The detection details of the adiponectin SNP +276G>T is summarized in 
Table 2.15.
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Table 2.15 Summary of the detection details of adiponectin SNP 
+276G>T
Forward primer* 5 ’ -CT AC ACT GATAT AAACT AT AT G GAG-3’ 
Reverse primer* 5 -CCCCAAATCÂCTTCAGGTTG-3’
Temperature Time No. of cycles
95°C 5 m 1x cycle
95°C 30 s
55°C 30 s 35x cycles
72°C 30 s
72°C 7 m 1x cycle
PCR product length 110 bp
Restriction enzyme Hinff
RFLP conditions 37 °CI overnight
RFLP product length
G/G T/G T/T
(homozygote wild type) (heterozygote) (homozygote mutant)
110 bp 110 bp
83 bp 83 bp
27 bp 27 bp
*Primer sequences from Mackevics etal. (Mackevics et al., 2006) 
* Fermentas life science
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2 .9  S ta tis tic a l A n a ly s is
Statistical analysis was performed using SPSS for Windows version 12.0 
(SPSS Inc., Chicago, IL, USA). All results were presented as mean ± 
standard deviation (SD). Comparisons between means were performed 
using the Student’s independent t-test (two-tailed) for normally distributed 
data or the Mann-Whitney U test for parameters presenting with non­
normal distribution. Categorical variables were analyzed by the Chi- 
square test. Cramer's v test was used as post-test to determine strengths 
of association after chi-square has determined significance. The z-test 
was used to compare sample and population proportions to determine if 
there is a significant difference. P-values less than 0.05 were considered 
significant. Pearson and spearman coefficient was used to explore the 
association between total adiponectin, resistin and the metabolic and 
clinical variables.
The distribution of the alleles of SNP +45T>G and SNP +276G>T was 
tested for the Hardy-Weinberg equilibrium. The proportions of genotypes 
and alleles were compared by the Chi-square test analysis. Correlations 
of SNP +45T>G and SNP +276G>T genotypes with serum adiponectin 
concentrations and the various metabolic parameters were evaluated by 
univariate general linear model analyses. All analyses were adjusted for 
gender, age and BMI. Analyses were performed for the whole sample, as 
well as for men and women separately, to verify the homogeneity of 
genetic effect among men and women.
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C h a p t e r  3 -  R e s u l t s
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3.1 C lin ica l C h a ra c te ris tic s  o f th e  S tu d y  S u b je c ts
The clinical characteristics of type 2 diabetic patients and control 
participants of the present study are summarized in Table 3.1. The mean 
age of T2DM patients was 58 ± 11 years, and the mean BMI was 34.2 ± 
7 kg/m2. The mean age of the control group was 41 ± 6 years, and the 
mean BMI was 29.0 ± 4.5 kg/m2. The diabetic group consisted of 66 male 
and 74 female subjects, while the control group consisted of 60 male and
6 females. The difference in the number between genders was due to 
unavailability of female control subjects and issues related to time 
constrains. In tests where unequal numbers of male/ female subjects 
are known to affect the final results, a correction for gender and statistical 
adjustments was made. 80% of T2DM patients are classified as obese, 
while only 43% of the control subjects are classified as obese. Using the 
ATP-III definition (NCEP, 2001), 60% of T2DM patients fulfilled the 
criteria for metabolic syndrome.
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T a b le  3.1 C lin ica l c h a ra c te r is tic s  o f  th e  s tu d y  s u b je c ts
T2DM patients Control
Meant SD Mean± SD
n (%) 140 (68) 66 (32)
Male/ Female 66/74 60/6**
Age (yrs) 58± 11 41± 6
Height (cm) 161.2± 8.9 172.9± 5.3
Weight (kg) 85.7± 17.8 87.4± 14.0
BMI (kg/m") 34.2± 7.0 29.0± 4.5
Obese(%) 80. 43
SBP (mmHg) 147± 22 121 ±6
DBP (mmHg) 77± 13 70 ±8
HbA1C (%) 8.12± 1.74 6.2211.20
FBG (mmol/l) 9.8± 4.1 6.5± 2.0
IR 2.1± 2.4 ■
Hypertension (%) 110 (78.6) •
Smoking (%) 19.0 39.3
MetS (%) 60 •
Data are means ± standard deviation. For the dichotomously coded, obese hypertension, 
smokers and metabolic syndrome, percentages are given. Number of subjects for each 
characteristic varies slightly due to occasional missing values. BMI body mass index; 
SBP systolic blood pressure; DBP diastolic blood pressure; HbA1c glycated 
hemoglobin; FBG fasting blood glucose; MetS metabolic syndrome; IR insulin 
resistance value estimated using the triglyceride/HDL-cholesterol index, values of ^ 3 
were considered insulin resistant. *Hypertension is defined as a systolic blood pressure 
(SBP)£ 130 mm Hg or diastolic blood pressure (DBP) £ 85 mm Hg or receiving 
antihypertensive medication therapy.
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3.2  S eru m  A d ip o n e c tin  Leve ls  in T 2 D M  P a tie n ts  and  in C o n tro ls
Samples without measured adiponectin and those which had readings 
outside the optical density range of the standards (either lower or higher) 
were excluded from the analysis. Twenty nine samples were excluded 
(eleven T2DM patient samples and eighteen control samples) for the 
following reasons: First, no serum sample was obtained from some 
participants (n= 5); only EDTA-coated tubes was available for the 
molecular analysis and there was a difficulty in obtaining a second 
sample from those participants. Second, some serum samples (n= 9) 
gave readings either below (n=5) or above (n= 4) the linear range of the 
serum adiponectin standards. Samples with low readings were below the 
limit of detection for this kit. Unfortunately it was not possible to dilute and 
re-analyze the samples which fell beyond the linear range because of 
logistical complications of delivery of additional ELISA kits to Bahrain 
coupled with funding constraints. Third, some serum samples tubes were 
not stored or handled properly (for example, 15 number of samples in 
plain tubes had not been centrifuged to separate the serum, or some 
were completely hemolyzed.
The serum adiponectin levels were measured in 129 T2DM patients and 
48 control subjects. The mean serum levels of adiponectin were 
significantly lower in subjects with T2DM compared to the control healthy 
subjects (total adiponectin 5.6 ± 4.1 vs 7.3 ± 4.6 pg/ml, P=0.020). 
Adjustment for age and BMI did not change mean adiponectin levels.
Table 3.2 Difference in serum adiponectin concentration between 
T2DM patients and controls
T2DM patients Control P-value*
n= 129
00IIc
Meant SD Meant SD
Adiponectin Cone, pg/ml 5.6t 4.1 7.314.6 0.020
Data are means ± standard deviation 
*T-test. P-value is significant at 0.05 level.
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To exclude that the results regarding the association of adiponectin with 
T2DM are subjected to bias due to unequal numbers of males and 
females in the diabetic and control groups given the higher level of 
adiponectin in females overall, a second comparison was conducted 
between male subjects (Table 3.3) and female subjects (Table 3.4) of 
both group. The mean serum levels of adiponectin were significantly 
lower in male subjects with T2DM compared to the control healthy 
subjects (total adiponectin 4.7± 3.5 vs 6.7± 3.6 pg/ml, 0.006) (Table 3.3).
Table 3.3 Difference in serum adiponectin concentration between 
male T2DM patients and controls
MaleT2DM 
patients 
n= 59
Male control 
subjects 
n= 42
P-value*
Meant SD Meant SD
Adiponectin Cone. |jg/ml 4.7± 3.5 6.7± 3.6 0.006
Data are means ± standard deviation 
*T-test. P-value is significant at 0.05 level.
The mean serum levels of adiponectin were significantly lower in female 
subjects with T2DM compared to the control healthy subjects (total 
adiponectin 6.3± 4.4 vs 11.0± 8.5 jjg/ml, 0.023) (Table 3.3).
Table 3.4 Difference in serum adiponectin concentration between 
female T2DM patients and controls
Female T2DM Female control
patients subjects P-value*
ii o n= 6
Meant SD Meant SD
Adiponectin Cone, pg/ml 6.3± 4.4 11.0± 8.5 0.023
Data are means ± standard deviation 
*T-test. P-value is significant at 0.05 level.
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Consistent with the results of previous studies (Arita et al., 1999, 
Nishizawa et al., 2002), total adiponectin levels were significantly higher 
in women than in men (6.3 ± 4.4 vs 4.7 ± 3.5 |jg/ml, P=0.024) in T2DM 
(Table 3.5) and (11 ± 8.5 vs 6.7 ± 3.6 pg/ml, P=0.032) in controls (Table 
3.6). Further, in men and women pair-matched for age, BMI, adiponectin 
concentrations remained greater in women (Data are not shown).
Table 3.5 Difference in serum adiponectin concentration between 
male and female subjects with T2DM
Diabetic
Male Female P-value*
n= 59
or-nc
Meant SD Mean± SD
Adiponectin Cone, pg/ml 4.7t 3.5 6.3± 4.4 0.024
Data are means ± standard deviation
*T-test. P-value is significant at 0.05 level.
Table 3.6 Difference in serum adiponectin concentration between
healthy control male and female subjects
Controls
Male Female P-value*
n= 42 n= 6
Meant SD Meant SD
Adiponectin Cone, pg/ml 6.7t 3.6 11.01 8.5 0.032
Data are means ± standard deviation
*T-test. P-value is significant at 0.05 level.
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3.3 Association between Serurri Adiponectin Levels and Clinical and 
Metabolic Parameters of the Study Population
The various cross-sectional associations of adiponectin in T2DM patients 
and controls are shown in Table 3.7. The demographic, clinical and 
metabolic characteristics of T2DM patients and controls were analyzed 
with serum adiponectin levels. Considering all diabetic subjects, serum 
adiponectin level showed significant inverse correlations with HbA1c, 
triglycerides and IR value estimated by the triglyceride/HDL-cholesterol 
index (P=0.039, P=0.020 and P=0.012 respectively), and also showed a 
positive correlation with HDL-C (P=0.036). No association was found 
with BMI, SBP, DBP, TC, LDL-C and FBG (P>0.05).
In the control group, there is no statistically significant association in the 
majority of the clinical and metabolic parameters with serum adiponectin 
levels. However, a very strong negative significant association was 
observed between SBP and serum adiponectin levels (P<0.0001). Other 
parameters were less strongly related to adiponectin levels.
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Table 3.7 Correlations of adiponectin to various clinical and 
metabolic parameters in both T2DM patients and control group
Adiponectin level
Diabetic Controls
n= 129 n= 48
Pearson Pearson
P-value P-value
Correlation Correlation
Age (yrs) 0.072 0.418 -0.093 0.531
BMI -0.151 0.236 0.077 0.618
SBP (mmHg) -0.050 0.582 -0.692 0.000**
DBP (mmHg) -0.059 0.510 -0.205 0.347
HbA1C (%) -0.182 0.039* -0.531 0.279
TC (mmol/l) 0.028 0.764 -0.545 0.342
HDL-C (mmol/l) 0.197 0.036* -0.531 0.357
LDL -C (mmol/l) -0.008 0.929 -0.462 0.433
TG (mmol/l) -0.217 0.020* 0.286 0.641
FBG (mmol/l) -0.013 0.882 -0.574 0.234
IR -0.235 0.012* • •
Data is presented as pearson coefficients. Correlation is significant at the 0.05 level (2- 
tailed). **Correlation is significant at the 0.01 level (2-tailed). BMI body mass index; SBP 
systolic blood pressure; DBP diastolic blood pressure; HbA1c glycated hemoglobin; TC 
total cholesterol; HDL-C high density lipoprotein cholesterol; LDL-C Low density 
lipoprotein cholesterol; TG triglycerides; FBG fasting blood glucose; IR insulin 
resistance value estimated using the triglyceride/HDL-cholesterol index, values of ^ 3 
were considered insulin resistant.
Gender-based analysis was evaluated for both T2DM Patients and 
controls to assess the impact of the demographic, clinical and metabolic 
parameters on serum adiponectin levels in men and women.
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3.3.1 T 2 D M  P a tien ts
Among T2DM patients, adiponectin had significant positive correlations 
with HDL-cholesterol levels and an inverse correlation with IR in men 
(P=0.015 and P=0.018 respectively). In women however, there were no 
statistically significant differences in any demographic, clinical and 
metabolic characteristics (Table 3.8).
Table 3.8 Correlations of adiponectin to various clinical and 
metabolic parameters among males and females of T2DM patients
Adiponectin level
Male Female
n= 59 n= 70
Pearson Pearson
P-value P-value
Correlation Correlation
Age (yrs) -0.057 0.670 0.204 0.090
BMI -0.299 0.103 -0.097 0.596
SBP (mmHg) -0.013 0.921 -0.093 0.449
DBP (mmHg) 0.071 0.599 -0.120 0.327
HbA1C (%) -0.231 0.078 -0.135 0.263
TC (mmol/l) 0.013 0.929 -0.022 0.866
HDL-C (mmol/l) 0.340 0.015* 0.034 0.794
LDL -C (mmol/l) -0.044 0.754 -0.012 0.926
TG (mmol/l) -0.263 0.059 -0.152 0.235
FBG (mmol/l) -0.049 0.713 0.036 0.768
IR -0.331 0.018* -0.124 0.339
Data is presented as pearson coefficients. Correlation is significant at the 0.05 level (2- 
tailed). BMI body mass index; SBP systolic blood pressure; DBP diastolic blood 
pressure; HbA1c glycated hemoglobin; TC total cholesterol; HDL-C high density 
lipoprotein cholesterol; LDL-C Low density lipoprotein cholesterol; TG triglycerides; FBG 
fasting blood glucose; IR insulin resistance value estimated using the triglyceride/HDL- 
cholesterol index, values of £ 3 were considered insulin resistant.
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3 .3 .2  C o n tro ls
In the control subjects, adiponectin did not show any significant 
correlations with the majority of the metabolic and clinical parameters in 
both genders. However, a strong negative association was observed 
between adiponectin levels and SBP in men (Table 3.9).
Table 3.9 Correlations of adiponectin to various clinical and 
metabolic parameters among males and females of the control 
group
Adiponectin level
Male Female
n= 42 n= 6
Pearson Spearman 
P-value P-value
Correlation* Correlation*
Age (yrs) -0.034 0.830 -0.696 0.125
BMI -0.052 0.744 1.000 •
SBP (mmHg) -0.630 0.002** -1.000 •
DBP (mmHg) -0.349 0.121 -1.000 •
HbA1C (%) -0.600 0.208
TC (mmol/l) -0.791 0.111
HDL-C (mmol/l) -0.500 0.391
LDL -C (mmol/l) -0.700 0.188
TG (mmol/l) -0.359 0.553
FBG (mmol/l) -0.771 0.072
*Data is presented as pearson coefficients, because the sample size of female control 
subjects is only 6, spearman coefficients were used (pearson coefficients could not be 
applied for female control subjects (n= 6)). **Correlation is significant at the 0.01 level 
(2-tailed). BMI body mass index; SBP systolic blood pressure; DBP diastolic blood 
pressure; HbA1c glycated hemoglobin; TC total cholesterol; HDL-C high density 
lipoprotein cholesterol; LDL-C Low density lipoprotein cholesterol; TG triglycerides; 
FBG fasting blood glucose; IR insulin resistance value estimated using the 
triglyceride/HDL-cholesterol index, values of £ 3 were considered insulin resistant.
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In pearson and spearman correlations, serum adiponectin levels did not 
show an independent role on BMI in both T2DM patients and controls. 
The only possible interaction between the serum adiponectin levels and 
the BMI status was therefore tested by subdividing the study participants 
according to the universal obesity cut-off point (ie below or above 30 
kg/m2). Number of subjects varies slightly due to occasional missing 
values. Serum adiponectin levels were significantly different between 
subjects with BMI above or below 30 (obese vs non-obese subjects) in 
T2DM patients (P=0.0013) (Table 3.10) and in controls (P=0.0008) 
(Table 3.11).
3.4  T h e  R e la tio n s h ip  b e tw e e n  S e ru m  A d ip o n e c tin  and  B M I
Table 3.10 Serum adiponectin levels of patients with T2DM 
according to the universal obesity cut-off point (< or > 30)
Diabetic
Adiponectin Cone, pg/ml P-value*
n Mean± SD
BMI < 30 16 6.6± 4.5 0.0013
>30 99 4.4± 2
Data are means ± standard deviation. BMI; body mass index. 
*T-test. P-value is significant at 0.05 level.
Table 3.11 Serum adiponectin levels of control subjects according 
to the universal obesity cut-off point (< or > 30)
Control
Adiponectin Cone, pg/ml P-value*
n Mean± SD
BMI <30 21 8± 3.1 0.0008
>30 18 4.9± 2
Data are means ± standard deviation. BMI; body mass index. 
*T-test. P-value is significant at 0.05 level.
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Figure 3.1 demonstrates the significantly lower adiponectin levels among 
obese (BMI <30) versus non obese (BMI > 30) diabetic and control 
subjects. It clearly appears from the graph that adiponectin levels in 
T2DM patients were uniformly low when compared to non- diabetic 
subjects.
i i 
D»ab*tic (P-value»0 0013) Control (P-valo#»0.001)
Figure 3.1 Comparison of plasma adiponectin levels in lean (BMI 
<30) and obese (BMI > 30) diabetic and control subjects. Vertical bars 
represent the mean adiponectin levels.
3.5 Serum Resistin Levels in T2DM Patients and Controls
Samples which were received with no serum or those which were not 
stored or handled properly were excluded (for details refer to section 
3.3). Six T2DM patients and 14 control cases were excluded from the 
analysis. As demonstrated in Table 3.12, T2DM patients had significantly 
higher serum resistin levels than healthy subjects (6.9 ± 6.2 ng/ml in 
patients vs. 4.9± 4.8 ng/ml in controls; P=0.022).
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T a b le  3 .12  D iffe re n c e  in se ru m  res is tin  c o n c e n tra tio n  b e tw een  T 2D M
p a tie n ts  and  co n tro ls
Diabetic Control P-value*
n= 134
CNJLOIIc
Meani SD Mean± SD
Resistin conc. (ng/ml) 6.9± 6.2 4.9± 4.8 0.022
Data are means ± standard deviation 
*T-test. P-value is significant at 0.05 level.
Gender-based analysis showed that serum resistin level is higher in male 
subjects than in females (8.1 ±7.3 ng/ml vs. 5.9 ± 4.9 ng/ml, P=0.033, 
Table 3.13) in T2DM patients. However, further adjustment for BMI 
decreased the magnitude of the associations and made it insignificant 
(P=0.184, Table 3.13). In healthy control subjects, resistin levels did not 
correlate with gender and their values remained unchanged after further 
adjustment of BMI and age (Table 3.14).
Table 3.13 Difference in serum resistin concentration between T2DM 
male and female patients
Diabetic
Male Female P-value* P-value**
n= 60______ n= 74
Mean± SD Mean± SD
Resistin conc. (ng/ml) 8.1±7.3 5.9±4.9 0.033 0.184
Data are means ± standard deviation. *P-value unadjusted; **P-value after adjustment 
for age and BMI.
T-test was used for P-value calculation. P-value is significant at 0.05 level.
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T a b le  3 .1 4  D iffe re n c e  in se ru m  res is tin  c o n c e n tra tio n  b e tw een
h e a lth y  co n tro l m a le  and  fe m a le  s u b je c ts
Control
Male Female P-value*
n= 46 n= 6
Meant SD Meant SD
Resistin conc. (ng/ml) 4.9± 5.0 5.0i 3.2 0.963
Data are means ± standard deviation 
*T-test. P-value is significant at 0.05 level.
3.6 Association between Serum Resistin Levels and Clinical and 
Metabolic Parameters of the Study Population
The demographic, clinical and metabolic characteristics of T2DM patients 
and controls were analyzed with serum resistin levels as shown in Table 
3.15. Considering all diabetic subjects, serum resistin level did not show 
significant correlations with any of the clinical and metabolic parameters. 
BMI index did not show any correlation with serum resistin levels, even 
after subdividing the study participants according to the universal obesity 
cut-off point (BMI > or < 30) (data are not shown).
In the control group, however, there was a weak negative association 
between BMI and serum resistin levels. Other clinical and metabolic 
parameters did not show significant correlations (P>0.05).
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Table 3.15 Correlations of serum resistin levels to various clinical 
and metabolic parameters in both T2DM patients and control group
Resistin level
Diabetic 
n= 134
Controls 
n= 52
Pearson
Correlation
P-value
Pearson
Correlation
P-value
Age (yrs) 0.109 0.202 -0.033 0.793
BMI -0.084 0.486 -0.266 0.037*
SBP (mmHg) -0.003 0.972 -0.002 0.992
DBP (mmHg) -0.078 0.364 0.000 0.999
HbA1C (%) 0.009 0.917 -0.617 0.192
TC (mmol/l) -0.075 0.403 0.726 0.165
HDL-C (mmol/l) -0.107 0.238 0.222 0.719
LDL -C (mmol/l) 0.007 0.938 0.797 0.107
TG (mmol/l) 0.127 0.156 0.667 0.218
FBG (mmol/l) -0.022 0.799 -0.591 0.217
IR 0.069 0.443 • •
Data is presented as pearson coefficients. Correlation is significant at the 0.05 level (2- 
tailed). BMI body mass index; SBP systolic blood pressure; DBP diastolic blood 
pressure; HbA1c glycated hemoglobin; TC total cholesterol; HDL-C high density 
lipoprotein cholesterol; LDL-C Low density lipoprotein cholesterol; TG triglycerides; FBG 
fasting blood glucose; IR insulin resistance value estimated using the triglyceride/HDL- 
cholesterol index, values of £ 3 were considered insulin resistant.
Gender-based analysis was evaluated for both T2DM Patients and 
controls to assess the impact of the demographic, clinical and metabolic 
parameters on serum resistin levels in men and women.
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3.6.1 T 2 D M  P a tien ts
There was no statistically significant difference in the relationship 
between the metabolic parameters and resistin level in men and women 
with T2DM (Table 3.16).
Table 3.16 Correlations of serum resistin levels to various clinical
and metabolic 
patients
parameters among males and females of T2DM
Resistin level
Male 
n= 60
Female 
n= 74
Pearson
Correlation
P-value
Pearson
Correlation
P-value
Age (yrs) 0.08 0.507 0.11 0.352
BMI -0.09 0.602 -0.095 0.629
SBP (mmHg) 0.08 0.529 -0.123 0.35
DBP (mmHg) -0.101 0.433 -0.216 0.10
HbA1C (%) 0.07 0.554 -0.169 0.197
TC (mmol/l) -0. 067 0.617 -0.14 0.266
HDL-C (mmol/l) -0.18 0.166 0.11 0.369
LDL -C (mmol/l) 0.08 0.562 -0.06 0.644
TG (mmol/l) 0.21 0.103 -0.14 0.245
FBG (mmol/l) 0.06 0.643 -0.15 0.197
IR 0.11 0.397 -0.17 0.175
Data is presented as pearson coefficients. Correlation is significant at the 0.05 level (2- 
tailed). BMI body mass index; SBP systolic blood pressure; DBP diastolic blood 
pressure; HbA1c glycated hemoglobin; TC total cholesterol; HDL-C high density 
lipoprotein cholesterol; LDL-C Low density lipoprotein cholesterol; TG triglycerides; FBG 
fasting blood glucose; IR insulin resistance value estimated using the triglyceride/HDL- 
cholesterol index, values of £ 3 were considered insulin resistant.
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3.6.2 Controls
As shown on Table 3.17, weak negative correlation was observed in the 
association between BMI and serum resistin in men (P= 0.033).
Table 3.17 Correlations of serum resistin levels to various clinical 
and metabolic parameters among males and females of the control 
group
Resistin level
Male Female
n= 46 n= 6
Pearson Spearman
P-value P-value
Correlation* Correlation*
Age (yrs) -0.011 0.935 -0.46 0.354
BMI -0.276 0.033** 0.20 0.747
SBP (mmHg) 0.011 0.952 • •
DBP (mmHg) -0.001 0.995 ■ •
HbA1 C (%) 0.79 0.111
TC (mmol/l) 0.30 0.624
HDL-C (mmol/l) 0.30 0.624
LDL -C (mmol/l) 0.67 0.219
TG (mmol/l) -0.37 0.468
FBG (mmol/l) -0.46 0.354
*Data is presented as pearson coefficients, because the sample size of female control
subjects is only 6, spearman coefficients were used (pearson coefficients could not be 
applied for female control subjects (n= 6). **Correlation is significant at the 0.05 level (2- 
tailed). BMI body mass index; SBP systolic blood pressure; DBP diastolic blood 
pressure; HbA1c glycated hemoglobin; TC total cholesterol; HDL-C high density 
lipoprotein cholesterol; LDL-C Low density lipoprotein cholesterol; TG triglycerides; FBG 
fasting blood glucose.
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3.7 Adiponectin and Resistin Levels in Relation to the Metabolic and 
Clinical Parameters in the whole Study Population
In an attempt to compare the role of adiponectin and resistin and 
emphasize their relations with the metabolic parameters, we analyzed 
the relationships of both adipokines with the various metabolic 
parameters in the whole study subjects. Adiponectin was found to 
correlate with a wide number of different biomarkers. Serum adiponectin 
correlated negatively to HbA1c (P=0.005), TG (P=0.017), and IR index 
(P=0.012). On the other hand, serum resistin showed no statistical 
significance in the association with the various metabolic parameters 
except a weak positive correlation with age (Table 3.18).
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Table 3.18 Comparison between the association of adiponectin and 
resistin with the metabolic and clinical parameter in the whole study 
subjects
Adiponectin Resistin
n= 177 n= 186
Pearson Pearson
P-vaiue P-vaiue
Correlation Correlation
Age (yrs) -.0068 0.371 0.165 0.018*
BMI -0.128 0.188 -0.044 0.613
SBP (mmHg) -0.130 0.114 0.041 0.596
DBP (mmHg) -0.096 0.246 -0.048 0.539
HbA1C (%) -0.238 0.005** 0.014 0.863
TC (mmol/l) -0.019 0.836 -0.062 0.484
HDL-C (mmol/l) 0.177 0.055 -0.116 0.190
LDL -C (mmol/l) -0.042 0.649 0.019 0.832
TG (mmol/l) -0.217 0.017* 0.137 0.120
FBG (mmol/l) -0.074 0.393 -0.016 0.845
IR -0.235 0.012* 0.069 0.443
Data is presented as pearson coefficients. Correlation is significant at the 0.05 level (2- 
tailed). ^Correlation is significant at the 0.01 level (2-tailed). BMI body mass index; SBP 
systolic blood pressure; DBP diastolic blood pressure; HbA1c glycated hemoglobin; TC 
total cholesterol; HDL-C high density lipoprotein cholesterol; LDL-C Low density 
lipoprotein cholesterol; TG triglycerides; FBG fasting blood glucose; IR insulin 
resistance value estimated using the triglyceride/HDL-cholesterol index, values of ^ 3 
were considered insulin resistant.
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3.8.1 Detection of Adiponectin Gene SNP +45T>G Polymorphism
The SNP +45T>G was detected by PCR and enzyme restriction 
reactions (Mackevics et al., 2006). The allele frequencies of the T and G 
alleles of the SNP +45T>G were 0.83 and 0.17 in T2DM patients and 
0.924 and 0.076 in the controls respectively (Table 3.19). Genotype 
frequencies were found to be in agreement with the Hardy-Weinberg 
equilibrium which is described by the binominal distribution: p2 + 2pq + 
q2= 1.0, thus fulfilling this requirement for the present study population.
The Hardy-Weinberg principle is one of the most fundamental principles 
in human genetics. It is the concept that both allele frequencies and 
genotype frequencies will remain constant from generation to generation 
in an infinitely large, interbreeding population in which mating is at random 
and there is no selection, migration or mutation. According to this 
principle under the mentioned conditions, distribution of genotypes in a 
population follows the law of the statistical probability.
3.8.2 Adiponectin Gene SNP +45T>G Distribution in T2DM Patients 
and Controls
The allele frequencies and genotype distributions of SNP +45T>G in 
T2DM patients and non-diabetic controls are summarized in Table 3.19. 
In T2DM group, 100 (71.4%) subjects were homozygous for the wild-type 
allele (TT), 32 (22.9%) were heterozygous (TG) and 8 (5.7%) were 
homozygous for the minor allele (GG). In the non-diabetic control group 
56 (84.8%) subjects were homozygous for the wild-type allele (TT), 10 
(15.2%) were heterozygous (TG) and none of the subjects were 
homozygous for the mutation (GG) (Table 3.19). The rare G allele of the
3.8 Analysis of the Adiponectin Gene SNP +45T>G Polymorphism
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SNP +45T>G showed a minor allele frequency (MAF) of 17.1% in T2DM 
patients and 7.6% in the controls.
There was a statistically significant difference in allele frequencies and 
genotype distributions of SNP +45T>G in the diabetic and control groups 
(T frequency 83% vs. 92.4%, and G frequency 17% vs. 7.6%, P=0.009, 
OR= 1.8) and (TT genotype 71.4% vs. 84.8%, P=0.046 and TG+GG 
genotype 28.6% vs. 15.2%, P=0.046, OR= 2.52), respectively (Table 
3.19). The G allele and T/G + G IG  genotype occurred more frequently 
than the T allele in T2DM patients compared to the controls (P<0.05). 
Subjects with the G IG  genotype were at increased risk for T2DM 
compared with those having the T/T genotype. This finding is consistent 
with published data showing that the G allele of SNP +45 is significantly 
associated with T2DM (Hara et al., 2002, Mohammadzadeh and 
Zarghami, 2009).
Table 3.19 Differences in genotype and allele frequencies of 
adiponectin gene SNP +45 between diabetic and control subjects
Diabetic Control P-value*
n % n %
Genotype T/T 100 71.4 56 84.8
frequency SNP +45 T/G 32 22.9 10 15.2 0.046
G IG 8 5.7 0 0
Allele
SNP +45
T 232 83 122 92.4
0.009
frequency G 48 17 10 7.6
Data are numbers (n) and percentages (%).*Chi-square test. P-value is significant at 
0.05 level.
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3.8.3 Relationship between the SNP +45T>G Genotypes and Serum 
Adiponectin Levels in T2DM Patients and Controls
Table 3.20 states the mean serum adiponectin concentrations per SNP 
+45T>G genotypes. The mean values were divided via a general linear 
model adjusting for age, gender and BMI. Twenty nine samples without 
measured adiponectin were excluded from the analysis but their 
genotypes were detected and calculated in allele and genotypes 
frequencies. The P-values testing for association of a single nucleotide 
polymorphism (SNP) genotypes with adiponectin concentrations with and 
without adjustment are given. All analyses were readjusted for age, BMI 
and gender. Adjustment for age neither changed mean adiponectin levels 
nor the gene effect. Adjustment for gender changed the mean adiponectin 
values as adiponectin plasma levels differ between male and female 
subjects. Adjustment for BMI did slightly reduce the strength of 
association the difference of the mean adiponectin levels between the 
genotype groups, but the effect of adjusting for BMI was relatively small 
compared to the strong gene effect of adiponectin.
Considering all study population, the mean serum adiponectin levels were 
significantly different between the three genotype subgroups of the SNP 
+45T>G. It can be seen that there is a significant association between the 
SNP +45T>G genotypes and serum adiponectin levels. Further 
adjustment for BMI, age and gender did not substantially change these 
results. A clear multiplicative trend of decreasing adiponectin levels per 
copy of the rare allele (G) can be observed (6.9, 3.7, 2.1 pg/ml for the T/T, 
the T/G and the G/G genotypes in the +45 locus respectively, P-values <
0.0001), thus suggesting a possible influence of the SNP +45T>G on 
adiponectin levels. When the male and female subjects were analyzed 
separately, same gene effects on serum adiponectin levels were 
observed.
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Table 3.20 Serum adiponectin levels in whole study subjects with
different genotypes for the +45T>G polymorphism
n
Adiponectin Cone, pg/ml 
Meant SD
P* p**
T/T 134 6.9t 4.3
SNP +45T>G, T/G 36 3.7± 3.2 0.000 0.000
Total G IG 7 2.1± 2.2
T/T 79 6.4± 3.6
SNP +45T>G, T/G 19 2.7±1.9 0.000 0.001
Males G IG 3 1.4± 2.5
T/T 55 7.5± 5.1
SNP +45T>G, T/G 17 4.9± 3.9 0.035 0.038
Females G IG 4 2.6 ±2.1
Data presented as mean ± standard deviation, *P-value unadjusted; **P-value adjusted 
for age, BMI (and gender in case total sample was tested). P-values are calculated from 
univariate general linear model. P-value is significant at 0.05 level.
Further analysis of T2DM patients revealed that the plasma adiponectin 
concentration of TG+GG genotype carriers were significantly different 
from that of TT genotype. The G allele was associated with lower serum 
adiponectin levels compared to the T allele carriers (6.5± 4.1 pg/ml for 
T/T genotype, 3.7± 3.4 pg/ml for the T/G genotype and 2.1±2.2 pg/ml for 
the G IG  genotype, P<0.001). When male and female subjects with T2DM 
were analyzed separately, same gene effects on serum adiponectin levels 
were observed with a more significant association towards the male 
subjects (P=0.001 vs 0.044) (Table 3.21).
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Table 3.21 Serum adiponectin levels in T2DM patients with different
genotypes for the +45T>G polymorphism
n
Adiponectin Cone, pg/ml 
Mean± SD P* p**
T/T 92 6.5± 4.1
SNP +45T>G, T/G 30 3.7±3.4 0.000 0.005
Total G IG 7 2.1±2.2
T/T 43 5.7± 3.5
SNP +45T>G, T/G 13 2.2± 2 0.001 0.013
Males G IG 3 1.4± 2.5
T/T 49 7.1± 4.5
SNP +45T>G, T/G 17 4.9+ 3.9 0.044 0.341
Females G IG 4 2.6± 2.1
Data presented as mean ± standard deviation, *P-value unadjusted; **P-value adjusted 
for age, BMI (and gender in case total sample was tested). P-values are calculated from 
univariate general linear model. P-value is significant at 0.05 level.
In the control group, the frequency of the G IG  genotype was zero; 
therefore the comparison was made between the T/G and T/T genotypes 
only. As demonstrated from Table 3.22, the plasma levels of adiponectin 
of TG genotype were significantly lower than that of the TT genotype and 
the same was observed when analyzing the male subjects separately 
(Table 3.22).
89
Table 3.22 Serum adiponectin levels in control subjects with
different genotypes for the +45T>G polymorphism
Adiponectin Cone, pg/ml
n Mean ± SD P* P**
T/T 42 7.8± 4.3
- - A  rv Q
SNP +45T>G, T/G 6 3.8± 1.1 0.048 uuy
Total G IG 0 •
T/T 36 7.2± 3.7
SNP +45T>G, T/G 6 3.8± 1.1 0.032 0.037
Males G IG 0 -
T IT 6 11 ± 8.5
SNP +45T>G, TIG 0 .
Females G IG 0 ■
Data presented as mean ± standard deviation, *P-value unadjusted; **P-value adjusted 
for age, BMI (and gender in case total sample was tested). P-values are calculated from
univariate general linear model. P-value is significant at 0.05 level.
3.8.4 Association between the SNP +45T>G Genotypes and Clinical 
and Metabolic Parameters of the Study Subjects
To assess whether the SNP +45T>G genotypes had any effect on 
anthropometric and insulin resistance indices; we compared 
anthropometric and metabolic characteristics among genotype 
subgroups. A series of metabolic and clinical parameters (Age, BMI, 
systolic and diastolic blood pressure, HbA1c, total cholesterol, HDL and 
LDL cholesterol, triglycerides, fasting blood glucose and insulin 
resistance estimated by triglyceride/HDL-cholesterol index) were 
analyzed with respect to their association with SNP +45T>G genotypes 
in T2DM patients (Table 3.23). Due to incomplete clinical data for the 
control cohort, the correlation was only evaluated for T2DM patients. 
Considering all diabetic patients, no significant difference in metabolic 
parameters among T/T, T/G and G IG  carriers was observed. The values
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of BMI, SBP, DBP, HbA1c, total, HDL and LDL cholesterol, triglycerides, 
fasting blood glucose and insulin resistance were not different in these 
three genotype subgroups.
Table 3.23 Clinical and metabolic characteristics of the diabetic 
subjects according to adiponectin SNP +45T>G genotypes
SNP +45T>G
T IT  T IG  G IG
Meant SD Mean± SD Mean± SD P* p~
n 100 32 8
Age (yrs) 59±12 59± 10 52±7.6 0.231 0.489
BMI 34.0± 7.3 35.2±6.9 32.2±3.4 0.690 0.509
SBP (mmHg) 145± 20 150±28 156±19 0.295 0.352
DBP (mmHg) 77±12 74±14 81 ±19 0.377 0.516
HbA1c % 8.08±1.64 8.39±2.08 7.4±1.4 0.314 0.497
TC (mmol/l) 4.5±1.0 4.7±1.0 4.5±0.7 0.542 0.531
HDL-C (mmol/l) 1.2±0.4 1.2±0.3 1.2±0.4 0.915 0.802
LDL-C (mmol/l) 2.7±0.8 2.9±0.8 2.8±0.6 0.701 0.223
TG (mmol/l) 2.0+1.6 2.4±1.9 1.5±0.6 0.328 0.679
FBG (mmol/l) 9.8±4.1 10.2±4.3 7.7±1.1 0.285 0.649
IR 2.0±2.5 2.5±2.6 1.5±1.0 0.5 0.861
Data presented as mean ± standard deviation, *P-value unadjusted; **P-value adjusted 
for age, BMI and gender. P-values are calculated from univariate general linear model. 
P-value is significant at 0.05 level.
Further analysis of male and female subjects with T2DM revealed no 
significant association in the metabolic parameters among the different 
genotype subgroups of SNP +45T>G (Table 3.24) and (Table 3.25). 
Tested indices were not different in the three genotype subgroups in both 
genders (P-value > 0.05).
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Table 3.24 Clinical and metabolic characteristics of the diabetic
male subjects according to adiponectin SNP +45T>G genotypes
SNP +45T>G
T/T T/G G IG P* p..
Mean± SD Meant SD Mean± SD
n 47 15 4
Age (yrs) 60± 12 61 ± 12 52.8±10 0.464 0.946
BMI 32.1± 6.4 36.9± 6.6 34± 5 0.170 0.178
SBP (mmHg) 142± 22 149± 17 153.8±14.7 0.363 0.521
DBP (mmHg) 77± 12 76± 12 79.3±10.1 0.881 0.508
HbA1c % 8.11± 1.87 8.76± 2.28 7.4±1.7 0.369 0.518
TC (mmol/l) 4. 4± 1.2 4.5± 1.0 4.6± 0.7 0.886 0.948
HDL-C (mmol/l) 1.1± 0.4 1.0± 0.3 1.3±0.6 0.529 0.867
LDL-C (mmol/l) 2.7± 0.9 2.7± 0.9 2.9± 0.31 0.885 0.850
TG (mmol/l) 2.2± 2.1 2.7± 1.9 1.8± 0.56 0.635 0.946
FBG (mmol/l) 10.0± 3.8 11.0± 4.9 7.5± 0.8 0.285 0.174
IR 2.4± 3.4 3.1± 2.5 1.7± 1.2 0.690 0.943
Data presented as mean ± standard deviation, *P-value unadjusted; **P-value adjusted 
for age and BM1. P-values are calculated from univariate general linear model. P-value 
is significant at 0.05 level.
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Table 3.25 Clinical and metabolic characteristics of the female
subjects according to adiponectin SNP +45T>G genotypes
SNP +45T>G
T IT T/G G IG
Meant SD Mean± SD Mean± SD P* P**
n 53 17 4
Age (yrs) 58± 12 58± 9 50.815.6 0.486 0.460
BMI 35.9± 7.6 33.2± 7.2 31± 2.5 0.391 0.291
SBP (mmHg) 147± 18 150± 36 158.5± 25.3 0.656 0.721
DBP (mmHg) 77± 13 73± 15 83± 27.1 0.395 0.070
HbA1c % 8.05± 1.43 8.07± 1.90 7.3± 1.4 0.656 0.956
TC (mmol/l) 4.6± 0.8 4.9± 1.0 4.4± 0.7 0.375 0.341
HDL-C (mmol/l) 1.2± 0.3 1.3± 0.3 1.2±0.4 0.832 0.742
LDL-C (mmol/l) 2.8± 0.7 3.0± 0.8 2.7±0.4 0.631 0.307
TG (mmol/l) 1.8± 0.8 2 .1 l 1.9 1.310.5 0.421 0.327
FBG (mmol/l) 9.7± 4.3 9.5+ 3.7 811.3 0.703 0.522
IR 1.6± 0.9 2.0± 2.7 1.3+ 0.9 0.625 0.846
Data presented as mean ± standard deviation, *P-value unadjusted; **P-value adjusted 
for age and BMI. P-values are calculated from univariate general linear model. P-value 
is significant at 0.05 level.
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3.9 Analysis of the Adiponectin SNP +276G>T Polymorphism
3.9.1 Detection of the Adiponectin Gene SNP +276G>T 
Polymorphism
The SNP +276G>T was detected by PCR and enzyme restriction 
reactions (Mackevics et al., 2006). The allele frequencies of the G and T 
alleles of the SNP +276G>T were 0.957 and 0.043 in T2DM patients 
and 0.923 and 0.077 in the controls respectively. Genotype frequencies 
were found to be in agreement with the Hardy-Weinberg equilibrium 
which is described by the binominal distribution: p2 + 2pq + q2= 1.0
3.9.2 Adiponectin Gene SNP +276G>T Distribution in T2DM Patients 
and Controls
The genotype and allele frequencies of SNP +276G>T polymorphism in 
T2DM patients and in controls are shown in Table 3.26. The frequencies 
of the G/G, T/G, and TfT  genotypes of SNP +276G>T were 92.9%, 
5.7%, and 1.4% in T2DM patients and 87.9%, 9.1%, and 3% in the 
controls, respectively. The rare T allele of the SNP +276G>T showed a 
minor allele frequency (MAF) of 4.3% and 7.6% in T2DM patients and 
controls respectively. As can be seen from Table 3.26 there was no 
statistically significant difference in allele frequencies and genotype 
distributions of SNP +276G>T comparing type 2 diabetic subjects with 
control group (T frequency 4.3% vs. 7.6%, and G frequency 95.7% vs. 
92.4%, P=0.166) and GG genotype 92.9% vs. 87.9%, P=0.480 and T/G 
+ TfT  genotype 7.1% vs. 12.1%, P=0.480), respectively.
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Table 3.26 Differences In genotype and allele frequencies of 
adiponectin SNP +276G>T between diabetic and non-diabetic 
subjects
Diabetic Control P-value
n % n %
Genotype
SNP
G IG 130 92.9 58 87.9
Frequency
+276
J IG 8 5.7 6 9.1 0.480*
T/T 2 1.4 2 3.0
Allele SNP G 268 95.7 122 92.4 0.166**
frequency +276 T 12 4.3 10 7.6
Data are numbers (n) and percentages (%). *Cramer’s V test, **Chi-square test. P-value 
is significant at 0.05 level.
3.9.3 Relationship between SNP +276G>T and Serum Adiponectin 
Levels in T2DM Patients and Controls
Table 3.27 displays the mean serum adiponectin concentrations per 
genotype. The mean values were divided via a general linear model 
adjusting for age, gender and BMI. Twenty nine samples without 
measured adiponectin were excluded from the analysis but their 
genotypes were detected and calculated in allele and genotypes 
frequencies. The P-values testing for association of a single nucleotide 
polymorphism (SNP) genotypes with adiponectin concentrations with and 
without adjustment are given. All analyses we adjusted for age, BMI and 
gender. Adjustment for age neither changed mean adiponectin levels nor 
the gene effect. Adjustment for gender changed the mean adiponectin 
values as adiponectin differ between male and female subjects. 
Adjustment for BMI did slightly reduce the strength of association the 
difference of the mean adiponectin levels between the genotype groups, 
but the effect of adjusting for BMI was relatively small compared to the 
strong gene effect of adiponectin.
95
Considering all the study population, there was no significant difference in 
the mean serum adiponectin levels between the three genotypes 
subgroups of the SNP +276G>T (P>0.05). When the male and female 
subjects were analyzed separately, no significant difference of serum 
adiponectin levels were observed in male subjects. Although females 
showed a slight association with serum adiponectin level in G/G and T/G 
genotypes of SNP +276G>T, further adjustment for age and BMI changed 
the results substantially, thus the association can’t prove to be significant 
as the frequency of the T/T genotype among females is zero.
Table 3.27 Serum adiponectin levels in whole study subjects with 
different genotypes for the SNP +276G>T polymorphism
n
Adiponectin Cone, pg/ml 
Mean± SD P* p**
G/G 160 5.8±4.7
SNP +276G>T, T/G 13 8.3+5 0.082 0.186
Total T/T 4 8± 2.6
G/G 88 5.3± 3.7
SNP +276G>T, T/G 9 6.5± 3.4 0.273 0.322
Males T/T 4 8± 2.6
G/G 72 6.4±2.6
SNP +276G>T, T/G 4 12.4±6.2 0.016 0.254
Females T/T 0 ■
Data presented as mean ± standard deviation, *P-value unadjusted; **P-value adjusted 
for age, BMI (and gender in case total sample was tested). P-values are calculated from 
univariate general linear model. P-value is significant at 0.05 level.
Further analysis of T2DM patients revealed that the effects of the SNP 
+276G>T genotypes on adiponectin concentration did not prove to be 
statistically significant. When males and female subjects with T2DM were 
analyzed separately, there was no significant association between the 
different genotypes of SNP +276G>T with serum adiponectin levels in the 
male subjects with T2DM. Although females showed an association in the
unadjusted serum levels, but as mentioned earlier, since the frequency of 
T/T genotype among females was zero, this association could not be 
confirmed (Table 3.28).
Table 3.28 Serum adiponectin levels in diabetic subjects with 
different genotypes for the SNP +276G>T polymorphism
n
Adiponectin Cone, pg/ml 
Meant SD P* p**
G IG 119 5.3± 3.9
SNP +276G>T, T/G 8 9.1± 5.8 0.042 0.101
Total T/T 2 5.8± 1.7
G IG 53 4.6± 3.6
SNP +276G>T, T/G 4 5.8± 3.5 0.732 0.283
Males T/T 2 5.9± 1.7
G IG 66 6.0± 4.0
SNP +276G>T, T/G 4 12.4±6.2 0.004 0.080
Females T/T 0 ■
Data presented as mean ± standard deviation, *P-value unadjusted; **P-value adjusted 
for age, BMI (and gender in case total sample was tested). P-values are calculated from 
univariate general linear model. P-value is significant at 0.05 level.
In the control group, as demonstrated from Table 3.29, there was no 
statistically significant association between the serum adiponectin levels 
and the different genotypes of SNP +276G>T. No association was 
observed when analyzing the male subjects separately. The association 
between the serum levels and SNP +276G>T genotypes can’t be 
evaluated on females as the frequencies of the T/G and T/T genotypes 
were zero.
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Table 3.29 Serum adiponectin levels in control subjects with different
genotypes for the SNP +276G>T polymorphism
n
Adiponectin Cone. Mg/ml 
Mean± SD P* p**
G IG 41 7.15± 4.9
SNP +276G>T, T/G 5 7.1± 3.6 0.694 0.239
Total T/T 2 10.1± 0.23
G IG 35 6.5± 3.7
SNP +276G>T, T/G 5 7.1± 3.6 0.403 0.389
Males T/T 2 10.1 ± 0.23
G IG 6 11 ±8.5
SNP +276G>T, T/G 0 • •
Females T/T 0
Data presented as mean ± standard deviation, *P-value unadjusted; **P-value adjusted 
for age, BMI (and gender in case total sample was tested). P-values are calculated from 
univariate general linear model. P-value is significant at 0.05 level.
3.9.4 Association between SNP +276G>T Genotypes and Clinical 
and Metabolic Parameters of the Study Subjects
In a secondary analysis, a series of metabolic and clinical parameters 
(age, BMI, systolic and diastolic blood pressure, HbA1c, total, HDL and 
LDL cholesterol, triglycerides, fasting blood glucose and insulin 
resistance estimated by triglyceride/HDL-cholesterol index) were 
analyzed with respect to their association with SNP +276G>T genotypes 
in T2DM patients (Table 3.23). Due to incomplete clinical data for the 
control cohort, the correlation was only evaluated for T2DM patients. 
Considering all diabetic patients, no significant difference in the metabolic 
parameters among G IG , T/G and T/T carriers was observed. The values 
of BMI, HbA1c, total, HDL and LDL cholesterol, triglycerides, fasting 
blood glucose and insulin resistance were not different in these three 
genotype subgroups (P>0.05). Concerning adiposity, we did not find an
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association between any genotypes in SNP +276G>T and adiposity 
measurements, including BMI.
Table 3.30 Clinical and metabolic characteristics of the diabetic 
subjects according to adiponectin SNP +276G>T genotypes
SNP +276G>T
G IG  J IG T/T
Mean ±SD Mean ±SD Mean ±SD P* p..
n 130 8 2
Age (yrs) 58+ 11 59± 16 68±21 0.530 0.128
BMI 34.0± 7.0 36.6± 7.2 36.7± 7.5 0.673 0.434
SBP (mmHg) 147± 23 143± 20 128± 23 0.447 0.210
DBP (mmHg) 77± 13 77± 8 65± 23 0.423 0.125
HbA1c % 8.12+1.70 8.65± 2.26 5.93± 0.89 0.143 0.248
TC (mmol/l) 4.6± 1.0 4.3± 1.1 3.6± 0.9 0.266 0.231
HDL-C (mmol/l) 1.2±0.3 1.1± 0.3 1.3± 0.2 0.691 0.460
LDL-C (mmol/l) 2.8±0.8 2.8±0.9 2.1± 0.6 0.445 0.281
TG (mmol/l) 2.1 ±1.7 1.8± 0.6 0.8± 0.1 0.479 0.858
FBG (mmol/l) 9.7± 4.0 _12.2± 4.4 7.4± 0.8 0.158 0.188
IR 2.1± 2.5 1,7± 0.7 0.6± 0.1 0.642 0.901
Data presented as mean ± standard deviation, *P-value unadjusted; **P-value adjusted 
for age, BMI and gender. P-values are calculated from univariate general linear model. 
P-value is significant at 0.05 level.
Further analysis of male subjects with T2DM revealed no significant 
association in the metabolic parameters among the different genotype 
subgroups of SNP +276G>T (Table 3.31). However in female subjects, 
HbA1c showed a significant association in which the T allele carriers 
showed higher values of HbA1c compared to the G allele carriers 
(P<0.05) (Table 3.32). Other indices were not different in the three 
genotype subgroups in both genders (P>0.05). The results suggested 
that adiponectin gene SNP +276G>T has a very weak effect on the
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metabolic and clinical parameters in the subjects with T2DM of the 
present study.
It should be acknowledged that there is a large number of significance 
tests carried out in this study and this is bound to give rise to false 
positives (multiple testing) which could not be ruled out.
Table 3.31 Clinical and metabolic characteristics of the male diabetic 
subjects according to adiponectin SNP +276G>T genotypes
SNP +276G>T
G IG T/G T/T
Meant SD Mean± SD Mean± SD P* P**
n 60 4 2
Age (yrs) 59±12 61 ±11 68±21 0.595 0.180
BMI 32.9+6.5 40. 3±7.1 36.7±7.5 0.275 0.267
SBP (mmHg) 145±21 142±23 128± 23 0.520 0.136
DBP (mmHg) 78±11 77±9 65± 23 0.299 0.094
HbA1c % 8.3±1.95 7.6±2.03 5.9 0.89 0.192 0.088
TC (mmol/l) 4.4±1.1 4.3±1.4 3.6± 0.9 0.528 0.261
HDL-C (mmol/l) 1.1 ±0.4 1.0±0.4 1.3± 0.2 0.794 0.599
LDL-C (mmol/l) 2.7±0.8 2.9±1.1 2.1± 0.6 0.489 0.177
TG (mmol/l) 2.4±2.1 1.6±0.6 0.8± 0.1 0.429 0.919
FBG (mmol/l) 10.2±4.1 9.5±3.7 7.4± 0.8 0.599 0.210
IR 2.6±3.3 1.7±0.8 0.6± 0.1 0.585 0.968
Data presented as mean ± standard deviation, *P-value unadjusted; **P-value adjusted 
for age and BMI. P-values are calculated from univariate general linear model. P-value 
is significant at 0.05 level.
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Table 3.32 Clinical and metabolic characteristics of the diabetic
female subjects according to adiponectin SNP +276G>T genotypes
SNP +276G>T
G IG T/G T/T
Mean± SD Meant SD Mea n± SD P* P**
n 70 4 0
Age (yrs) 58±11 56±22 0.770 0.716
BMI 35.1 ±7.5 34.2±7.5 0.849 0.979
SBP (mmHg) 149±24 145±21 0.719 0.918
DBP (mmHg) 76±15 77±7 0.996 0.920
HbA1c % 7.9±1.6 9.7±2.2 0.024 0.003
TC (mmol/l) 4.7±0.9 4.2±0.7 0.358 0.614
HDL-C (mmol/l) 1.2±0.3 1.1±0.1 0.557 0.526
LDL-C (mmol/l) 2.8±0.7 2.5±0.6 0.497 0.787
TG (mmol/l) 1.8±1.2 2.0±0.6 0.815 0.631
FBG (mmol/l) 9.3±4.0 15±3.5 0.006 0.000
IR 1.7±1.6 1.8±0.6 0.903 0.629
Data presented as mean ± standard deviation, *P-value unadjusted; **P-value adjusted 
for age and BMI. P-values are calculated from univariate general linear model. P-value 
is significant at 0.05 level.
It was not possible to perform haplotype analysis for the SNPs +45T>G 
and +276G>T. Due to the small sample size, the number of cases that 
harbored the homozygous polymorphic allele of both SNPs was very 
small; this did not allow us to see the expected variations in haplotypes 
defined by these two SNPs. For example, none of the subjects harbored 
the homozygous or heterozygous genotype of both SNPs at a time. The 
most frequently seen haplotype was of one allele showing the wild type 
genotype of one SNP and another allele showing the homozygous or 
heterozygous genotype of the other SNP. Thus, haplotypes analysis 
does not add any significance to the findings of studying these SNPs 
separately.
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C h a p t e r  4 -  D i s c u s s i o n
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4.1 Analysis of Serum Adipokines Levels
4.1.1 The Relationship between Adiponectin, T2DM and Metabolic 
Parameters
Over the last 10 years, several clinical and experimental data have 
radically modified the concept of adipose tissue as an organ devoted to 
energy storage and release. Adipose tissue is now considered to be an 
important endocrine organ. It can release hormones into the blood 
stream in response to specific extra-cellular stimuli or changes in 
metabolic status. The factors secreted by adipose tissue are actively 
involved in energy homeostasis. They signal to the brain, the pancreatic 
3-cells, the liver and skeletal muscle in order to adapt to changes in 
energy stores through modulating feeding, insulin secretion and insulin 
sensitivity (Richelsen et al., 2001). Secreted factors include leptin; 
steroids and glucocorticoids; peptide hormone precursors, e.g. 
angiotensinogen; complement factors, e.g. adiponectin (which resembles 
complement factor C1q), adipsin, acylation-stimulating protein (ASP); 
pro-inflammatory cytokines, e.g. tumor necrosis factor a (TNF-a), 
interleukin 6 (IL-6); resistin; etc. These adipokines engage, through 
endocrine, paracrine, autocrine or juxtacrine mechanisms of action, in a 
wide variety of physiological or pathological processes, including 
immunity and inflammation (Otero et al., 2005, Karastergiou and 
Mohamed-Ali, 2010).
Adiponectin is an adipocyte derived hormone expressed abundantly in 
adipose tissue whose levels are lower in T2DM patients than in non 
diabetic subjects (Wannamethee et al., 2007). Thus, adiponectin has 
increasingly been considered to be a potential biomarker and possible 
therapeutic target for T2DM. Adiponectin has many metabolic actions 
involving the regulation of energy homeostasis, particularly energy 
expenditure. In the present study, we examined the serum 
concentrations of adiponectin in a sample of Bahraini type 2 diabetic
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patients and in non diabetic subjects with varying degrees of obesity. The 
results demonstrate that serum adiponectin levels are significantly lower 
in subjects with T2DM than in those without diabetes even after 
correction for age and BMI. However, after dividing the study participants 
according to the universal obesity cut-off point (ie below or above 30 
kg/m2), obese diabetic patients (BMI > 30) showed a more decreased 
adiponectin level than non-obese diabetic patients (BMI < 30). 
Additionally, when adiponectin levels were compared in lean and obese 
diabetic and non-diabetic subjects (Figure 3.1), it was evident that 
adiponectin levels in T2DM patients were uniformly low comparing to non 
diabetic subjects. These results demonstrate a clear significant 
relationship between plasma adiponectin concentrations and T2DM.
These results are consistent with findings of a longitudinal study on 
Japanese population by Daimon et a/. who indicated 
hypoadiponectinemia to be a risk factor for the development of type 2 
diabetes mellitus (Daimon et al., 2003). Baratta et al. and Vendrell et al. 
also found decreased levels of serum adiponectin concentrations in 
obese and diabetic subjects and significant inverse associations with 
some measures of insulin resistance (Baratta et al., 2004, Vendrell et al., 
2004). There are some possible explanations for the association between 
T2DM and serum adiponectin concentrations. The lower levels of 
adiponectin seen in diabetic patients are believed to be associated with 
the disorder of metabolism of glucose and lipid in diabetes (Lu et al.,
2006, Karbowska and Kochan, 2006). Diabetic obese patients 
demonstrate more deteriorated glucose metabolism exhibited by 
impaired glucose tolerance, or impaired fasting glucose and had also 
higher serum free fatty acids, higher total and LDL-cholesterol, higher 
triglycerides, and lower HDL levels, which could also be contributing 
factors to the lower adiponectin levels.
Our finding of an inverse relationship between BMI and adiponectin 
concentrations in Bahraini subjects is in agreement with previous reports 
in Japanese subjects (Arita et al., 1999), Pima Indians and Caucasians
(Weyer et al., 2001). Arita et al. in 1999 showed that adiponectin was 
abundantly present in the plasma of healthy volunteers; whereas in 
obese subjects, the levels were significantly lower, although adiponectin 
is secreted only from adipose tissue. Weyer et al. in their study in 2001 
found that obesity and type 2 diabetes are associated with low plasma 
adiponectin concentrations in different ethnic groups and indicate that the 
degree of hypoadiponectinemia is more closely related to the degree of 
insulin resistance than to the degree of adiposity and glucose 
intolerance. It is interesting that adiponectin levels are decreased in 
obese subjects with more fat tissue which could produce more 
adiponectin. Some researchers speculate that the suppression of 
adiponectin production in obesity may be mediated by an autocrine 
negative feedback inhibition in white adipose tissue (WAT), for instance, 
lower expression of adiponectin mRNA was found in cultured human 
visceral WAT from obese subjects as compared to visceral WAT from 
lean subjects. Moreover, microarray studies demonstrated that 
adiponectin expression is suppressed with the development of obesity 
and diabetes in mice (Lopez et al., 2004).
Previous reports showed that plasma adiponectin levels are affected by 
multiple factors including gender, age and lifestyle (Kadowaki et al., 
2006). In this study we aimed to elucidate the impact of gender on 
adiponectin levels in T2DM and control subjects. Female subjects have 
significantly higher adiponectin levels compared to male subjects in both 
T2DM patients and controls. Our observations of the influence of gender 
suggest that adiponectin production is also related to factors independent 
of body weight. At any particular body size or body weight, adiponectin 
concentrations are greater in women than in men. Further, in men and 
women pair-matched for age, BMI, adiponectin concentrations were 
greater in women. This finding of a sex-based difference in plasma 
adiponectin concentrations is supported by some (Arita et al., 1999, 
Zoccali et al., 2002, Nishizawa et al., 2002) but not all other studies 
(Weyer et al., 2001, Comuzzie et al., 2001). However, the current 
findings strongly support the concept that gender has an additional
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independent effect to modulate adiponectin concentrations. The reasons 
for this remain speculative. It is suggested that the sex hormones 
regulate the production of adiponectin, although it is controversial how 
these hormones are involved in the regulation of plasma adiponectin 
levels (Kadowaki et al., 2006). Nishizawa et al. reported in their study 
that androgens decrease plasma adiponectin concentrations in vivo as 
well as adiponectin secretion from 3T3-L1 adipocytes in vitro (Nishizawa 
et al., 2002). The variation in adiponectin concentrations can also be 
explained in terms of body fat variation between genders. The number of 
fat cells and fat cell size, both of which differ between genders, are 
possible determinants of adiponectin production rates (Blaak, 2001).
Hypoadiponectinemia has been shown to be closely associated with the 
clinical phenotype of metabolic syndrome (Ryo et al., 2004, Hulthe et al.,
2003). Associations between adiponectin and hypertension (Imatoh et 
al., 2008), insulin resistance (Hivert et al., 2008, Weyer et al., 2001) and 
dyslipdemia (Komatsu et al., 2007) have been reported. The present 
study assessed the association between serum adiponectin and various 
metabolic parameters. We examined the relationships between plasma 
adiponectin concentrations, blood pressure, glycemic profile, lipid profile 
and insulin resistance. The impact of gender was also assessed in these 
relationships. Our data is consistent with the findings of the above- 
mentioned studies and indicate that adiponectin plays an important role 
in metabolic syndrome. While our study is cross-sectional and therefore 
does not establish cause and effect relationships, we observed a number 
of interesting associations. We found that in T2DM patients, plasma 
adiponectin correlate negatively with insulin resistance index, triglyceride 
and HbA1c and correlate positively with HDL-C. In control subjects, we 
did not find such associations, but we did find a strong negative 
correiation between systolic blood pressure and adiponectin levels. 
These findings agree well with those published by Wang et al. in which 
fasting serum adiponectin values were found to be positively correlated 
with serum HDL-C and negatively with serum TG concentration in 
patients with the metabolic syndrome and coronary artery disease (Wang
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et al., 2010). Our results are also confirmed by the findings of Eizadi et 
al. who conducted a study to determine the relationship between 
anthropometrical and lipid profile indices and serum adiponectin in obese 
men. They found that serum adiponectin level had a significant 
correlation with total cholesterol, low density lipoprotein, systolic and 
diastolic blood pressure and age of subjects, suggesting a functional link 
to insulin resistance (Eizadi et al., 2011). Moreover, Asdie et a/, in their 
study to determine the relationship between serum adiponectin and lipid 
profile in obese people found that there was a significant correlation 
between low levels of adiponectin with triglyceride, HDL cholesterol and 
Homeostatic model assessment-insulin resistance (HOMA IR) (Asdie et 
al., 2007).
The current finding support the hypothesis that adiponectin has a 
profound effect on lipid metabolism (Tsao et al., 2002, Karbowska and 
Kochan, 2006). One mechanism by which adiponectin mediates its effect 
is through activating 5 '-AMP-activated protein kinase (AMPK), which 
plays a central role in the regulation of cellular energy metabolism 
(Carling, 2004). AMPK activates hepatic FFA oxidation and ketogenesis, 
inhibits triglyceride synthesis, and stimulates skeletal muscle FFA 
oxidation and glucose uptake (Winder and Hardie, 1999). In accordance 
with these mechanisms, we found that total triglyceride level was 
negatively associated with adiponectin concentration. In contrast, the 
HDL cholesterol level was positively associated with the adiponectin 
level. Interestingly, among several proposed lipid markers, TG and HDL- 
C are considered key metabolic markers in patients with insulin 
resistance (Kannel et al., 2008). Kannel et al. found that triglyceride 
versus high-density lipoprotein cholesterol ratio is useful for predicting 
insulin resistance and cardiometabolic risk in 3,014 patients from 
Framingham. The results of this study support our findings that the 
association between adiponectin and TG and HDL-C is considered as a 
major predictor not only of insulin resistance but for metabolic syndrome 
as a whole.
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The fact that HbA1c, an index of blood glucose control, was identified as 
a statistically significant variable in our results confirms the relationship 
between diabetes and serum adiponectin levels. Therefore, we can 
conclude that blood glucose control in diabetic patients is associated with 
serum adiponectin levels. This can be partially explained by adiponectin 
playing a role in glucose metabolism as previously mentioned.
Our finding of a negative relationship between adiponectin and insulin 
resistance supports the hypothesis that adiponectin concentrations could 
modulate insulin action. It is well known that adiponectin improves insulin 
sensitivity of the whole body (Fu et al., 2005); therefore we suggest the 
decreased adiponectin in type 2 diabetes may be one of the factors 
leading to insulin resistance among diabetic patients. Similar to our 
findings, a recent study in Japanese subjects has demonstrated a strong 
relationship between serum adiponectin and insulin resistance index, 
lipids and blood pressure (Yamamoto et al., 2002), showing, as 
previously described, lower levels of adiponectin in insulin-resistant 
subjects. Soebijanto and Waspadji have also found that individuals with 
low adiponectin concentration have a 10.5 times greater risk of insulin 
resistance than individuals who have normal or high adiponectin 
concentration. They concluded that low adiponectin concentration may 
be a predictor for the occurrence of insulin resistance (Soebijanto and 
Waspadji, 2010).
4.1.2 The Relationship between Resistin, T2DM and Metabolic 
Parameters
Resistin is another protein identified recently as a hormone implicated 
with insulin resistance in vivo and in vitro and might therefore be an 
important link between obesity and diabetes. Studies in rodents suggest 
that resistin is up-regulated in obesity and participates in the 
pathogenesis of insulin resistance (Steppan et al., 2001, Gabriely et al., 
2002, Levy et al., 2002). However, studies in humans have been
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controversial. The apparent differences between rodents and humans in 
the role of resistin in the pathogenesis of T2DM could in part reflect 
different expression and regulatory mechanisms of resistin in these 
species. For example, murine resistin is almost exclusively expressed in 
adipocytes, whereas human resistin is expressed at substantially lower 
concentrations in adipocytes but is readily detectable in other cell types, 
especially macrophages (Pang and Le, 2006). Furthermore, mouse and 
human resistin share only 59% homology at the amino acid level (Pang 
and Le, 2006). The majority of the studies investigating resistin regulation 
have analyzed the mRNA adipose tissue expression in different models 
of rodents with insulin resistance or in adipose tissue from obese and 
type 2 diabetic patients (Ukkola, 2002, McTernan et al., 2002, Shuidiner 
et al., 2001, Kern et al., 2003). In this study, we examined serum resistin 
concentrations in a cohort of Bahraini non diabetic subjects and diabetic 
patients with varying degrees of obesity. We found that serum resistin 
concentrations were increased significantly in the diabetes group 
compared to healthy subjects. Our results are in agreement with the 
findings of a Saudi study by Al-Harithy and Al-Ghamdi, who found that 
resistin concentrations are elevated in patients with type 2 diabetes and 
are associated with obesity and insulin resistance. These data indicate 
that resistin might be involved in the development of diabetes in humans 
(Al-Harithy and Al-Ghamdi, 2005). Similarly, several studies 
demonstrated higher resistin concentrations in insulin-resistant or 
diabetic subjects compared with their healthy counterparts (Al-Harithy 
and Al-Ghamdi, 2005, Chanchay et al., 2006, Lu et al., 2006, Tokuyama 
et al., 2007, Youn et al., 2004), whereas other studies did not find such a 
difference (Heilbronn et al., 2004, Utzschneider et al., 2005, Norata et al.,
2007, Vozarova de Courten et al., 2004, Lee et al., 2003, Yaturu et al., 
2006). Although the previous studies did not perform any sort of 
adjustment, these conflicting data may result from lack of adjustment for 
potential confounding variables such as age and body fat distribution, 
limited power due to small sample sizes, and cross-sectional design. 
Population variation and ethnicity issues could also be considered as 
potential causes. To our knowledge, this study is the first investigation of
resistin and the associated risk of type 2 diabetes in a Bahraini 
population.
In contrast to adiponectin, resistin levels did not exhibit a sexual 
dimorphism. Gender-based analysis showed that serum resistin levels 
were higher in male subjects than in females (P=0.033, Table 3.13) in 
T2DM patients. However, further adjustment for BMI decreased the 
magnitude of the associations and made it insignificant (P=0.184, Table 
3.13). It is noteworthy that resistin level variation associated with gender 
which was seen in T2DM patients was entirely accounted for by the 
difference in BMI rather than a real variation among genders. This agrees 
with the majority of studies which showed that resistin levels don’t 
correlate with gender (Li et al., 2009).
The association between resistin and insulin resistance in humans has 
been controversial. Many studies did not find an association between 
resistin and measures of insulin resistance (Lee et al., 2003, Vozarova 
de Courten et al., 2004); whereas others found a relationship that was 
weakened when adjusted for adiposity (Heilbronn et al., 2004, Degawa- 
Yamauchi et al., 2003). A lot of those studies included small numbers of 
participants, which limited their power. Our findings are consistent with 
several previous studies, which reported no evidence supporting a role 
for serum resistin in mediating insulin resistance or reflecting metabolic 
parameters in humans. Specifically, we found no associations between 
resistin and insulin resistance, hypertension, hyperlipidemia, 
hyperglycemia parameters, in healthy and diabetic male and female 
subjects. Additionally, we found no difference in resistin levels between 
obese and non-obese subjects in T2DM patients. Similar findings were 
published by Heilbronn et al. who found that serum resistin 
concentrations were not different among nonobese, and obese diabetic 
subjects, and were not significantly correlated to glucose disposal rate 
during a hyperinsulinemic glucose clamp across groups (Heilbronn et al.,
2004). Surprisingly and interestingly, we found a weak negative 
correlation with resistin levels and BMI in healthy male subjects. The
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present findings deviate from those in the study by Degawa- Yamauchi et 
al. who found that there was a significant positive correlation between 
resistin and BMI. They found that there was more serum resistin protein 
in the obese than that in the lean subjects (Degawa-Yamauchi et al., 
2003). The reason for the lack of stronger association of resistin with BMI 
is not clear. However, plenty of studies failed to confirm a significant 
positive correlation between resistin and BMI and found that circulating 
resistin levels are not associated with obesity or insulin resistance in 
normal, insulin-resistant, and diabetic subjects (Lee et al., 2003, 
Anderlova et al., 2006). Although this could be due to obviously a false 
negative association, a possible explanation for the discrepancy may be 
due to the fact that in humans, the main sources of this hormone are 
probably monocytes and macrophages residing in the adipose tissue and 
not the adipocytes themselves. Several reports indicated that resistin 
may also be involved in inflammatory processes suggesting that 
inflammatory status rather than body fat content itself may be the major 
regulator of serum resistin levels (Lehrke et al., 2004). Some pro- 
inflammatory agents, such as tumor necrosis factor-a (TNF-a), interleukin 
6 (IL-6) and lipopolysaccharide (LPS), can regulate resistin gene 
expression (Pang and Le, 2006, Lehrke et al., 2004). Resistin mRNA was 
strongly increased by TNF-a in human peripheral blood mononuclear 
cells (PBMC) (Kaser et al., 2003). It was also shown that serum resistin is 
directly correlated with inflammatory markers (C-reactive protein (CRP)) 
and oxidative stress (nytrotirosine (NT)) (Bo et al., 2005). An intriguing 
hypothesis, which needs to be tested, is that resistin is secreted in 
response to a chronic low-grade inflammation, and has antioxidant 
properties. Since patients inflammatory condition was not characterized, 
this hypothesis could not be ruled out. Our data does not reveal a 
significant association between circulating resistin and degree of obesity 
in humans and thus do not support a role for resistin in mediating the 
effect of obesity on insulin resistance or diabetes. Our findings are in 
accordance with a previous report which showed that serum resistin is 
not associated with metabolic abnormalities in overweight/obese
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Despite these discrepancies, it should be emphasized that our finding of 
a negative association between resistin and BMI in controls is not 
necessarily in conflict with previous reports that resistin concentrations 
are positively correlated with the degree of obesity. However, our study 
design permitted us to demonstrate only that resistin levels are 
independent of BMI; and not all measures of obesity, such as waist 
circumference and percentage body fat, which were included in the 
framework of the present study. Finally, identification of the receptor 
system for resistin, relevant signaling pathway(s), and their sensitivity 
state are needed for a complete evaluation of the role of the resistin 
system in humans (Hotamisligil, 2003).
4.2 Adiponectin and Resistin Levels in Relation to Metabolic and 
Clinical Parameters
In the present study, we observed clustering of the metabolic risk factors 
with decreased adiponectin levels. In our study, models including 
adiponectin as the dependent variable showed significantly higher 
correlations with the clinical and metabolic parameters compared with a 
model of resistin as the dependent variable, suggesting that adiponectin 
is a stronger marker for insulin resistance in humans compared to 
resistin. This finding would be consistent with prior literature on 
adiponectin (Baratta et al., 2004, Vendrell et al., 2004, Eizadi et al., 
2011). Adiponectin demonstrated slightly stronger associations with IR, 
TG and HbA1c. Our study results are in line with previous studies 
demonstrating that adiponectin but not resistin is associated with insulin 
resistance-related phenotypes (Tejero et al., 2004). Adiponectin showed 
a significant negative correlation with the parameters related to insulin 
resistance, such as IR, TG and HbA1c, in contrast to resistin, which 
showed only positive correlation with age.
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patients, perhaps due to the higher fat content in these subjects (Bo et
al., 2005).
This data suggests that the relationship between adiponectin and resistin 
and insulin resistance is probably not one of direct cause and effect in all 
instances. It is possible that in some situations their inverse relationship 
may be mediated in part by insulin levels, by other hormones such as 
catecholamines or androgens (Fasshauer et al., 2002, Yu et al., 2002, 
Fasshauer et al., 2001), by proinflammatory cytokines (Maeda et al., 
2001, Fasshauer et al., 2003), by medications (Fasshauer et al., 2003, 
Yu et al., 2002), or possibly by changes in clearance of adiponectin and 
resistin. An alternative explanation may be related to the different forms 
of adiponectin and its receptors now identified in animals and humans 
and the possibility that the biological action of adiponectin may differ 
among these structural variants and isoforms (Wang et al., 2002, 
Yamauchi et al., 2003). Although our data Indicated a less robust 
relationship of resistin with insulin resistance and obesity, some or all of 
these factors may also be influenced by the extent and location of 
obesity. Although resistin was firstly postulated to contribute to insulin 
resistance, more and more evidence indicates that it may also be 
involved in inflammatory processes. Resistin levels are markedly 
increased by endotoxin administration in humans suggesting that 
inflammatory status may be the major regulator of serum resistin levels 
(Lehrke et al., 2004). Additionally, the molecular mechanisms modulating 
insulin resistance may vary between individuals and in different 
population and circumstances (e.g., obesity and exercise), and thus the 
relevance of adiponectin and resistin in these situations may also vary. 
The results of the current study do not permit us to choose between 
these alternate explanations, but do indicate that elucidating the 
relationship between adiponectin, resistin and insulin resistance may be 
more complex than initially thought.
This is the first study to investigate the relationship between adiponectin, 
resistin and metabolic parameters in a Bahraini population. We have 
observed that resistin is not associated with insulin resistance. However, 
previous observations of relationships with weight, T2DM, insulin
resistance-related phenotypes and adiponectin are confirmed. In 
humans, the metabolic role of resistin is even less clear since receptors 
have not been identified yet. More work is needed to characterize its 
target tissues and its receptor, to define its role in signal transduction 
especially that of insulin, and to delineate a possible role in diabetes and 
insulin resistance. In contrast to resistin, the adipocyte-hormone 
adiponectin is considered an important link between insulin resistance 
and disorders of metabolism of lipid and glucose in diabetes (Cederberg 
and Enerback, 2003, Soebijanto and Waspadji, 2010). Given the high 
incidence of diabetes and obesity in Gulf States, particularly in Bahrain 
(Al-Mahroos and McKeigue, 1998), studies of the roles of adiponectin 
and resistin in these populations remain a research priority. These 
studies will shed new light on the prevention and treatment of type 2 
diabetes mellitus, and open new avenues for the development of novel 
therapeutics to treat insulin resistance- related phenotypes.
4.3 Analysis of Adiponectin Gene SNPs +45T>G and +276G>T 
Polymorphisms
Several susceptibility loci for type 2 diabetes have been identified by 
genome wide linkage scans (McCarthy, 2003). Among these regions, 
3q27 appears to be of special interest, because it harbours the ADIPOQ- 
gene-encoding adiponectin, which is known to modulate insulin 
sensitivity and glucose homeostasis (Kissebah et al., 2000, Kondo et al., 
2002). It has been demonstrated that serum adiponectin level is highly 
heritable (Vasseur et al., 2002, Comuzzie et al., 2001) and the plasma 
level, expression, and biological effects of adiponectin are associated 
with polymorphisms in the ADIPOQ gene. A series of SNPs in the 
adiponectin gene have been reported in various ethnic populations. 
Among these SNPs, two common SNPs, a silent T>G substitution in 
exon 2, SNP +45T>G (rs2241766) and a G<T substitution in intron 2, 
SNP +276G<T (rs1501299) have been studied in several populations 
including Europeans, Asians, and Americans (Gable et al., 2006,
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Vasseur et al., 2006). Although there is a lack of consistency among 
studies, the results indicate that genetic variation in the ADIPOQ gene is 
associated with insulin resistance and T2DM (Hara et al., 2002, 
Menzaghi et al., 2002, Stumvoll et al., 2002, Vasseur et al., 2002, Xita et 
al., 2005, Filippi et al., 2004, Jang et al., 2006). Moreover, the strong 
association with T2DM, insulin levels, and metabolic syndrome, found in 
the chromosomal region where the ADIPOQ gene is located, suggests 
that somewhere in this locus, common genetic variant(s) may have a 
measurable effect on insulin resistance-related phenotypes.
Gonzalez-Sanchez et al. found that the SNPs +45T>G and +276G>T of 
the adiponectin gene are associated with decreased serum adiponectin 
levels and risk for impaired glucose tolerance in 747 unrelated Spanish 
subjects (Gonzalez-Sanchez et al., 2005). Also in the Japanese 
population, Hara et al. found that both SNPs +45T>G and +276G>T had 
strong associations with T2DM, serum adiponectin level and insulin 
resistance in patients with T2DM (Hara et al., 2002). However, similar 
associations were not completely revealed either in a Chinese population 
(Xia et al., 2004) or in a Korean population (Xia et al., 2004, Lee et al.,
2005). In the Korean study, plasma levels of adiponectin were not 
statistically different according to SNP +45T>G and SNP +276G>T, in 
either control or type 2 diabetic subjects. The genotype distributions of 
these SNPs had no association with the risk of type 2 diabetes and 
metabolic parameters of insulin resistance. In the Chinese study 
however, only variation at position +45 was demonstrated to be 
associated with T2DM. However, in Arabs, no data is available regarding 
the genetic contribution of adiponectin gene polymorphisms on serum 
adiponectin level, T2DM and metabolic parameter. The present study 
investigates whether or not SNPs +45T>G and +276G>T in the 
adiponectin gene are associated with serum adiponectin levels, type 2 
diabetes mellitus and insulin resistance in Bahraini patients with T2DM.
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4.3.1 Association of Genetic Variants in the Adiponectin Gene with 
Adiponectin Level and T2DM
To our knowledge, this is the first study that investigates the association 
between the SNPs +45T>G and +276G>T of the adiponectin gene and 
serum adiponectin level and its relation to T2DM and metabolic 
syndrome in the Bahraini population. We assessed whether SNPs 
+45T>G and +276G>T in the ADIPOQ gene are associated with total 
adiponectin concentrations, T2DM, metabolic parameters, measures of 
insulin sensitivity, and obesity. Genotypes data from 206 individuals were 
available for analysis in our study. In the current study we observed that 
the G allele and TG/GG genotype of SNP +45T>G occurred more 
frequently than the T allele and TT genotype in Bahraini T2DM patients 
compared to the controls. Subjects with the G/G + TG genotype of SNP 
+45T>G were associated with lower serum adiponectin levels and were 
at increased risk for T2DM compared with those having the J f T  
genotype. Our findings are in agreement with the previous reports 
published separately by Zacharova et al. and Mohammadzadeh and 
Zarghami, who found that the G allele of SNP +45T>G was associated 
with lower serum adiponectin levels and increased risk for development 
of T2DM compared to the common T-allele in the STOP-NIDDM trial 
(which was conducted in Canada, Germany, Austria, Norway, Denmark, 
Sweden, Finland, Israel, and Spain) and in an Iranian population 
respectively (Zacharova et al., 2005, Mohammadzadeh and Zarghami, 
2009).
The associations of the SNP +276G>T alleles and genotypes with T2DM 
were also assessed, however, no significant association was found in 
Bahraini men and women. For the SNP +276G>T, no significant 
difference was found in allele or genotype frequencies between T2DM 
patients and the controls. Furthermore, no significant association 
between the genotypes and serum adiponectin levels was seen. These 
results were similar to some previous studies in French (Vasseur et al., 
2002), American (Hu et al., 2004), and Swedish (Kang et al., 2005)
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populations, but contradicted other studies that showed there was a 
significant association of SNP +276G>T with T2DM. The study in the 
Japanese population demonstrated that SNP +276G>T was significantly 
associated with type 2 diabetes, and decreased levels of circulating 
adiponectin (Hara et al., 2002). SNP +276G>T was also reported to be 
associated with T2DM and low adiponectin levels in Italian subjects (Gu 
et al., 2004). The conflicting results indicated that strong racial and 
regional variations in these different populations could play a key role in 
the distribution of these SNPs and determining their related phenotypes.
Prior data on adiponectin gene variation, serum adiponectin levels and 
risk of type 2 diabetes have been inconsistent. In a Japanese study that 
included 384 type 2 diabetic subjects and 480 nondiabetic control 
subjects, subjects with the G/G genotype at position +45 or the G/G 
genotype at position +276 had a significantly increased risk of diabetes 
compared with those with the T/T genotype at these loci (Hara et al., 
2002). In a study conducted in Germany, subjects with G/G + G/T 
genotypes at position +45 had higher BMI, lower insulin sensitivity and 
lower serum adiponectin level, but these associations were significant 
only among subjects without a family history of diabetes (Stumvoll et al., 
2002). Moreover, Menzaghi et al. reported that a haplotype defined by 
the SNPs +45T>G and +276G>T was associated with several 
components of the insulin resistance syndrome. However, neither the two 
individual SNPs nor their haplotype were associated with risk of type 2 
diabetes (Menzaghi et al., 2002). Similarly, a study conducted in French 
Caucasian families did not detect any significant associations between 
these two SNPs and risk of type 2 diabetes (Vasseur et al., 2002).
Cross-sectional studies have yielded controversial findings concerning 
the association of SNP +45T>G in particular. The G-allele of SNP 
+45T>G has been reported to be associated with an increased risk of 
type 2 diabetes in Japanese subjects (Hara et al., 2002). However, other 
studies have reported that the T-allele is a risk allele for the insulin 
resistance syndrome and type 2 diabetes In Italian (Menzaghi et al.,
117
2002), French (Vasseur et al., 2002), and healthy Caucasians subjects 
(Mackevics et al., 2006). Other studies have not found any effect of SNP 
+45T>G on adiponectin level and risk for type 2 diabetes, an example 
being the study published by Vozarova de Courten et al. who found no 
association between SNP +45T>G and serum adiponectin or diabetes in 
Pima Indians (Vozarova de Courten et al., 2005). These conflicting 
findings could be due to true differences in allelic association with the 
disease phenotype in various ethnic populations which is believed to be 
caused by variation in the response to environmental and genetic 
influences. In agreement with this hypothesis are differences in allele 
frequencies of SNPs in the adiponectin gene and its related phenotypes 
in various populations (Takahashi et al., 2000, Yang et al., 2003, Ukkola 
et al., 2003, Hara et al., 2002).
Mechanisms explaining the effect of the G-allele of SNP +45T>G on the 
risk of type 2 diabetes have not yet been demonstrated. T2DM is 
characterized by lower levels of serum adiponectin compared to non- 
diabetic subjects. Therefore, the role of the G IG  genotype of the SNP 
+45T>G in increasing the risk for T2DM in some populations, as 
demonstrated, is consistent with its role in decreasing serum adiponectin 
levels. This could also be due to the effect of adiponectin on both glucose 
and lipid metabolism (Tsao et al., 2002). Fumeron et al. found that the 
G IG  genotype of SNP +45T>G was associated with the risk of 
hyperglycemia in a 3-year prospective study in approximately 4,500 
French Caucasian subjects (Fumeron et al., 2004).
The association of adiponectin gene variants with adiponectin levels 
remains unclear; therefore, other mechanisms must be considered to 
explain our findings. It has been recently reported that SNP +45T>G is in 
strong linkage disequilibrium with other SNPs of the adiponectin gene or 
other close genes having an effect on adiponectin expression, secretion, 
structure, or action that might by itself explain the observed association 
with adiponectin concentrations. It is interesting to note that the SNP 
+45T>G is in almost complete linkage disequilibrium with an
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insertion/deletion polymorphism in the 3' UTR (position 2019) (Menzaghi 
et al., 2002). As the 3' UTR region plays a key role in the control of gene 
expression by binding proteins that regulate mRNA processing, 
translation or degradation, it could have a strong influence on the 
investigated protein and related diseases (Conne et al., 2000). Though 
the SNP +45T>G is located in exon 2 of the adiponectin gene and does 
not cause an amino acid change (GGT to GGG, Gly15Gly) (Takahashi et 
al., 2000), Yang et al. showed that the silent +45T>G mutation may alter 
RNA splicing or stability, suggesting an allele-specific differential 
expression of adiponectin (Yang et al., 2003).
Other factors rather than adiponectin SNPs have been shown to regulate 
adiponectin levels. A Mediterranean diet or a diet rich in whole grain and 
fat was shown to produce increased adiponectin levels (Mantzoros et al., 
2006, Mantzoros et al., 2005). Physical activity was also shown to 
influence adiponectin, with high levels of physical activity shown to 
elevate adiponectin levels (Yu et al., 2009). There is also a consensus 
report by Nelson et al. in which adiponectin levels are altered 
independently of ADIPOQ polymorphisms after dietary supplementation 
with a-linolenic acid (Nelson et al., 2007). The small sample size (n=57) 
in the previous study cannot allow interpretation of the genetic effect, 
thus a possible assumption can be made that specific effects of dietary 
factors (i.e., high omega-3 fatty acids) can mask the genetic effects in 
relatively insulin sensitive healthy subjects. Because we did not evaluate 
diet and exercise interventions in our study, the effect of these factors on 
serum adiponectin levels could not be excluded. In addition, direct 
comparisons between studies are difficult, considering the differences in 
the characteristics of the subjects populations studied (healthy, young, 
primarily female, versus hyperglycemic patients, middle-aged, fewer 
female, different ethnicities) and study intervention program.
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Although we observed an association between genetic variations in the 
ADIPOQ gene and adiponectin levels, we could not detect an association 
between the SNPs +45T>G and +276G>T with the anthropometric and 
metabolic parameters related to insulin resistance. In the current study, a 
reasonable implication is that the genetic effect of SNPs +45T>G on the 
circulating adiponectin levels is mediated through an alteration of gene 
expression that would eventually affect some of the metabolic 
parameters. Nevertheless, statistical analysis did not reveal any 
significant association of SNPs +45T>G and +276G>T with the majority 
of the clinical and metabolic parameters. This discrepancy has also been 
shown in other studies where both SNPs did relate to adiponectin 
concentrations but not to the metabolic parameters. Mackevics et al. 
found a strong association of the adiponectin SNPs +45T>G and 
+276G>T genotypes with adiponectin levels in healthy Caucasians. 
However, no association of this gene locus with metabolic parameters of 
the Insulin resistance syndrome could be confirmed (Mackevics et al.,
2006). Although adiponectin levels vary significantly with sex, prospective 
genotype effects on the metabolic parameters were very similar between 
men and women. This confirms that a mechanism other than an effect on 
adiponectin concentrations could be involved.
Previous studies showed that the association between ADIPOQ +45T>G 
and ADIPOQ +276G>T polymorphism with the obesity and metabolic 
syndrome is conflicting (Laclaustra et al., 2007). Although these two 
SNPs have been associated with obesity in Japanese subjects, 
Caucasians residents and Taiwan residents (Hara et al., 2002, Menzaghi 
et al., 2002, Yang et al., 2007); Gonzalez-Sanchez et al. have shown no 
association between these polymorphisms and BMI in Spanish subjects 
(Gonzalez-Sanchez et al., 2005). This would agree with our data which 
did not show an evidence for linkage between BMI and ADIPOQ SNPs 
and detected no correlation between the genotype and clinical data.
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4.3.2 Adiponectin Gene Variations and Aspects of the Metabolic
Syndrome
The reasons for not finding a positive association between SNPs 
+45T>G and +276G>T and the metabolic parameters are not clear, 
however, several possibilities should be considered. First, metabolic 
parameters of the insulin resistance syndrome are not only determined 
by serum adiponectin levels, but are influenced by other multiple genetic 
and environmental factors or lifestyle intervention (Corpeleijn et al., 2007, 
Dedoussis et al., 2007). Second, there might be several genes, which 
have an influence on adiponectin levels and the ADIPOQ gene is only 
one gene regulating adiponectin concentration (Maeda et al., 2001, Yang 
and Chuang, 2006). Third, different patterns of linkage disequilibrium and 
ethnicity among populations could be a reason. It should be noted that 
the study sample included only Arab subjects and in particular Bahraini. 
Therefore, our findings might be unique to the Bahraini population and it 
may not be applicable to other ethnic and racial groups. Fourth, the 
disparity between our results and expectations may be due to lack of 
power caused by the relatively small number of patients tested. Large, 
varied populations of patients should be tested to avoid a statistical false 
negative. This study is the first report that clarifies the association 
between ADIPOQ and clinical and metabolic data in Bahraini diabetic 
patients. Further large-scale genome-wide association studies are 
recommended to resolve the relationship between ADIPOQ gene 
variations and the metabolic syndrome.
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4.6 Study Limitations
The limitations of this study need to be addressed. First, the 
antihypertensive, antidiabetic and lipid-lowering medications might have 
influenced the results from the study. The association analysis with 
related traits has been carried out using samples of diabetes and a group 
of them were on current medications. The result may be influenced by 
medical care, therefore, further studies are required to determine whether 
the association of T2DM with serum levels is more general and whether 
other variants explain the association. Second was the difference in 
gender distribution between the groups. To minimize the confusion, we 
demonstrated and compared the level of adipocytokines according to 
gender in both diabetic and control subjects. Third, the study sample only 
included Bahraini, and it is possible that results from the present study 
may not be applicable to other ethnic and racial groups. Limitations of the 
present study also include its cross-sectional design, so we cannot 
exclude potential biases. The possibility of selection bias from the 
hospital-based case-control study is a relevant issue. Although the study 
subjects were a general population, they might have better health-related 
behavior or higher socioeconomic status than others because they chose 
to take a routine health examination. In addition, the results were based 
on single measurements of the adipokines and therefore may not reflect 
long-term levels of these hormones. However, single measurements of 
resistin and adiponectin have been suggested to be reliable for the risk 
assessment in longitudinal studies for adiponectin over 3 years (Kaplan 
et al., 2007). Further long-term prospective studies with a larger sample 
size are required to reveal the predictive value of the adipokines in 
association with metabolic syndrome and to establish a causal 
relationship between adiponectin gene and metabolic syndrome in 
patients with T2DM.
4.6.1 Analysis of Serum Adipokines Levels
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4.6.2 Analysis of Adiponectin Gene SNPs +45T>G and +276G>T 
Polymorphisms
Our study is limited by relatively low numbers of subjects; therefore our 
results of genetic analyses need to be interpreted with caution, and 
should be replicated in future studies with much larger sample numbers. 
Some minor genotype-induced differences in metabolic factors may have 
been missed due to lower statistical power. Further additional studies 
with a larger sample size are needed to confirm our findings. Despite 
these limitations, we showed that ADIPOQ genetic variants can impact 
the inter-individual differences in adiponectin levels. We found the 
greatest decrease in adiponectin levels in obese diabetic subjects who 
carry the GG/TG genptype of ADIPOQ +45T>G. However, long-term 
prospective studies are needed to examine the relationship between 
adiponectin levels and clinical outcomes in these subjects. Limitations of 
the present study also include the limited amount of data available about 
the genetic contribution of ADIPOQ on serum adiponectin levels and 
metabolic syndrome among Arabs; thus we were unable to compare our 
results with individuals from same ethnicity but rather with different ethnic 
and racial groups.
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Conclusion
In conclusion, this study confirmed that obesity and type 2 diabetes are 
associated with low serum adiponectin concentrations in a Bahraini 
diabetic population. We have also observed that resistin levels correlate 
positively to the risk of diabetes. The genetic analysis revealed that SNP 
+45T>G polymorphism is associated with lower serum adiponectin levels 
in a Bahraini population, and it might contribute to the genetic risk for 
hypoadiponectinemia in T2DM but no association with metabolic 
parameters of the insulin resistance syndrome was detected. SNPs that 
are associated with T2DM or insulin resistance vary in different ethnic 
populations, therefore, the possibility of other SNPs that playing a major 
role in the developing of T2DM or insulin resistance requires further 
study. Additional investigations are also needed to explore the complex 
interaction between environmental factors and ADIPOQ gene 
polymorphisms in terms of susceptibility to the metabolic syndrome.
Further studies aimed at screening for polymorphisms within the entire 
adiponectin gene along with other candidate genes located in the 3q27 
region and subsequent functional studies of the identified SNPs are 
warranted to understand the molecular mechanisms of the observed 
associations.
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Future Plans
The initial results have been presented in poster presentation at the 
RCSI-Bahrain research day on 13th Dec 2011. The poster information is 
as follow:
Poster Title
The Influence of SNPs +45T>G and +276G>T at the Adiponectin Gene 
Locus on Serum Adiponectin Levels, Type 2 Diabetes Mellitus and 
Related Metabolic Parameters in the Bahraini Population
Authors and affiliations
Al Hannan FA1, Culligan KG1, O’Farrell PA1, Morgan MP2, Tighe O2 
1School of Medicine, RCSI Bahrain, 2Molecular & Cellular Therapeutics, 
RCSI Dublin
Since the final data has just been analyzed and results obtained, it is the 
intention to present and publish the data locally and internationaly.
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Appendices
Royal College of Surgeons in Ireland- Medical University of Bahrain 
Research Clinical Data Sheet- Controls
Appendix 1
Title: Resistin and Adiponectin in the Bahraini Population: Plasma Levels, 
Gene Polymorphisms and Association with Type 2 Diabetes and Related
Metabolic Parameters
Personal Specifications
Patient Name:-------------
Patient CPR:---------------
Date of Birth:---------------
Nationality:-----------------
Telephone No.:------------
History
....,..„... , S l i p ^ :^esV Ex";
£ ■: ê z :- smokëiv ?
. Are^ rau E : ' i M
hiaa^iiSflHasatelS ilg ila tf 
Do you suffer from the following Illnesses?r^ r;—rrs^ :^ rrr-- zrrrTa3&*r-n. , y . ,
 ^Hypertension;' :• r ,:jt} £;;;-TMfv;; - «  No
Dislipdeima Yes
s a f p s i î ^ i i i  m
No
Metabolic disease Yes No
Congestive heart failure
I: Qfrnkp - • •' *. ■ •• ,• , .) .-^ v ■ '■ ■ -..
T wTZT::: >}""•’
Yes
r ‘~- iM t"■ ilf f i" ' ■;:
No
i i i i i w Æ n
Chronic renal disease 
! Active hepatic disease
Yes
. ....... .
No
Chronic diseases Yes No
[^nyStheracute;or chronic inflàmr^^ 
If yes, specify 
[ Are you on m e d ic^^
If yes, specify
i■’ yyQQ hv3^ ....  ■' ji.=g- ;ii. trjy- <:!-j! " ;! " i'“" ‘I..«¡¿Ï0V.,!. f 1 A". :! !
If yes, specify 
Clinical Parameter
Height (cm):--------------------------
Weight (Kg):--------------------------
Systolic blood pressure (mmHg): ■ 
Diastolic blood pressure (mmHg):
Subject ID
Royal College of Surgeons in Ireland- Medical University of Bahrain 
Research Clinical Data Sheet- Diabetic cases
Title: Resistin and Adiponectin in the Bahraini Population: Plasma Levels, 
Gene Polymorphisms and Association with Type 2 Diabetes and Related
Metabolic Parameters
General Information
1.1 CPR------------------------------------------------------------------------------------------
1.2 Gender:--------------------------------------------------------------------------------------
1.3 Date of birth:-------------------------------------------------------------------------------
1.4 Nationality:---------------------------------------------------------------------------------
1.5 Smoker?------------------------------------------------------------------------------------
1.6 Family History of T2DM------------------------------------------------------------------
Clinical Parameters
2.1 Height (cm)---------------------------------------------------------------------------------
2.2 Weight (Kg)--------------------------------------------------------------------------------
2.3 Fasting blood glucose (FBG) (mmol/l)------------------------------------------------
2.4 Systolic Blood pressure (mmHg)-------- ------------------- ---------------------------
2.5 Diastolic Blood pressure (mmHg)------------------------------------------------------
2.6 HbA1 c %-------------------------------------------------------------------------------------
2.7 TC (mmol/l)---------------------------------------------------------------------------------
2.8 HDL (mmol/l)---------------------------- ---------------------------------------------------
2.9 LDL (mmol/l)-------------------------------------------------------------------------------
2.10 TG (mmol/l)--------------------------------------------------------------------------------
HbA1c: glycated heamoglobin, TC: Total cholesterol, HDL: high density lipoprotein, LDL: low 
density lipoprotein, TG: Triglycerides
Management
If yes, specify dose and frequency____________________________________
!;QralfAritiflia^etib#Kei^plM  : - ■ •
Name of the medication/s
Specify dose and frequency________________________________________
DietiBfflExerciseslllfiM : ■
If yes, specify dose and frequency____________________________________
Complications
Have you ever had the following?________________________________
Appendix 2
iG M H cä tiÖ h ä jS  ; ...... vfi", ' -i \ *>■
Macrovascular PVD
IHD
TIA
Microvascular Eye
Kidney
Nerve
PVD: Peripheral vascular disease, IHD: Ischemic heart disease, TIA: transient ischemic attack 
Subject ID ------------
128
Bibliography
AHN, J., LEE, H., KIM, S. & HA, T. (2007) Resveratrol inhibits TNF- 
alpha-induced changes of adipokines in 3T3-L1 adipocytes. 
Biochem Biophys Res Commun, 364, 972-7.
AL-HARITHY, R. N. & AL-GHAMDI, S. (2005) Serum resistin, adiposity 
and insulin resistance in Saudi women with type 2 diabetes 
mellitus. Ann Saudi Med, 25, 283-7.
AL-MAHROOS, F. & AL-ROOMI, K. (2001) Obesity among adult Bahraini 
population: impact of physical activity and educational level. Ann 
Saudi Med, 21, 183-7.
AL-MAHROOS, F. & MCKEIGUE, P. M. (1998) High prevalence of 
diabetes in Bahrainis. Associations with ethnicity and raised 
plasma cholesterol. Diabetes Care, 21, 936-42.
ALBERTI, K. G„ ZIMMET, P. & SHAW, J. (2006) Metabolic syndrome-a 
new world-wide definition. A Consensus Statement from the 
International Diabetes Federation. Diabet Med, 23,469-80.
ALMEDA-VALDES, P., CUEVAS-RAMOS, D„ MEHTA, R„ GOMEZ- 
PEREZ, F. J., CRUZ-BAUTISTA, I., ARELLANO-CAMPOS, O., 
NAVARRETE-LOPEZ, M. & AGUILAR-SALINAS, C. A. (2010) 
Total and high molecular weight adiponectin have similar utility for 
the identification of insulin resistance. Cardiovasc Diabetol, 9, 26.
AMERICAN DIABETES ASSOCIATION (2009) Diagnosis and 
classification of diabetes mellitus. Diabetes Care, 32 Suppl 1, S62- 
7.
ANDERLOVA, K., KREMEN, J., DOLEZALOVA, R„ HOUSOVA, J., 
HALUZIKOVA, D„ KUNESOVA, M. & HALUZIK, M. (2006) The 
influence of very-low-calorie-diet on serum leptin, soluble leptin 
receptor, adiponectin and resistin levels in obese women. Physiol 
Res, 55, 277-83.
ANTUNA-PUENTE, B„ FEVE, B„ FELLAHI, S. & BASTARD, J. P. (2008) 
Adipokines: the missing link between insulin resistance and 
obesity. Diabetes Metab, 34, 2-11.
ARITA, Y., KIHARA, S., OUCHI, N„ TAKAHASHI, M„ MAEDA, K., 
MIYAGAWA, J„ HOTTA, K., SHIMOMURA, I., NAKAMURA, T„ 
MIYAOKA, K., KURIYAMA, H„ NISHIDA, M„ YAMASHITA, S., 
OKUBO, K„ MATSUBARA, K., MURAGUCHI, M„ OHMOTO, Y„ 
FUNAHASHI, T. & MATSUZAWA, Y. (1999) Paradoxical decrease 
of an adipose-specific protein, adiponectin, in obesity. Biochem 
Biophys Res Commun, 257, 79-83.
ARUNA, B„ GHOSH, S., SINGH, A. K„ MANDE, S. C„ SRINIVAS, V., 
CHAUHAN, R. & EHTESHAM, N. Z. (2003) Human recombinant
130
resistin protein displays a tendency to aggregate by forming 
intermolecular disulfide linkages. Biochemistry, 42, 10554-9.
ASDIE, A. H., ASDIE, R. H., PRAMONO, B. & SINORITA, H. (2007) 
Relationship between adiponectin and glucose tolerance In obese 
people. In: Grant PJ, Bailey CJ, Marso SP, Marx N, eds. The 2nd 
International Conggress on Prediabetes and the Metabolic 
Syndrome, Barcelona. Diabetes & Vascular Disease Research 
;4(Suppl.1):S115.
AVRAM, M. M., AVRAM, A. S. & JAMES, W. D. (2005) Subcutaneous fat 
in normal and diseased states: 1. Introduction. J  Am Acad 
Dermatol, 53, 663-70.
BANERJEE, R. R., RANGWALA, S. M., SHAPIRO, J. S., RICH, A. S., 
RHOADES, B., Ql, Y., WANG, J., RAJALA, M. W., POCAl, A., 
SCHERER, P. E., STEPPAN, C. M., AHIMA, R. S., OBICI, S., 
ROSSETTI, L. & LAZAR, M. A. (2004) Regulation of fasted blood 
glucose by resistin. Science, 303, 1195-8.
BARATTA, R., AMATO, S., DEGANO, C., FARINA, M. G., PATANE, G., 
VIGNERI, R. & FRITTITTA, L. (2004) Adiponectin relationship with 
lipid metabolism is independent of body fat mass: evidence from 
both cross-sectional and intervention studies. J  Clin Endocrinol 
Metab, 89, 2665-71.
BERG, A. H., COMBS, T. P., DU, X., BROWNLEE, M. & SCHERER, P. 
E. (2001) The adipocyte-secreted protein Acrp30 enhances 
hepatic insulin action. Nat Med, 7, 947-53.
BERTHIER, M. T., HOUDE, A., COTE, M., PARADIS, A. M., 
MAURIEGE, P., BERGERON, J., GAUDET, D., DESPRES, J. P. 
& VOHL, M. C. (2005) Impact of adiponectin gene polymorphisms 
on plasma lipoprotein and adiponectin concentrations of viscerally 
obese men. J  Lipid Res, 46, 237-44.
BIK, W. & BARANOWSKA, B. (2009) Adiponectin - a predictor of higher 
mortality in cardiovascular disease or a factor contributing to 
longer life? Neuro Endocrinol Lett, 30, 180-4.
BLAAK, E. (2001) Gender differences in fat metabolism. Curr Opin Clin 
Nutr Metab Care, 4, 499-502.
BLUHER, M., WILLIAMS, C. J., KLOTING, N., HSI, A., RUSCHKE, K., 
OBERBACH, A., FASSHAUER, M., BERNDT, J., SCHON, M. R., 
WOLK, A., STUMVOLL, M. & MANTZOROS, C. S. (2007) Gene 
expression of adiponectin receptors in human visceral and 
subcutaneous adipose tissue is related to insulin resistance and 
metabolic parameters and is altered in response to physical 
training. Diabetes Care, 30, 3110-5.
131
BO, S., GAMBINO, R., PAGANI, A., GUIDI, S., GENTILE, L., 
CASSADER, M. & PAGANO, G. F. (2005) Relationships between 
human serum resistin, inflammatory markers and insulin 
resistance. Int J  Obes (Lond), 29, 1315-20.
BOSY-WESTPHAL, A., GEISLER, C., ONUR, S., KORTH, 0., 
SELBERG, 0., SCHREZENMEIR, J. & MULLER, M. J. (2006) 
Value of body fat mass vs anthropometric obesity indices in the 
assessment of metabolic risk factors. Int J  Obes (Lond), 30, 475- 
83.
BRUUN, J. M., LIHN, A. S., VERDICH, C., PEDERSEN, S. B., TOUBRO, 
S., ASTRUP, A. & RICHELSEN, B. (2003) Regulation of 
adiponectin by adipose tissue-derived cytokines: in vivo and in 
vitro investigations in humans. Am J  Physiol Endocrinol Metab, 
285, E527-33.
CARLING, D. (2004) The AMP-activated protein kinase cascade-a 
unifying system for energy control. Trends Biochem Sci, 29, 18- 
24.
CEDERBERG, A. & ENERBACK, S. (2003) Insulin resistance and type 2 
diabetes--an adipocentric view. Curr Mol Med, 3,107-25.
CHANCHAY, S., TUNGTRONGCHITR, R., HARNROONGROJ, T., 
PHONRAT, B., RUNGSEESAKORN, O., PAKSANONT, S., 
POOUDONG, S., SAOWAKONTHA, S. & VARONGCHAYAKUL,
C. (2006) Plasma resistin, insulin concentration in non-diabetic 
and diabetic, overweight/obese Thai. Int J  Vitam Nutr Res, 76, 
125-31.
CHARLES, M. A., ESCHWEGE, E., THIBULT, N , CLAUDE, J. R., 
WARNET, J. M., ROSSELIN, G. E., GIRARD, J. & BALKAU, B. 
(1997) The role of non-esterified fatty acids in the deterioration of 
glucose tolerance in Caucasian subjects: results of the Paris 
Prospective Study. Diabetologia, 40, 1101-6.
CIVITARESE, A. E., JENKINSON, C. P., RICHARDSON, D., BAJAJ, M., 
CUSI, K., KASHYAP, S., BERRIA, R., BELFORT, R., 
DEFRONZO, R. A., MANDARINO, L. J. & RAVUSSIN, E. (2004) 
Adiponectin receptors gene expression and insulin sensitivity in 
non-diabetic Mexican Americans with or without a family history of 
Type 2 diabetes. Diabetologia, 47, 816-20.
COMMITTEE ON DIABETIC TWINS, J. D. S. (1988) Diabetes mellitus in 
twins: a cooperative study in Japan. Committee on Diabetic Twins, 
Japan Diabetes Society. Diabetes Res Clin Pract, 5, 271-80.
COMUZZIE, A. G., FUNAHASHI, T., SONNENBERG, G , MARTIN, L. J., 
JACOB, H. J , BLACK, A. E., MAAS, D., TAKAHASHI, M.,
132
KIHARA, S., TANAKA, S., MATSUZAWA, Y., BLANGERO, J., 
COHEN, D. & KISSEBAH, A. (2001) The genetic basis of plasma 
variation in adiponectin, a global endophenotype for obesity and 
the metabolic syndrome. J  Clin Endocrinol Metab, 86, 4321-5.
CONNE, B., STUTZ, A. & VASSALLI, J. D. (2000) The 3' untranslated 
region of messenger RNA: A molecular 'hotspot' for pathology? 
Nat Med, 6, 637- 641.
CORPELEIJN, E., FESKENS, E. J., JANSEN, E. H., MENSINK, M., 
SARIS, W. H. & BLAAK, E. E. (2007) Lifestyle intervention and 
adipokine levels in subjects at high risk for type 2 diabetes: the 
Study on Lifestyle intervention and Impaired glucose tolerance 
Maastricht (SLIM). Diabetes Care, 30, 3125-7.
CURAT, C. A., WEGNER, V., SENGENES, C., MIRANVILLE, A., 
TONUS, C., BUSSE, R. & BOULOUMIE, A. (2006) Macrophages 
in human visceral adipose tissue: increased accumulation in 
obesity and a source of resistin and visfatin. Diabetologia, 49, 744- 
7.
DAIMON, M., OIZUMI, T., SAITOH, T., KAMEDA, W., HIRATA, A., 
YAMAGUCHI, H., OHNUMA, H., IGARASHI, M., TOMINAGA, M. 
& KATO, T. (2003) Decreased serum levels of adiponectin are a 
risk factor for the progression to type 2 diabetes in the Japanese 
Population: the Funagata study. Diabetes Care, 26, 2015-20.
DAS, K., LIN, Y., WIDEN, E., ZHANG, Y. & SCHERER, P. E. (2001) 
Chromosomal localization, expression pattern, and promoter 
analysis of the mouse gene encoding adipocyte-specific secretory 
protein Acrp30. Biochem Biophys Res Commun, 280,1120-9.
DEDOUSSIS, G. V., KALIORA, A. C. & PAN AG IOT AKOS, D. B. (2007) 
Genes, diet and type 2 diabetes mellitus: a review. Rev Diabet 
Stud, 4, 13-24.
DEGAWA-YAMAUCHI, M., BOVENKERK, J. E., JULIAR, B. E., 
WATSON, W., KERR, K., JONES, R., ZHU, Q. & CONSIDINE, R. 
V. (2003) Serum resistin (FIZZ3) protein is increased in obese 
humans. J  Clin Endocrinol Metab, 88, 5452-5.
DOLINKOVA, M., DOSTALOVA, I., LACINOVA, Z., MICHALSKY, D., 
HALUZIKOVA, D., MRAZ, M., KASALICKY, M. & HALUZIK, M. 
(2008) The endocrine profile of subcutaneous and visceral 
adipose tissue of obese patients. Mol Cell Endocrinol, 291, 63-70.
DUNCAN, B. B., SCHMIDT, M. I., PANKOW, J. S., BANG, H., COUPER,
D., BALLANTYNE, C. M., HOOGEVEEN, R. C. & HEISS, G.
(2004) Adiponectin and the Development of Type 2 Diabetes. 
Diabetes, 53, 2473-2478.
133
EIZADI, M., KHORSHIDI, D. & DOALI, H. (2011) Relationship between 
serum adiponectin with anthropometrical and lipid profile
biochemical indexes in obese adult men. 2011 International 
Conference on Environmental, Biomedical and Biotechnology 
IPCBEE vol. 16 (2011)© (2011)IACSIT Press, Singapoore.
FASSHAUER, M., KLEIN, J., NEUMANN, S., ESZLINGER, M. &
PASCHKE, R. (2001) Adiponectin gene expression is inhibited by
beta-adrenergic stimulation via protein kinase A in 3T3-L1 
adipocytes. FEB S Lett, 507, 142-6.
FASSHAUER, M., KLEIN, J., NEUMANN, S., ESZLINGER, M. &
PASCHKE, R. (2002) Hormonal regulation of adiponectin gene 
expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun, 
290, 1084-9.
FASSHAUER, M., KRALISCH, S., KLIER, M., LOSSNER, U., BLUHER, 
M., KLEIN, J. & PASCHKE, R. (2003) Adiponectin gene 
expression and secretion is inhibited by interleukin-6 in 3T3-L1 
adipocytes. Biochem Biophys Res Commun, 301,1045-50.
FILIPPI, E., SENTINELLI, F., ROMEO, S., ARCA, M., BERNI, A., 
TIBERTI, C., VERRIENTI, A., FANELLI, M., FALLARINO, M., 
SORROPAGO, G. & BARONI, M. G. (2005) The adiponectin gene 
SNP+276G>T associates with early-onset coronary artery disease 
and with lower levels of adiponectin in younger coronary artery 
disease patients (age <or=50 years). J  Mol Med, 83, 711-9.
FILIPPI, E., SENTINELLI, F., TRISCHITTA, V., ROMEO, S., ARCA, M., 
LEONETTI, F., Dl MARIO, U. & BARONI, M. G. (2004) 
Association of the human adiponectin gene and insulin resistance. 
E u rJ  Hum Genet, 12,199-205.
FLAKOLL, P. J., JENSEN, M. D. & CHERRINGTON, A. C. (2004) 
Physiological action of insulin. In: LeRoith, D. Taylor, S. I 
Olefasky, J.M Diabetes Mellitus: A Fundamental and Clinical Text. 
3rd ed. Philadelphia, PA: Lippcott Williams & Wilkins. p165-181.
FU, Y., LUO, N., KLEIN, R. L. & GARVEY, W. T. (2005) Adiponectin 
promotes adipocyte differentiation, insulin sensitivity, and lipid 
accumulation. Journal of Lipid Research, 46,1369-1379.
FUMERON, F., AUBERT, R., SIDDIQ, A., BETOULLE, D., PEAN, F., 
HADJADJ, S., TICHET, J., WILPART, E., CHESNIER, M. C„ 
BALKAU, B., FROGUEL, P. & MARRE, M. (2004) Adiponectin 
gene polymorphisms and adiponectin levels are independently 
associated with the development of hyperglycemia during a 3-year 
period: the epidemiologic data on the insulin resistance syndrome 
prospective study. Diabetes, 53, 1150-7.
134
FUNAHASHI, T. & MATSUZAWA, Y. (2006) Hypoadiponectinemia: a 
common basis for diseases associated with overnutrition. Carr 
Atherosder Rep, 8, 433-8.
GABLE, D. R., HUREL, S. J. & HUMPHRIES, S. E. (2006) Adiponectin 
and its gene variants as risk factors for insulin resistance, the 
metabolic syndrome and cardiovascular disease. Atherosclerosis, 
188, 231-44.
GABRIELY, I., MA, X. H., YANG, X. M., ATZMON, G., RAJALA, M. W .f 
BERG, A. H., SCHERER, P., ROSSETTI, L. & BARZILAI, N.
(2002) Removal of visceral fat prevents insulin resistance and 
glucose intolerance of aging: an adipokine-mediated process? 
Diabetes, 51, 2951-8.
GANNAGE-YARED, M. H„ KHALIFE, S., SEMAAN, M., FARES, F., 
JAMBART, S. & HALABY, G. (2006) Serum adiponectin and leptin 
levels in relation to the metabolic syndrome, androgenic profile 
and somatotropic axis in healthy non-diabetic elderly men. Eur J  
Endocrinol, 155,167-76.
GOMEZ-AMBROSI, J., CATALAN, V., DIEZ-C AB ALLE RO, A.,
MARTINEZ-CRUZ, L. A., GIL, M. J., GARCIA-FONCILLAS, J., 
CIENFUEGOS, J. A., SALVADOR, J., MATO, J. M. & 
FRUHBECK, G. (2004) Gene expression profile of omental 
adipose tissue in human obesity. Faseb J f 18, 215-7,
GONZALEZ-CHAVEZ, A , SIMENTAL-MENDiA, L. & ELIZONDO- 
ARGUETA, S. (2011) Elevated triglycerides/HDL-cholesterol ratio 
associated with insulin resistance. CirC ir 79, 115-119.
GONZALEZ-SANCHEZ, J. L., ZABENA, C. A., MARTINEZ-LARRAD, M. 
T., FERNANDEZ-PEREZ, C., PEREZ-BARBA, M., LAAKSO, M. & 
SERRANO-RIOS, M. (2005) An SNP in the adiponectin gene is 
associated with decreased serum adiponectin levels and risk for 
impaired glucose tolerance. Obes Res, 13, 807-12.
GRUNDY, S. M., CLEEMAN, J. I., DANIELS, S. R., DONATO, K. A., 
ECKEL, R. H.f FRANKLIN, B. A., GORDON, D. J., KRAUSS, R. 
M., SAVAGE, P. J., SMITH, S. C., JR., SPERTUS, J. A. & 
COSTA, F. (2005) Diagnosis and management of the metabolic 
syndrome: an American Heart Association/National Heart, Lung, 
and Blood Institute Scientific Statement. Circulation, 112, 2735-52.
GU, H. F. (2009) Biomarkers of adiponectin: plasma protein variation and 
genomic DNA polymorphisms. Biomark Insights, 4, 123-33.
GU, H. F., ABULAITI, A., OSTENSON, C. G., HUMPHREYS, K.f 
WAHLESTEDT, C , BROOKES, A. J. & EFENDIC, S. (2004) 
Single nucleotide polymorphisms in the proximal promoter region
135
of the adiponectin (APM1) gene are associated with type 2 
diabetes in Swedish Caucasians. Diabetes, 53 Suppl 1, S31-5.
HAJER, G. R., VAN HAEFTEN, T. W. & VISSEREN, F. L. (2008) 
Adipose tissue dysfunction in obesity, diabetes, and vascular 
diseases. Eur Heart J, 29, 2959-71.
HARA, K., BOUTIN, P., MORI, Y., TOBE, K., DINA, C., YASUDA, K., 
YAMAUCHI, T., OTABE, S., OKADA, T., ETO, K., KADOWAKI,
H., HAGURA, R., AKANUMA, Y., YAZAKI, Y., NAGAI, R., 
TANIYAMA, M., MATSUBARA, K., YODA, M., NAKANO, Y., 
TOMITA, M., KIMURA, S., ITO, C., FROGUEL, P. & KADOWAKI, 
T. (2002) Genetic variation in the gene encoding adiponectin is 
associated with an increased risk of type 2 diabetes in the 
Japanese population. Diabetes, 51, 536-40.
HASLAM, D. W. & JAMES, W. P. (2005) Obesity. Lancet, 366, 1197-209.
HEID, I. M., HENNEMAN, P., HICKS, A., COASSIN, S., WINKLER, T., 
AULCHENKO, Y. S., FUCHSBERGER, C., SONG, K., HIVERT, 
M. F., WATERWORTH, D. M., TIMPSON, N. J., RICHARDS, J. B., 
PERRY, J. R., TANAKA, T., AMIN, N., KOLLERITS, B., PICHLER,
I.f OOSTRA, B. A., THORAND, B., FRANTS, R. R., ILLIG, T., 
DUPUIS, J., GLASER, B., SPECTOR, T., GURALNIK, J., EGAN, 
J. M., FLOREZ, J. C., EVANS, D. M., SORANZO, N., 
BANDINELLI, S., CARLSON, O. D., FRAYLING, T. M., BURLING, 
K., SMITH, G. D., MOOSER, V., FERRUCCI, L., MEIGS, J. B., 
VOLLENWEIDER, P., DIJK, K. W., PRAMSTALLER, P., 
KRONENBERG, F. & VAN DUIJN, C. M. (2010) Clear detection of 
ADIPOQ locus as the major gene for plasma adiponectin: results 
of genome-wide association analyses including 4659 European 
individuals. Atherosclerosis, 208, 412-20.
HEID, I. M., WAGNER, S. A., GOHLKE, H., IGLSEDER, B., MUELLER, 
J. C., CIP, P., LADURNER, G., REITER, R., STADLMAYR, A., 
MACKEVICS, V., ILLIG, T , KRONENBERG, F. & PAULWEBER,
B. (2006) Genetic architecture of the APM1 gene and its influence 
on adiponectin plasma levels and parameters of the metabolic 
syndrome in 1,727 healthy Caucasians. Diabetes, 55, 375-84.
HEIDEMANN, C., SUN, Q., VAN DAM, R. M., MEIGS, J. B., ZHANG, C., 
TWOROGER, S. S., MANTZOROS, C. S. & HU, F. B. (2008) Total 
and High-Molecular-Weight Adiponectin and Resistin in Relation 
to the Risk for Type 2 Diabetes in Women. Annals of Internal 
Medicine, 149, 307-316.
HEILBRONN, L. K., ROOD, J., JANDEROVA, L., ALBU, J. B., KELLEY,
D. E., RAVUSSIN, E. & SMITH, S. R. (2004) Relationship between 
serum resistin concentrations and insulin resistance in nonobese,
136
obese, and obese diabetic subjects. J  Clin Endocrinoi Metab, 89, 
1844-8.
HIROSE, H., YAMAMOTO, Y., SEINO-YOSHIHARA, Y., KAWABE, H. & 
SAITO, L (2010) Serum high-molecular-weight adiponectin as a 
marker for the evaluation and care of subjects with metabolic 
syndrome and related disorders. J  Atheroscler Thromb, 17, 1201-
11.
HIVERT, M. F., SULLIVAN, L. M., FOX, C. S., NATHAN, D. M , 
D’AGOSTINO, R. B., SR., WILSON, P. W. & MEIGS, J. B. (2008) 
Associations of adiponectin, resistin, and tumor necrosis factor- 
alpha with insulin resistance. J  Ciin Endocrinol Metab, 93, 3165- 
72.
HOLCOMB, I. N., KABAKOFF, R. C., CHAN, B., BAKER, T. W„ 
GURNEY, A., HENZEL, W., NELSON, C., LOWMAN, H. B., 
WRIGHT, B. D., SKELTON, N. J., FRANTZ, G. D., TUMAS, D. B., 
PEALE, F. V., JR., SHELTON, D. L. & HEBERT, C. C. (2000) 
FIZZ1, a novel cysteine-rich secreted protein associated with 
pulmonary inflammation, defines a new gene family. Embo J, 19, 
4046-55.
HOTAMISLIGIL, G. S. (2003) The irresistible biology of resistin. J  Clin 
Invest, 111,173-4.
HOTAMISLIGIL, G. S. (2006) Inflammation and metabolic disorders. 
Nature, 444, 860-7.
HOTTA, K., FUNAHASHI, T., ARITA, Y., TAKAHASHI, M., MATSUDA, 
M., OKAMOTO, Y., IWAHASHI, H., KURIYAMA, H., OUCHI, N., 
MAEDA, K., NISHIDA, M., KIHARA, S., SAKAI, N., NAKAJIMA, T., 
HASEGAWA, K., MURAGUCHI, M., OHMOTO, Y., NAKAMURA, 
T., YAMASHITA, S., HANAFUSA, T. & MATSUZAWA, Y. (2000) 
Plasma Concentrations of a Novel, Adipose-Specific Protein, 
Adiponectin, in Type 2 Diabetic Patients. Arterioscler Thromb 
Vase Biol, 20, 1595-1599.
HU, E., LIANG, P. & SPIEGELMAN, B. M. (1996) AdipoQ is a novel 
adipose-specific gene dysregulated in obesity. J  Biol Chem, 271, 
10697-703.
HU, F. B., DORIA, A., LI, T., MEIGS, J. B., LIU, S., MEMISOGLU, A., 
HUNTER, D. & MANSON, J. E. (2004) Genetic variation at the 
adiponectin locus and risk of type 2 diabetes in women. Diabetes, 
53, 209-13.
HUG, C., WANG, J., AHMAD, N. S., BOGAN, J. S., TSAO, T. S. & 
LODISH, H. F. (2004) T-cadherin is a receptor for hexameric and
137
high-molecular-weight forms of Acrp30/adiponectin. Proc Natl 
Acad Sci U S A .
HULTHE, J., HULTEN, L. M. & FAGERBERG, B. (2003) Low adipocyte- 
derived plasma protein adiponectin concentrations are associated 
with the metabolic syndrome and small dense low-density 
lipoprotein particles: atherosclerosis and insulin resistance study. 
Metabolism, 52, 1612-4.
IKEOKA, D., MADER, J. K. & PIEBER, T. R. (2010) Adipose tissue, 
inflammation and cardiovascular disease. Rev Assoc Med Bras, 
56,116-21.
IMATOH, T., MIYAZAKI, M., MOMOSE, Y., TANIHARA, S. & UNE, H.
(2008) Adiponectin levels associated with the development of 
hypertension: a prospective study. Hypertens Res, 31, 229-33.
INTERNATIONAL DIABETES FEDERATION (2009) IDF Diabetes Atlas, 
4th edn. Brussels, Belgium: International Diabetes Federation.
JANG, Y., LEE, J. H., KIM, O. Y , KOH, S. J., CHAE, J. S., WOO, J. H., 
CHO, H., LEE, J. E. & ORDOVAS, J. M. (2006) The SNP276G>T 
polymorphism in the adiponectin (ACDC) gene is more strongly 
associated with insulin resistance and cardiovascular disease risk 
than SNP45T>G in nonobese/nondiabetic Korean men 
independent of abdominal adiposity and circulating plasma 
adiponectin. Metabolism, 55, 59-66.
KADOWAKI, T. & KASUGA, M. (1991) [Mutations in the insulin receptor 
gene in patients with genetic forms of insulin resistance]. Nippon 
Rinsho, 49 Suppl, 721-30.
KADOWAKI, T., YAMAUCHI, T., KUBOTA, N., HARA, K., UEKI, K. & 
TOBE, K. (2006) Adiponectin and adiponectin receptors in insulin 
resistance, diabetes, and the metabolic syndrome. J  Clin Invest, 
116,1784-92.
KANG, E. S., PARK, S. Y., KIM, H. J., AHN, C. W., NAM, M., CHA, B. S., 
LIM, S. K.t KIM, K. R. & LEE, H. C. (2005) The influence of 
adiponectin gene polymorphism on the rosiglitazone response in 
patients with type 2 diabetes. Diabetes Care, 28, 1139-44.
KANNEL, W. B., VASAN, R. S., KEYES, M. J., SULLIVAN, L. M. & 
ROBINS, S. J. (2008) Usefulness of the triglyceride-high-density 
lipoprotein versus the cholesterol-high-density lipoprotein ratio for 
predicting insulin resistance and cardiometabolic risk (from the 
Framingham Offspring Cohort). A m J Cardiol, 101, 497-501.
KAPLAN, R. C., HO, G. Y., XUE, X., RAJPATHAK, S., CUSHMAN, M., 
ROHAN, T. E., STRICKLER, H. D , SCHERER, P. E. &
138
ANASTOS, K. (2007) Within-individual stability of obesity-related 
biomarkers among women. Cancer Epidemiol Biomarkers Prev, 
16, 1291-3.
KAPRIO, J., TUOMILEHTO, J., KOSKENVUO, M., ROMANOV, K., 
REUNANEN, A., ERIKSSON, J., STENGARD, J. & KESANIEMI, 
Y. A. (1992) Concordance for type 1 (insulin-dependent) and type 
2 (non-insulin-dependent) diabetes mellitus in a population-based 
cohort of twins in Finland. Diabetoiogia, 35, 1060-7.
KARASTERGIOU, K. & MOHAMED-ALI, V. (2010) The autocrine and 
paracrine roles of adipokines. Moi Ceil Endocrinol, 318, 69-78.
KARBOWSKA, J. & KOCHAN, Z. (2006) Role of adiponectin in the 
regulation of carbohydrate and lipid metabolism. J  Physiol 
Pharmacol, 57 Suppl 6, 103-13.
KASER, S., KASER, A., SANDHOFER, A., EBENBICHLER, C. F., TILG, 
H. & PATSCH, J. R. (2003) Resistin messenger-RNA expression 
is increased by proinflammatory cytokines in vitro. Biochem 
Biophys Res Commun, 309, 286-90.
KAWANISHI, K. (1977) [Insulin receptor antibody and insulin resistance]. 
Nippon Rinsho, 35, 242-7.
KERN, P. A., Dl GREGORIO, G. B., LU, T.( RASSOULI, N. & 
RANGANATHAN, G. (2003) Adiponectin expression from human 
adipose tissue: relation to obesity, insulin resistance, and tumor 
necrosis factor-alpha expression. Diabetes, 52, 1779-85.
KERSHAW, E. E. & FLIER, J. S. (2004) Adipose Tissue as an Endocrine 
Organ. J  Clin Endocrinol Metab, 89, 2548-2556.
KIM, S. M., CHO, G. J., YANNAKOULIA, M., HWANG, T. G., KIM, I. H., 
PARK, E. K. & MANTZOROS, C. S. (2011) Lifestyle modification 
increases circulating adiponectin concentrations but does not 
change vaspin concentrations. Metabolism, [Epub ahead of print].
KISSEBAH, A. H., SONNENBERG, G. E., MYKLEBUST, J., 
GOLDSTEIN, M., BROMAN, K., JAMES, R. G., MARKS, J. A., 
KRAKOWER, G. R., JACOB, H. J., WEBER, J.T MARTIN, L., 
BLANGERO, J. & COMUZZIE, A. G. (2000) Quantitative trait loci 
on chromosomes 3 and 17 influence phenotypes of the metabolic 
syndrome. Proc Natl Acad Sei U S A ,  97, 14478-83.
KNOWLES, K. M., PAIVA, L. L., SANCHEZ, S. E., REVILLA, L., LOPEZ, 
T., YASUDA, M. B., YANEZ, N. D., GELAYE, B. & WILLIAMS, M. 
A. (2011) Waist Circumference, Body Mass Index, and Other 
Measures of Adiposity in Predicting Cardiovascular Disease Risk 
Factors among Peruvian Adults. Int J  Hypertens, 2011, 931402.
139
KOBAYASHI, J., MURANO, S., KAWAMURA, I., NAKAMURA, F., 
MURASE, Y., KAWASHIRI, M. A., NOHARA, A., ASANO, A., 
INAZU, A. & MABUCHI, H. (2006) The relationship of percent 
body fat by bioelectrical impedance analysis with blood pressure, 
and glucose and lipid parameters. J  Atheroscler Thromb, 13, 221- 
6.
KOBAYASHI, M. (1992) Anti-insulin receptor antibody and insulin 
resistance. Nippon Naibunpi Gakkai Zasshi, 68,11-8.
KOMATSU, M., OHFUSA, H., AIZAWA, T. & HASHIZUME, K. (2007) 
Adiponectin inversely correlates with high sensitive C-reactive 
protein and triglycerides, but not with insulin sensitivity, in 
apparently healthy Japanese men. EndocrJ, 54, 553-8.
KONDO, H., SHIMOMURA, I., MATSUKAWA, Y., KUMADA, M., 
TAKAHASHI, M., MATSUDA, M., OUCHI, N., KIHARA, S., 
KAWAMOTO, T., SUMITSUJI, S., FUNAHASHI, T. & 
MATSUZAWA, Y. (2002) Association of adiponectin mutation with 
type 2 diabetes: a candidate gene for the insulin resistance 
syndrome. Diabetes, 51, 2325-8.
KRIZOVA, J., DOLINKOVA, M.( LACINOVA, Z., SULEK, S., 
DOLEZALOVA, R., HOUSOVA, J., KRAJICKOVA, J., 
HALUZIKOVA, D., BOSANSKA, L.f PAPEZOVA, H. & HALUZIK, 
M. (2008) Adiponectin and resistin gene polymorphisms in 
patients with anorexia nervosa and obesity and its influence on 
metabolic phenotype. Physiol Res, 57, 539-46.
KYRIAKOU, T., COLLINS, L. J., SPENCER-JONES, N. J., MALCOLM,
C., WANG, X., SNIEDER, H., SWAM I NATHAN, R., BURLING, K. 
A., HART, D. J., SPECTOR, T. D. & O’DELL, S. D. (2008) 
Adiponectin gene ADIPOQ SNP associations with serum 
adiponectin in two female populations and effects of SNPs on 
promoter activity. J  Hum Genet, 53, 718-27.
LACLAUSTRA, M., CORELLA, D. & ORDOVAS, J. M. (2007) Metabolic 
syndrome pathophysiology: the role of adipose tissue. Nutr Metab 
Cardiovasc Dis, 17, 125-39.
LAVIN, N. (2009) Manual of Endocrinology and Metabolism. 4th ed. 
Philadelphia, PA: Lippcott Williams & Wilkins. p634-635.
LE LAY, S., BOUCHER, J., REY, A., CASTAN-LAURELL, I., KRIEF, S., 
FERRE, P., VALET, P. & DUGAIL, I. (2001) Decreased resistin 
expression in mice with different sensitivities to a high-fat diet. 
Biochem Biophys Res Commun, 289, 564-7.
LEE, J. H., CHAN, J. L , YIANNAKOURIS, N., KONTOGIANNI, M., 
ESTRADA, E., SEIP, R., ORLOVA, C. & MANTZOROS, C. S.
140
(2003) Circulating resistin levels are not associated with obesity or 
insulin resistance in humans and are not regulated by fasting or 
leptin administration: cross-sectional and interventional studies in 
normal, insulin-resistant, and diabetic subjects. J  Clin Endocrinol 
Metab, 88, 4848-56.
LEE, J. M., KIM, S. R., YOO, S. J., HONG, O. K., SON, H. S. & CHANG, 
S. A. (2009) The relationship between adipokines, metabolic 
parameters and insulin resistance in patients with metabolic 
syndrome and type 2 diabetes. J  Int Med Res, 37,1803-12.
LEE, K., SONG, Y. M. & SUNG, J. (2008) Which obesity indicators are 
better predictors of metabolic risk?: healthy twin study. Obesity 
(Silver Spring), 16, 834-40.
LEE, Y. Y., LEE, N. S., CHO, Y. M., MOON, M. K., JUNG, H. S., PARK, 
Y. J., PARK, H. J., YOUN, B. S., LEE, H. K., PARK, K. S. & SHIN, 
H. D. (2005) Genetic association study of adiponectin 
polymorphisms with risk of Type 2 diabetes mellitus in Korean 
population. Diabet Med, 22, 569-75.
LEHRKE, M., REILLY, M. P., MILLINGTON, S. C., IQBAL, N., RADER,
D. J. & LAZAR, M. A. (2004) An inflammatory cascade leading to 
hyperresistinemia in humans. PLoS Med, 1, e45.
LEVY, J. R., DAVENPORT, B., CLORE, J. N. & STEVENS, W. (2002) 
Lipid metabolism and resistin gene expression in insulin-resistant 
Fischer 344 rats. Am J  Physiol Endocrinol Metab, 282, E626-33.
LI, M., FISETTE, A., ZHAO, X. Y., DENG, J. Y., Ml, J. & CIANFLONE, K.
(2009) Serum resistin correlates with central obesity but weakly 
with insulin resistance in Chinese children and adolescents. Int J  
Obes (Lond), 33, 424-39.
LOPEZ, I. P., MILAGRO, F. I., MARTI, A., MORENO-ALIAGA, M. J., 
MARTINEZ, J. A. & DE MIGUEL, C. (2004) Gene expression 
changes in rat white adipose tissue after a high-fat diet determined 
by differential display. Biochem Biophys Res Commun, 318, 234- 
9.
LU, H. L., WANG, H. W., WEN, Y., ZHANG, M. X. & LIN, H. H. (2006) 
Roles of adipocyte derived hormone adiponectin and resistin in 
insulin resistance of type 2 diabetes. World J  Gastroenterol, 12, 
1747-51.
MACKEVICS, V., HEID, I. M., WAGNER, S. A., CIP, P., DOPPELMAYR, 
H., LEJNIEKS, A., GOHLKE, H., LADURNER, G., ILLIG, T., 
IGLSEDER, B , KRONENBERG, F. & PAULWEBER, B. (2006) 
The adiponectin gene is associated with adiponectin levels but not
141
with characteristics of the insulin resistance syndrome in healthy 
Caucasians. E u rJ  Hum Genet, 14, 349-56.
MAEDA, K.f OKUBO, K., SHIMOMURA, I., FUNAHASHI, T., 
MATSUZAWA, Y. & MATSUBARA, K. (1996) cDNA cloning and 
expression of a novel adipose specific collagen-like factor, apM1 
(AdiPose Most abundant Gene transcript 1). Biochem Biophys 
Res Commun, 221, 286-9.
MAEDA, N., TAKAHASHI, M., FUNAHASHI, T., KIHARA, S., 
NISHIZAWA, H., KISHIDA, K., NAGARETANI, H., MATSUDA, M., 
KOMURO, R., OUCHI, N., KURIYAMA, H., HOTTA, K., 
NAKAMURA, T., SHIMOMURA, I. & MATSUZAWA, Y. (2001) 
PPARgamma ligands increase expression and plasma 
concentrations of adiponectin, an adipose-derived protein. 
Diabetes, 50, 2094-9.
MANTZOROS, C. S., LI, T., MANSON, J. E., MEIGS, J. B. & HU, F. B.
(2005) Circulating adiponectin levels are associated with better 
glycemic control, more favorable lipid profile, and reduced 
inflammation in women with type 2 diabetes. J  Clin Endocrinol 
Metab, 90, 4542-8.
MANTZOROS, C. S., WILLIAMS, C. J., MANSON, J. E., MEIGS, J. B. & 
HU, F. B. (2006) Adherence to the Mediterranean dietary pattern 
is positively associated with plasma adiponectin concentrations in 
diabetic women. Am J  Clin Nutr, 84, 328-35.
MATSUZAWA, Y. (2008) The role of fat topology in the risk of disease. 
Int J  Obes (Lond), 32 Suppl 7, S83-92.
MATSUZAWA, Y. (2010) Establishment of a concept of visceral fat 
syndrome and discovery of adiponectin. Proc Jpn Acad Ser B 
PhysBiol Sci, 86, 131-41.
MATTHEWS, D. R., HOSKER, J. P., RUDENSKI, A. S., NAYLOR, B. A., 
TREACHER, D. F. & TURNER, R. C. (1985) Homeostasis model 
assessment: insulin resistance and beta-cell function from fasting 
plasma glucose and insulin concentrations in man. Diabetologia, 
28,412-9.
MCCARTHY, M. I. (2003) Growing evidence for diabetes susceptibility 
genes from genome scan data. Curr Diab Rep, 3, 159-67.
MCCARTHY, M. I. (2010) Genomics, type 2 diabetes, and obesity. N 
Engl J  Med, 363, 2339-50.
MCTERNAN, C. L , MCTERNAN, P. G., HARTE, A. L., LEVICK, P. L , 
BARNETT, A. H. & KUMAR, S. (2002) Resistin, central obesity, 
and type 2 diabetes. Lancet, 359, 46-7.
142
MCTERNAN, P. G., KUSMINSKI, C. M. & KUMAR, S. (2006) Resistin. 
Curr Opin Lipidol, 17, 170-5.
MEIER, U. & GRESSNER, A. M. (2004) Endocrine regulation of energy 
metabolism: review of pathobiochemical and clinical chemical 
aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem, 50, 
1511-25.
MENZAGHI, C., ERCOLINO, T., Dl PAOLA, R., BERG, A. H., WARRAM, 
J. H., SCHERER, P. E., TRISCHITTA, V. & DORIA, A. (2002) A 
haplotype at the adiponectin locus is associated with obesity and 
other features of the insulin resistance syndrome. Diabetes, 51, 
2306-12.
MENZAGHI, C., TRISCHITTA, V. & DORIA, A. (2007) Genetic influences 
of adiponectin on insulin resistance, type 2 diabetes, and 
cardiovascular disease. Diabetes, 56,1198-209.
MOHAMMADZADEH, G. & ZARGHAMI, N. (2009) Associations between 
single-nucleotide polymorphisms of the adiponectin gene, serum 
adiponectin levels and increased risk of type 2 diabetes mellitus in 
Iranian obese individuals. Scand J  Clin Lab Invest, 69, 764-71.
MOORE, G. B., CHAPMAN, H., HOLDER, J. C., LISTER, C. A., PIERCY, 
V., SMITH, S. A. & CLAPHAM, J. C. (2001) Differential regulation 
of adipocytokine mRNAs by rosiglitazone in db/db mice. Biochem 
Biophys Res Commun, 286, 735-41.
MURDOLO, G., HERDER, C., WANG, Z., ROSE, B., SCHMELZ, M. & 
JANSSON, P. A. (2008) In situ profiling of adipokines in 
subcutaneous microdialysates from lean and obese individuals. 
Am J  Physiol Endocrinol Metab, 295, E1095-105.
NAKANO, Y., TAJIMA, S., YOSHIMI, A., AKIYAMA, H., TSUSHIMA, M., 
TANIOKA, T., NEGORO, T., TOMITA, M. & TOBE, T. (2006) A 
novel enzyme-linked immunosorbent assay specific for high- 
molecular-weight adiponectin. J  Lipid Res, 47,1572-82.
NAKANO, Y., TOBE, T., CHOI-MIURA, N. H., MAZDA, T. & TOMITA, M. 
(1996) Isolation and characterization of GBP28, a novel gelatin- 
binding protein purified from human plasma. J  Biochem, 120, 803-
12.
NANNIPIERI, M., BONOTTI, A., ANSELMINO, M., CECCHETTI, F., 
MADEC, S., MANCINI, E., BALDI, S., SANTINI, F., PINCHERA, 
A., ROSSI, M. & FERRANNINI, E. (2007) Pattern of expression of 
adiponectin receptors in human adipose tissue depots and its 
relation to the metabolic state. Int J  Obes (Lond), 31, 1843-8.
143
NCEP (2001) Executive Summary of The Third Report of The National 
Cholesterol Education Program (NCEP) Expert Panel on 
Detection, Evaluation, And Treatment of High Blood Cholesterol In 
Adults (Adult Treatment Panel III). Jama, 285, 2486-97.
NEELEY, W. E. (1972) Simple automated determination of serum or 
plasma glucose by a hexokinase-glucose-6 -phosphate 
dehydrogenase method. Clin Chem, 18, 509-15.
NELSON, T. L., STEVENS, J. R. & HICKEY, M. S. (2007) Adiponectin 
levels are reduced, independent of polymorphisms in the 
adiponectin gene, after supplementation with alpha-linolenic acid 
among healthy adults. Metabolism, 56, 1209-15.
NISHIZAWA, H., SHIMOMURA, I., KISHIDA, K., MAEDA, N., 
KURIYAMA, H., NAGARETANI, H., MATSUDA, M., KONDO, H., 
FURUYAMA, N., KIHARA, S., NAKAMURA, T., TOCHINO, Y., 
FUNAHASHI, T. & MATSUZAWA, Y. (2002) Androgens Decrease 
Plasma Adiponectin, an Insulin-Sensitizing Adipocyte-Derived 
Protein. Diabetes, 51, 2734-2741.
NORATA, G. D., ONGARI, M., GARLASCHELLI, K., RASELLI, S., 
GRIGORE, L. & CATAPANO, A. L. (2007) Plasma resistin levels 
correlate with determinants of the metabolic syndrome. Eur J 
Endocrinol, 156,279-84.
OLEFSKY, J. M. (2000) Treatment of insulin resistance with peroxisome 
proliferator-activated receptor gamma agonists. J Clin Invest, 106, 
467-72.
OTERO, M., LAGO, R., LAGO, F., CASANUEVA, F. F., DIEGUEZ, C., 
GOMEZ-REINO, J. J. & GUALILLO, O. (2005) Leptin, from fat to 
inflammation: old questions and new insights. FEBS Lett, 579, 
295-301.
OUCHI, N., KIHARA, S., ARITA, Y, MAEDA, K., KURIYAMA, H., 
OKAMOTO, Y., HOTTA, K., NISHIDA, M., TAKAHASHI, M., 
NAKAMURA, T., YAMASHITA, S., FUNAHASHI, T. & 
MATSUZAWA, Y. (1999) Novel modulator for endothelial 
adhesion molecules: adipocyte-derived plasma protein
adiponectin. Circulation, 100, 2473-6.
PAJVANI, U. B., DU, X., COMBS, T. P., BERG, A. H., RAJALA, M. W 
SCHULTHESS, T., ENGEL, J., BROWNLEE, M. & SCHERER, P.
E. (2003) Structure-function studies of the adipocyte-secreted 
hormone Acrp30/adiponectin. Implications fpr metabolic regulation 
and bioactivity. J Biol Chem, 278, 9073-85.
PAJVANI, U. B., HAWKINS, M., COMBS, T. P., RAJALA, M. W., 
DOEBBER, T., BERGER, J. P., WAGNER, J. A., WU, M.,
144
KNOPPS, A., XIANG, A. H., UTZSCHNEIDER, K. M.f KAHN, S.
E., OLEFSKY, J. M., BUCHANAN, T. A. & SCHERER, P. E.
(2004) Complex distribution, not absolute amount of adiponectin, 
correlates with thiazolidinedione-mediated improvement in insulin 
sensitivity. J Biol Chem, 279, 12152-62.
PANG, S. S. & LE, Y. Y. (2006) Role of resistin in inflammation and 
inflammation-related diseases. Cell Mol Immunol, 3, 29-34.
PINEIRO, R., IGLESIAS, M. J., GALLEGO, R., RAGHAY, K., EIRAS, S., 
RUBIO, J., DIEGUEZ, C., GUALILLO, O., GONZALEZ- 
JUANATEY, J. R. & LAGO, F. (2005) Adiponectin is synthesized 
and secreted by human and murine cardiomyocytes. FEBS Lett, 
579,5163-9.
PIRO, S., ANELLO, M.f Dl PIETRO, C., LIZZIO, M. N., PATANE, G., 
RABUAZZO, A. M., VIGNERI, R., PURRELLO, M. & PURRELLO,
F. (2002) Chronic exposure to free fatty acids or high glucose 
induces apoptosis in rat pancreatic islets: possible role of oxidative 
stress. Metabolism, 51, 1340-7.
PISCHON, T., GIRMAN, C. J., RIFAI, N., HOTAMISLIGIL, G. S. & RIMM,
E. B. (2005) Association between dietary factors and plasma 
adiponectin concentrations in men. The American Journal of 
Clinical Nutrition, 81, 780-786.
Ql, L., RIMM, E.f LIU, S., RIFAI, N. & HU, F. B. (2005) Dietary Glycemic 
Index, Glycemic Load, Cereal Fiber, and Plasma Adiponectin 
Concentration in Diabetic Men. Diabetes Care, 28, 1022-1028.
RABE, K., LEHRKE, M., PARHOFER, K. G. & BROEDL, U. C. (2008) 
Adipokines and insulin resistance. Mol Med, 14, 741-51.
REAVEN, G. M. (1988) Banting lecture 1988. Role of insulin resistance in 
human disease. Diabetes, 37, 1595-1607.
REAVEN, G. M. (1995) Pathophysiology of insulin resistance in human 
disease. Physiol Rev, 75, 473-86.
REAVEN, G. M. (2004) llnsulin resistance and its consequences. In: 
LeRoith, D. Taylor, S. I Olefasky, J.M Diabetes Mellitus: A 
Fundamental and Clinical Text.. 3rd ed. Philadelphia: Lippincott, 
Williams and Wilkins. p899-915.
RICHELSEN, B., BRUUN, J. M. & PEDERSEN, S. B. (2001) [Fatty tissue 
as a secretory organ. Significance for obesity-related diseases]. 
Ugeskr Laeger, 163, 2913-7.
145
ROBERT, J. J. (1995) [Methods for the measurement of insulin 
resistance. Hyperinsulinemic euglycemic clamp]. Presse Med, 24, 
730-4.
ROCHA, V. Z. & LIBBY, P. (2009) Obesity, inflammation, and 
atherosclerosis. Nat Rev Cardiol, 6, 399-409.
RODEN, M., PRICE, T. B., PERSEGHIN, G., PETERSEN, K. F., 
ROTHMAN, D. L., CLINE, G. W. & SHULMAN, G. I. (1996) 
Mechanism of free fatty acid-induced insulin resistance in humans. 
J d in  invest, 97, 2859-65.
RONTI, T., LUPATTELLI, G. & AND MANNARINO, E. (2006) The 
Endocrine Function of Adipose Tissue: An Update Clin Endocrinol 
(Oxf), 64, 355-365.
RUCHAT, S. M., LOOS, R. J., RANKINEN, T., VOHL, M. C., 
WEISNAGEL, S. J., DESPRES, J. P., BOUCHARD, C. & 
PERUSSE, L. (2008) Associations between glucose tolerance, 
insulin sensitivity and insulin secretion phenotypes and 
polymorphisms in adiponectin and adiponectin receptor genes in 
the Quebec Family Study. Diabet Med, 25, 400-6.
RYO, M., NAKAMURA, T., KIHARA, S., KUMADA, M., SHIBAZAKI, S., 
TAKAHASHI, M., NAGAI, M., MATSUZAWA, Y. & FUNAHASHI, 
T. (2004) Adiponectin as a biomarker of the metabolic syndrome. 
Circ J, 68, 975-81.
SAITO, K., TOBE, T., MINOSHIMA, S., ASAKAWA, S., SUMIYA, J., 
YODA, M., NAKANO, Y., SHIMIZU, N. & TOMITA, M. (1999) 
Organization of the gene for gelatin-binding protein (GBP28). 
Gene, 229, 67-73.
SALMENNIEMI, U., ZACHAROVA, J., RUOTSALAINEN, E., 
VAUHKONEN, I., PIHLAJAMAKI, J., KAINULAINEN, S., 
PUNNONEN, K. & LAAKSO, M. (2005) Association of adiponectin 
level and variants in the adiponectin gene with glucose 
metabolism, energy expenditure, and cytokines in offspring of type 
2 diabetic patients. J Clin Endocrinol Metab, 90, 4216-23.
SALTIEL, A. R. & KAHN, C. R. (2001) Insulin signalling and the 
regulation of glucose and lipid metabolism. Nature, 414, 799-Q06.
SATTAR, N., WANNAMETHEE, S. G. & FOROUHI, N. G. (2008) Novel 
biochemical risk factors for type 2 diabetes: pathogenic insights or 
prediction possibilities? Diabetologia, 51, 926-40.
SCHENK, S., SABERI, M. & OLEFSKY, J. M. (2008) Insulin sensitivity: 
modulation by nutrients and inflammation. J Clin Invest, 118, 
2992-3002.
146
SCHERER, P. E., WILLIAMS, S., FOGLIANO, M., BALDINI, G. & 
LODISH, H. F. (1995) A novel serum protein similar to C1q, 
produced exclusively in adipocytes. J Biol Chem, 270, 26746-9.
SCHNEIDER, H. J., GLAESMER, H., KLOTSCHE, J., BOHLER, S., 
LEHNERT, H., ZEIHER, A. M., MARZ, W., PITTROW, D., 
STALLA, G. K. & WITTCHEN, H. U. (2007) Accuracy of 
anthropometric indicators of obesity to predict cardiovascular risk. 
J Clin Endocrinol Metab, 92, 589-94.
SHOELSON, S. E., LEE, J. & GOLDFINE, A. B. (2006) Inflammation and 
insulin resistance. J Clin Invest, 116, 1793-801.
SHULDINER, A. R., YANG, R. & GONG, D. W. (2001) Resistin, obesity 
and insulin resistance--the emerging role of the adipocyte as an 
endocrine organ. N Engl J Med, 345, 1345-6.
SIITONEN N, PULKKINEN L, LINDSTROM J, KOLEHMAINEN M, 
ERIKSSON JG, VENOJARVI M, ILANNE-PARIKKA P,
KEINANEN-KIUKAANNIEMI S, TUOMILEHTO J AND 
UUSITUPAM (2011) Association of ADIPOQ gene variants with 
body weight, type 2 diabetes and serum adiponectin 
concentrations: The Finnish Diabetes Prevention Study. BMC Med 
Genet 12:5.
SIMONYTE, K., OLSSON, T., NASLUND, I., ANGELHED, J.-E., LONN, 
L., MATTSSON, C. & RASK, E. (2010) Weight Loss after Gastric 
Bypass Surgery in Women Is Followed by a Metabolically 
Favorable Decrease in 11{beta}-Hydroxysteroid Dehydrogenase 1 
Expression in Subcutaneous Adipose Tissue. J Clin Endocrinol 
Metab, 95,3527-3531.
SOEBIJANTO, N. & WASPADJI, S. (2010) Adiponectin levels and its role 
in insulin resistance among adult women with metabolic 
syndrome. Acta Med Indones, 42, 187-91.
SPRANGER, J., KROKE, A., MOHLIG, M., HOFFMANN, K., 
BERGMANN, M. M., RISTOW, M., BOEING, H. & PFEIFFER, A.
F. (2003) Inflammatory cytokines and the risk to develop type 2 
diabetes: results of the prospective population-based European 
Prospective Investigation into Cancer and Nutrition (EPIC)- 
Potsdam Study. Diabetes, 52, 812-7.
STEPPAN, C. M., BAILEY, S. T., BHAT, S., BROWN, E. J., BANERJEE, 
R. R., WRIGHT, C. M., PATEL, H. R., AHIMA, R. S. & LAZAR, M. 
A. (2001) The hormone resistin links obesity to diabetes. Nature, 
409, 307-12.
STERN, M. P. & O’CONNELL, P. (1999) Type 2 Diabetes Prediction and 
Prevention. Chichester, UK: John Wiley and Sons Ltd. p39-60.
147
STUMVOLL, M., GOLDSTEIN, B. J. & VAN HAEFTEN, T. W. (2005) 
Type 2 diabetes: principles of pathogenesis and therapy. Lancet, 
365, 1333-46.
STUMVOLL, M., TSCHRITTER, 0., FRITSCHE, A., STAIGER, H., 
RENN, W., WEISSER, M., MACHICAO, F. & HARING, H. (2002) 
Association of the T-G polymorphism in adiponectin (exon 2) with 
obesity and insulin sensitivity: interaction with family history of type 
2 diabetes. Diabetes, 51, 37-41.
SWARBRICK, M. M. & HAVEL, P. J. (2008) Physiological, 
pharmacological, and nutritional regulation of circulating 
adiponectin concentrations in humans. Metab Syndr Relat Disord, 
6, 87-102.
TABAK, A. G., JOKELA, M., AKBARALY, T. N., BRUNNER, E. J., 
KIVIMAKI, M. & WITTE, D. R. (2009) Trajectories of glycaemia, 
insulin sensitivity, and insulin secretion before diagnosis of type 2 
diabetes: an analysis from the Whitehall II study. Lancet, 373, 
2215-21.
TAKAHASHI, M., ARITA, Y., YAMAGATA, K., MATSUKAWA, Y., 
OKUTOMI, K., HORIE, M., SHIMOMURA, I., HOTTA, K., 
KURIYAMA, H., KIHARA, S., NAKAMURA, T., YAMASHITA, S., 
FUNAHASHI, T. & MATSUZAWA, Y. (2000) Genomic structure 
and mutations in adipose-specific gene, adiponectin. Int J Obes 
Reiat Metab Disord, 24, 861-8.
TAN, B. K., CHEN, J., DIGBY, J. E., KEAY, S. D., KENNEDY, C. R. & 
RANDEVA, H. S. (2006) Upregulation of adiponectin receptor 1 
and 2 mRNA and protein in adipose tissue and adipocytes in 
insulin-resistant women with polycystic ovary syndrome. 
Diabetoiogia, 49, 2723-8.
TATARANNI, P. A. & ORTEGA, E. (2005) A Burning Question Does an 
Adipokine-lnduced Activation of the Immune System Mediate the 
Effect of Overnutrition on Type 2 Diabetes? Diabetes, 54, 917- 
927.
TATARANNI, P. A. & RAVUSSIN, E. (2002) Energy metabolism and 
obesity. In: Wadden TA, Stunkard AJ Handbook of obesity 
treatment. New York: The Guilford Press. p42-72.
TAYLOR, S. I., ACCILI, D., CAMA, A., KADOWAKI, H., KADOWAKI, T., 
IMANO, E. & SIERRA, M. L. (1991) Mutations in the insulin 
receptor gene in patients with genetic syndromes of insulin 
resistance. Adv Exp Med Biol, 293, 197-213.
TAYLOR, S. I., KADOWAKI, T., ACCILI, D., CAMA, A., KADOWAKI, H., 
MCKEON, C, MONCADA, V., MARCUS-SAMUELS, B., BEVINS,
148
C., OJAMAA, K. & ET AL. (1990) Mutations in the insulin receptor 
gene in genetic forms of insulin resistance. Recent Prog Horm 
Res, 46, 185-213; discussion 213-7.
TEJERO, M. E., FREELAND-GRAVES, J. H., PROFFITT, J. M., 
PEEBLES, K. W., CAI, G., COLE, S. A. & COMUZZIE, A. G. 
(2004) Adiponectin but not resistin is associated with insulin 
resistance-related phenotypes in baboons. Obes Res, 12, 871-7.
TOKUYAMA, Y., OSAWA, H., ISHIZUKA, T., ONUMA, H.f MATSUI, K., 
EGASHIRA, T., MAKINO, H. & KANATSUKA, A. (2007) Serum 
resistin level is associated with insulin sensitivity in Japanese 
patients with type 2 diabetes mellitus. Metabolismf 56, 693-8.
TRAYHURN, P., BING, C. & WOOD, I. S. (2006) Adipose Tissue and 
Adipokines'— Energy Regulation from the Human Perspective. J. 
Nutr, 136, 1935S-1939S.
TRAYHURN, P. & WOOD, I. S. (2004) Adipokines: inflammation and the 
pleiotropic role of white adipose tissue. B rJ  Nutr, 92, 347-55.
TSAO, T. S., LODISH, H. F. & FRUEBIS, J. (2002) ACRP30, a new 
hormone controlling fat and glucose metabolism. Eur J Pharmacol, 
440,213-21.
UKKOLA, O. (2002) Resistin - a mediator of obesity-associated insulin 
resistance or an innocent bystander? Eur J Endocrinol, 147, 571- 
4.
UKKOLA, O., RAVUSSIN, E., JACOBSON, P., SJOSTROM, L. & 
BOUCHARD, C. (2003) Mutations in the adiponectin gene in lean 
and obese subjects from the Swedish obese subjects cohort. 
Metabolism, 52, 881-4.
UTZSCHNEIDER, K. M., CARR, D. B., TONG, J., WALLACE, T. M., 
HULL, R. L, ZRAIKA, S., XIAO, Q., MISTRY, J. S., RETZLAFF, B. 
M., KNOPP, R. H. & KAHN, S. E. (2005) Resistin is not associated 
with insulin sensitivity or the metabolic syndrome in humans. 
Diabetologia, 48, 2330-3.
VASSEUR, F., HELBECQUE, N., DINA, C., LOBBENS, S., DELANNOY, 
V., GAGET, S., BOUTIN, P., VAXILLAIRE, M., LEPRETRE, F., 
DUPONT, S., HARA, K., CLEMENT, K., BIHAIN, B., KADOWAKI, 
T. & FROGUEL, P. (2002) Single-nucleotide polymorphism 
haplotypes in the both proximal promoter and exon 3 of the APM1 
gene modulate adipocyte-secreted adiponectin hormone levels 
and contribute to the genetic risk for type 2 diabetes in French 
Caucasians. Hum Mol Genet, 11, 2607-14.
149
VASSEUR, F., MEYRE, D. & FROGUEL, P. (2006) Adiponectin, type 2 
diabetes and the metabolic syndrome: lessons from human 
genetic studies. Expert Rev Mol Med, 8, 1-12.
VENDRELL, J., BROCH, M., VILARRASA, N„ MOLINA, A., GOMEZ, J. 
M., GUTIERREZ, C., SIMON, I., SOLER, J. & RICHART, C. 
(2004) Resistin, adiponectin, ghrelin, leptin, and proinflammatory 
cytokines: relationships in obesity. Obes Res, 12, 962-71.
VOZAROVA DE COURTEN, B., DEGAWA-YAMAUCHI, M., 
CONSIDINE, R. V. & TATARANNI, P. A. (2004) High serum 
resistin is associated with an increase in adiposity but not a 
worsening of insulin resistance in Pima Indians. Diabetesf 53, 
1279-84.
VOZAROVA DE COURTEN, B., HANSON, R. L., FUNAHASHI, T., 
LINDSAY, R. S., MATSUZAWA, Y., TANAKA, S., THAMEEM, F., 
GRUBER, J. D., FROGUEL, P. & WOLFORD, J. K. (2005) 
Common Polymorphisms in the Adiponectin Gene ACDC Are Not 
Associated With Diabetes in Pima Indians. Diabetes, 54, 284-9.
WAJCHENBERG, B. L. (2000) Subcutaneous and visceral adipose 
tissue: their relation to the metabolic syndrome. Endocr Rev, 21, 
697-738.
WAKI, H., YAMAUCHI, T., KAMON, J., ITO, Y., UCHIDA, S., KITA, S., 
HARA, K., HADA, Y., VASSEUR, F., FROGUEL, P., KIMURA, S., 
NAGAI, R. & KADOWAKI, T. (2003) Impaired multimerization of 
human adiponectin mutants associated with diabetes. Molecular 
structure and multimer formation of adiponectin. J Biol Chem, 278, 
40352-63.
WANG, J. H.f LEE, C. J., LEE, C. C., CHEN, Y. C., LEE, R. P. & HSU, B.
G. (2010) Fasting adiponectin is inversely correlated with 
metabolic syndrome in patients with coronary artery disease. 
Intern Med, 49, 739-47.
WANG, Y., XU, A., KNIGHT, C., XU, L. Y. & COOPER, G. J. (2002) 
Hydroxylation and glycosylation of the four conserved lysine 
residues in the collagenous domain of adiponectin. Potential role 
in the modulation of its insulin-sensitizing activity. J Biol Chem, 
277, 19521-9.
WANNAMETHEE, S. G., LOWE, G. D., RUMLEY, A., CHERRY, L, 
WHINCUP, P. H. & SATTAR, N. (2007) Adipokines and risk of 
type 2 diabetes in older men. Diabetes Care, 30, 1200-5.
WARNICK, G. R., KNOPP, R. H.f FITZPATRICK, V. & BRANSON, L. 
(1990) Estimating low-density lipoprotein cholesterol by the
150
i\
Friedewald equation is adequate for classifying patients on the 
basis of nationally recommended cutpoints. Clin Chem, 36,15-19.
WAY, J. M., GORGUN, C. Z., TONG, Q., UYSAL, K. T., BROWN, K. K., 
HARRINGTON, W. W., OLIVER, W. R., JR., WILLSON, T. M.( 
KLIEWER, S. A. & HOTAMISLIGIL, G. S. (2001) Adipose tissue 
resistin expression is severely suppressed in obesity and 
stimulated by peroxisome proliferator-activated receptor gamma 
agonists. J Biol Chem, 276, 25651-3.
WEIGERT, J., NEUMEIER, M., WANNINGER, J., WURM, S., KOPP, A., 
SCHOBER, F., FILARSKY, M., SCHÄFFLER, A., ZEITOUN, M., 
ASLANIDIS, C. & BUECHLER, C. (2008) Reduced response to 
adiponectin and lower abundance of adiponectin receptor proteins 
in type 2 diabetic monocytes. FEBS Lett, 582, 1777-82.
WEISBERG, S. P., MCCANN, D., DESAI, M., ROSENBAUM, M.f 
LEIBEL, R. L. & FERRANTE, A. W., JR. (2003) Obesity is 
associated with macrophage accumulation in adipose tissue. J 
Clin Invest, 112, 1796-808.
WEYER, C., BOGARDUS, C., MOTT, D. M. & PRATLEY, R. E. (1999) 
The natural history of insulin secretory dysfunction and insulin 
resistance in the pathogenesis of type 2 diabetes mellitus. J Clin 
Invest, 104, 787-94.
WEYER, C., FUNAHASHI, T., TANAKA, S., HOTTA, K., MATSUZAWA, 
Y., PRATLEY, R. E. & TATARANNI, P. A. (2001) 
Hypoadiponectinemia in obesity and type 2 diabetes: close 
association with insulin resistance and hyperinsulinemia. J Clin 
Endocrinol Metab, 86,1930-5.
WHO (2002) The Impact of Chronic Disease in Bahrain. Available: 
http://www.who.int/chp/chronic disease report/media/impact/bahr 
ain.pdf. Last accessed 12th July 2011. .
WHO (2004) Appropriate body-mass index for Asian populations and its 
implications for policy and intervention strategies. Lancet, 363, 
157-63.
WI^CEK, A., ADAMCZAK, M. & CHUDEK, J. (2007) Adiponectin— an 
adipokine with unique metabolic properties. Nephrology Dialysis 
Transplantation, 22, 981-988.
WINDER, W. W. & HARDIE, D. G. (1999) AMP-activated protein kinase, 
a metabolic master switch: possible roles in type 2 diabetes. Am J 
Physiol, 277, E1-10.
151
XIA, H„ MO, Y„ BIAN, R„ SHEN, J. & MA, L. (2004) Correlation between 
single nucleotide polymorphism of adiponectin gene and type 2 
diabetes in Chinese. Chin J Endocrinol Metab, 20, 236-237.
XITA, N„ GEORGIOU, I., CHATZIKYRIAKIDOU, A., VOUNATSOU, M„ 
PAPASSOTIRIOU, G.-P., PAPASSOTIRIOU, I. & TSATSOULIS, 
A. (2005) Effect of Adiponectin Gene Polymorphisms on 
Circulating Adiponectin and Insulin Resistance Indexes in Women 
with Polycystic Ovary Syndrome. Clin Chem, 51,416-423.
YAMAMOTO, Y., HIROSE, H., SAITO, I., TOMITA, M„ TAN I YAM A, M.,
MATSUBARA, K„ OKAZAKI, Y„ ISHII, T„ NiSHIKAI, K. & 
SARUTA, T. (2002) Correlation of the adipocyte-derived protein 
adiponectin with insulin resistance index and serum high-density 
lipoprotein-cholesterol, independent of body mass index, in the 
Japanese population. Clin Sc/ (Lond), 103,137-42.
YAMAUCHI, T„ KAMON, J„ ITO, Y„ TSUCHIDA, A., YOKOMIZO, T., 
KITA, S., SUGIYAMA, T., MIYAGISHI, M„ HARA, K„ TSUNODA, 
M., MURAKAMI, K„ OHTEKI, T„ UCHIDA, S., TAKEKAWA, S., 
WAKI, H., TSUNO, N. H„ SHIBATA, Y., TERAUCHI, Y., 
FROGUEL, P., TOBE, K., KOYASU, S., TAIRA, K„ KITAMURA, 
T., SHIMIZU, T., NAGAI, R. & KADOWAKI, T. (2003) Cloning of 
adiponectin receptors that mediate antidiabetic metabolic effects. 
Nature, 423, 762-9.
YAMAUCHI, T„ KAMON, J., WAKI, H„ TERAUCHI, Y„ KUBOTA, N., 
HARA, K„ MORI, Y„ IDE, T„ MURAKAMI, K„ TSUBOYAMA- 
KASAOKA, N„ EZAKI, O., AKANUMA, Y„ GAVRILOVA, O., 
VINSON, C., REITMAN, M. L„ KAGECHIKA, H„ SHUDO, K., 
YODA, M., NAKANO, Y., TOBE, K„ NAGAI, R„ KIMURA, S., 
TOMITA, M„ FROGUEL, P. & KADOWAKI, T. (2001) The fat- 
derived hormone adiponectin reverses insulin resistance 
associated with both lipoatrophy and obesity. Nat Med, 7, 941-6.
YANG, W. S. & CHUANG, L. M. (2006) Human genetics of adiponectin in 
the metabolic syndrome. J Mol Med, 84,112-21.
YANG, W. S., TSOU, P. L„ LEE, W. J., TSENG, D. L„ CHEN, C. L„ 
PENG, C. C„ LEE, K. C., CHEN, M. J., HUANG, C. J„ TAI, T. Y. & 
CHUANG, L. M. (2003) Allele-specific differential expression of a 
common adiponectin gene polymorphism related to obesity. J Mol 
Med, 81,428-34.
YANG, W. S., YANG, Y. C„ CHEN, C. L„ WU, I. L„ LU, J. Y„ LU, F. H„ 
TAI, T. Y. & CHANG, C. J. (2007) Adiponectin SNP276 is 
associated with obesity, the metabolic syndrome, and diabetes in 
the elderly. Am J Clin Nutr, 86, 509-13.
152
YATURU, S., DABERRY, R. P., RAINS, J. & JAIN, S. (2006) Resistin 
and adiponectin levels in subjects with coronary artery disease 
and type 2 diabetes. Cytokine, 34, 219-23.
YOUN, B. S., YU, K. Y., PARK, H. J., LEE, N. S., MIN, S. S., YOUN, M. 
Y., CHO, Y. M., PARK, Y. J., KIM, S. Y., LEE, H. K. & PARK, K. S. 
(2004) Plasma resistin concentrations measured by enzyme- 
linked immunosorbent assay using a newly developed monoclonal 
antibody are elevated in individuals with type 2 diabetes mellitus. J 
d in  Endocrinol Metab, 89,150-6.
YU, J. G., JAVORSCHl, S., HEVENER, A. L, KRUSZYNSKA, Y. T., 
NORMAN, R. A., SINHA, M. & OLEFSKY, J. M. (2002) The effect 
of thiazolidinediones on plasma adiponectin levels in normal, 
obese, and type 2 diabetic subjects. Diabetes, 51, 2968-74.
YU, Z., YE, X., WANG, J., Ql, Q., FRANCO, O. H., RENNIE, K. L., PAN, 
A., LI, H., LIU, Y.f HU, F. B. & LIN, X. (2009) Associations of 
physical activity with inflammatory factors, adipocytokines, and 
metabolic syndrome in middle-aged and older Chinese people. 
Circulation, 119, 2969-77.
ZACHAROVA, J., CHIASSON, J. L. & LAAKSO, M. (2005) The common 
polymorphisms (single nucleotide polymorphism [SNP] +45 and 
SNP +276) of the adiponectin gene predict the conversion from 
impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM 
trial. Diabetes, 54, 893-9.
ZOCCALI, C., MALLAMACI, F., TRIPEPI, G., BENEDETTO, F. A., 
CUTRUPI, S., PARLONGO, S., MALATINO, L. S., BONANNO, G., 
SEMINARA, G., RAPISARDA, F., FATUZZO, P, BUEMI, M., 
NICOCIA, G., TANAKA, S., OUCHI, N., KIHARA, S., 
FUNAHASHI, T. & MATSUZAWA, Y. (2002) Adiponectin, 
metabolic risk factors, and cardiovascular events among patients 
with end-stage renal disease. J Am Soc Nephrol, 13, 134-41.
153
